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Ischaemic heart disease is a major cause of death worldwide and a leading cause of mortality 
and morbidity in New Zealand.  Older adults and those of Māori and Pacific ancestry are 
particularly affected. Ischaemic heart disease accounts for over half of all cardiovascular 
disease mortality and, again, rates are more than twice as high among Māori than non-Māori.  
Ischaemic heart disease can lead to myocardial infarction (heart attack) which, if not fatal, can 
then lead to heart failure, a complex, multifactorial disease characterised by neurohormonal 
signalling and remodelling of the heart.  Currently the natriuretic peptides are the international 
gold standard for diganosing heart failure and are also excellent prognostic markers in patients 
with heart failure. However, there is still a clinical need for early biomarkers of myocardial 
ischaemia (to identify people at risk of myocardial infarction) and to identify patients at risk 
of developing heart failure before detrimental remodelling has occurred. 
As sequencing technologies have evolved there has been intense research in the fields of 
circulating cell free DNA and RNA, especially non-coding RNA. As RNA is actively 
transcribed, it has the advantage of providing a ‘real time’ insight into the disease status of an 
individual.  Recent discoveries have highlighted the regulatory roles and diseases associated 
with non-coding RNAs, including long non-coding RNAs (lncRNAs) and circular RNAs 
(circRNAs). LncRNAs have been demonstrated to have mutliple functional roles both within 
the nucleus and cytoplasm such as chromatin remodelling, histone modification, transcription 
factor recruitment, formation of subnuclear structures and control of mRNA translation and 
decay. CircRNA, a relative newcomer, has also been demonstrated to have functional roles 
such as sequestering miRNAs, binding proteins and even coding for peptides. There is great 
excitment for the potential utility of circRNAs as biomarkers as, due to their circular 
structure, they are more resistant to degradation in the circulation than their linear RNA 
counterparts. 
The overall aim of this thesis was to identify non-coding RNAs associated with ischaemic 
heart disease. To address this aim, a bioinformatics pipeline was developed to identify 
mRNAs, lncRNAs including putative novel lncRNAs, and circRNAs using short-read RNA 
Sequencing (RNA-Seq) data. This pipeline was tested and validated with publicly available 
data and used to screen for candidate mRNA and lncRNA biomarkers associated with 
ischaemic heart disease in human heart tissue.  A whole genome network correlation approach 
identified several promising candidate biomarkers for myocardial ischaemia including several 
 iii 
novel lncRNAs, which were validated with long-read Nanopore sequencing in independent 
samples.  The sub-cellular localisation of three promising lncRNAs candidates (two annotated 
lncRNAs, one novel lncRNA) was identified using the in-situ hybridisation assay, 
RNAscope®.  Next, an RNA-Seq protocol was developed to detect mRNAs, lncRNAs and 
circRNAs in human plasma. This protocol was applied to plasma from patients with 
ischaemic heart disease and healthy controls to screen for candidate mRNA, lncRNA and 
circRNA biomarkers for progression from ischaemic heart disease to heart failure. Although 
candidate biomarkers for disease progression could not be detected in these patients several 
additional lncRNA candidates for the presence of ischaemic heart disease were identified. 
In summary, this study has established a bioinformatics pipeline and methodology for 
identifying and validating putative novel lncRNAs and circRNAs in human tissue and plasma. 
This work has identified several promising candidate lncRNA biomarkers for ischaemic heart 
disease, which, if validated, may provide early diagnostic information in high-risk patients. 
The pipeline is freely available to download at https://github.com/zoeward-nz/PhD 
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     Chapter 1 
Introduction 
Despite the discovery of the cardiac troponins and the natriuretic peptides as powerful 
diagnostic and prognostics biomarkers for myocardial infarction (MI) and heart failure (HF), 
it remains difficult to identify high-risk individuals early in the disease course. Traditionally, 
clinical biomarkers have taken the form of proteins, peptides or neurohormones, but more 
recently DNA and RNA have been detected in biofluids which has opened up a whole new 
field of biomarker discovery. DNA and RNA biomarkers have already begun to appear 
clinically for cancer and are starting to gain attention in the cardiovascular field. RNA-Seq 
technology has evolved at a rapid pace since its inception in the genomic world roughly 15 
years ago and is starting to shed light on the relatively new non-coding RNA players, long 
non-coding RNAs (lncRNAs) and circular RNAs (circRNAs).  These represent an exciting 
new source of biomarkers as they have been associated with a wide range of cardiovascular 
diseases and are detectable in various body fluids.  In parallel, bioinformatics software 
involved in RNA detection and analysis has been developed to allow detection of mRNAs, 
lncRNAs and circRNAs at a greater precision.  
1.1 Aims of the thesis 
The overall aim of this thesis is to identify new candidate RNA markers to improve detection 
of myocardial ischaemia and progression from ischaemic heart disease to HF. Specific aims 
are: 
1. To develop a bioinformatic pipeline that identifies annotated mRNAs, lncRNAs and 




2. To identify coding and lncRNAs (including novel lncRNAs) that are associated with 
myocardial ischaemia in human heart tissue (data provided in collaboration with 
Harvard Medical School). 
3. To establish an RNA-Seq method to detect mRNAs, lncRNAs and circRNAs in 
human plasma. 
4. To identify coding and lncRNAs in human plasma (including novel lncRNAs and 
circRNAs) that are associated with the presence of ischaemic heart disease or 
progression from ischaemic heart disease to heart failure. 
1.2 Hypotheses:    
This thesis is founded on the hypothesis that novel RNA biomarkers will aid cardiovascular 
diagnosis and prognosis. Specific hypotheses are: 
• That putative novel RNA transcripts can be identified from RNA-Seq data using a 
bioinformatics approach. 
• That expression of genes and regulatory RNA transcripts (mRNAs, lncRNAs and 
circRNAs) coordinate the cascade of cellular, inflammatory, and biochemical events triggered 
in response to myocardial ischaemia. Some of these transcripts (or their translated protein 
products) will be secreted from cardiomyocytes into the circulation in detectable 
concentrations and have clinical utility as biomarkers. 
• That circulating RNA transcripts (mRNAs, lncRNAs and circRNAs) reflect the 
disease status of an individual and can be detected by RNA-Seq in human plasma.  Some 
transcripts will have utility as biomarkers for detecting the presence of ischaemic heart 





1.3 Thesis outline 
The first part of Chapter 2 of this thesis includes an introduction to the physiology of the 
ischaemic heart and heart failure, the current clinical biomarkers for diagnosis and prognosis 
and their limitations. The second part of Chapter 2 reviews our current understanding of 
lncRNAs and circRNAs including biogenesis and functions and their roles in cardiovascular 
disease. Experimental methods are outlined on Chapter 3. Chapter 4 explains the development 
of the bioinformatic pipeline after which its validation is presented and discussed. This 
pipeline is the used to analyse ischaemic heart tissue data in Chapter 5 with further analysis 
using a second data set from human plasma is presented in Chapters 6 and 7.  The results are 






     Chapter 2 
Literature Review 
2.1 Heart Disease in New Zealand 
 
Ischaemic heart disease (IHD) occurs when the major blood vessels in the heart become 
narrow and stiff due to the build-up of fatty, atherosclerotic plaques and is a major cause of 
death in both developed and developing countries [1]. Similarly, IHD is a leading cause of 
mortality and morbidity in New Zealand, accounting for 14 deaths per day [2] and loss of 
>90,000 disability-adjusted life years each year [3]. One in twenty adults in NZ live with IHD 
[4] with older New Zealanders and those of Māori and Pacific ancestry, particularly affected 
[5, 6]. Ischaemic heart disease accounts for over half of all cardiovascular disease mortality 
and the mortality rate among Māori was more than twice as high as that among non-Māori[7]  
The chronic result of IHD is angina (pain due to inadequate blood supply to the heart), or 
myocardial infarction (MI, a blockage of blood flow to the heart or prolonged ischaemia 
usually caused by blood clot). MI remains the most common cause of heart failure (HF) 
worldwide [8].  
In lay terms, HF is where the heart can no longer pump enough blood to meet the 
physiological demands of the body and is associated with compensatory and adverse 
structural remodelling of the heart. Clinically, HF is defined as a syndrome characterised by 
typical symptoms (including breathlessness, ankle swelling and fatigue) that may be 
accompanied by signs (including elevated jugular venous pressure, pulmonary crackles and 
peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a 
reduced cardiac output and/or elevated intracardiac pressures at rest or during stress [9].  
HF is a complex syndrome that can be caused by multiple factors that lead to disorders of the 




endocardium (the inner most layer of the heart), heart valves, the great vessels (the superior 
and inferior vena cava, the pulmonary artery and vein, and the aorta). Risk factors for HF 
include IHD, hypertension, metabolic abnormalities, congenital heart defects, 
cardiomyopathy, inflammation, and toxins. [10].   
The good news is that the rates of death from acute MI have reduced with improved coronary 
care –a 60% reduction in mortality during the first 30 days post MI in the last 30 years [11]. 
However, the consequences of patients living longer is an increased incidence of post-
infarction HF [11].  HF is now a global pandemic estimated to affect 26 million people 
worldwide [12] and 80,000 New Zealanders [13], and this is set to increase with an aging 
population. Again, Māori fare worse than non- Māori: HF mortality rate among Māori is more 
than twice as high as that of non-Māori and Māori are about 4 times as likely as non-Māori to 
be hospitalised for HF [7] 
Coronary heart disease and heart failure involve many different genes, pathways, and tissues. 
There have been exciting discoveries in recent years with regards to the potential of long non-
coding RNAs and circular RNAs as biomarkers and regulators of cardiovascular disease. 
Also, as Because these relatively newly discovered classes of non-coding RNAs are less 
studied than mRNAs and microRNAs this thesis will focus on long non-coding RNAs 
involved in myocardial ischaemia, MI and ischaemic HF. 
2.1.1 IHD, Atherosclerosis, and plaque formation 
To understand myocardial ischaemia, it is important to understand the underlying 
pathophysiology of CAD which begins with atherosclerosis. Atherosclerosis is a silent, 
chronic, inflammatory, vascular pathology [14]. Over the decades, our understanding of 
atherosclerosis has evolved from a model of passive cholesterol deposition to a dynamic, 
complex interplay of different cell types and cytokines (cell signalling molecules) resulting in 




driven by excessive exposure to ‘bad’ cholesterol - low density lipoproteins (LDLs) along 
with other pathogenic factors such as infectious disease, hypertension, diabetes and smoking 
which cause injury to endothelial cells (the cells that line our blood vessels). This sets off a 
chain reaction of inflammatory responses which begins with normal LDLs becoming 
internalised inside the artery wall and damaged by free radicals through oxidation (Figure 2-
1A-C).  This causes endothelial cells to secrete adhesion proteins which encourage capture 
and activation of monocytes, a type of white blood cell capable of differentiating into a 
macrophage that can phagocytose (engulf) various substances such as cell debris, microbes 
and any other foreign substances. A second consequence is recruitment of platelets to the 
injury site, which release additional inflammatory cytokines to encourage further aggregation 
of leukocytes (a type of white blood cell involved with counteracting foreign substances).  
The monocytes penetrate the compromised endothelial wall and differentiate into 
macrophages [16]. The process continues with further recruitment and ingestion of 
lipoproteins and cholesterols by the macrophages. The macrophages phagocytose the oxidised 
cholesterol and become ‘foam cells’.  The foam cells, along with cell debris and further 
inflammatory cells, form a fatty core [17], over which a fibrous cap of collagen, smooth 
muscle cells and elastin is formed, resulting in an atherosclerotic plaque [14] (Figure 2-1D). 
Accumulation of these plaques over time can narrow the lumen of the artery and, if severe 
enough, will restrict the flow of blood.  When this occurs within a coronary artery and oxygen 
demand outstrips supply, for example during physical activity, ischaemia results, leading to 
angina pectoris (otherwise known as angina) which causes chest pain but is not fatal [18]. If 
the plaque cap ruptures, blood clots can quickly form at the site of rupture, which can either 
completely block blood flow or can break away to cause a blockage elsewhere (Figure 2-1E). 
If this blockage is formed in one of the coronary arteries, then heart muscle (myocardium) 
downstream of the blockage can die as it is starved of oxygen, resulting in myocardial 





Figure 2-1 Development of atherosclerosis, leading to myocardial infarction and heart failure   
A) A healthy coronary artery: the lumen is lined with endothelial cells which are surrounded by 
smooth muscle cells. B) Damage to the lining of the lumen results in inflammation. The lining becomes 
permeable allowing LDLs inside the wall of the artery. Once inside, LDLs become oxidised which 
attracts white blood cells to the area. These penetrate the endothelial cells and mature into 
macrophages which can engulf the LDLs. C) Macrophages full of LDL cholesterol become foam cells 
which eventually burst to deposit cholesterol.  Accumulation of cholesterol results in plaque 
formation. D) This process continues, narrowing the lumen of the artery, reducing the blood flow and 
causing angina. Proteins and smooth muscle cells form a thin, fibrous cap over the plaque. E) If the 
cap ruptures blood clots can form that can block the artery or break away and block an artery 
elsewhere F) If blood flow in the coronary artery which supplies the heart muscle becomes blocked 
the heart muscle is starved of oxygen and can die causing myocardial infarction. G) An example of a 
normal, normal heart (left), a heart in failure with altered morphology and dilated left ventricle 




2.1.2 Myocardial Infarction, left ventricular remodelling and heart failure 
Under normal, aerobic conditions the heart generates most of its energy (90-95%) from fatty 
acid and carbohydrate (glucose and lactate) breakdown via mitochondrial oxidative 
phosphorylation, with the remainder supplied by glycolysis (the process of breaking down 
glucose without the need of oxygen). In the presence of oxygen, cardiomyocytes produce 
energy in the form of ATP using the aerobic oxidative phosphorylation pathway in 
mitochondria to produce 32 molecules of ATP per molecule of glucose. In contrast, under 
ischaemic conditions, mitochondrial oxidative phosphorylation decreases, and energy 
production is immediately shifted to anaerobic glycolysis which only produces 2 molecules of 
ATP per glucose molecule [20]. As there are no energy reserves in the heart, in severely 
ischaemic hearts a depletion of mitochondrial ATP occurs rapidly [21] The reduction in ATP 
leads to cell swelling caused by an increase in intracellular calcium and chloride ions 
(approximately a third of energy consumption under normal conditions is used to drive ion 
pumps). Eventually the osmotic overload becomes too much and the myocyte is irreversibly 
damaged leading to cell death [20]. 
Human cardiomyocytes have limited capacity to regenerate and cannot regenerate after MI 
[22]. MI causes both apoptosis (a controlled, programmed cell death) and necrosis (a less 
tightly controlled, unregulated cell death) of cardiomyocytes due to reduced oxygen supply 
[23].  After MI, a two-phase process is initiated in an attempt to repair the heart. An initial 
inflammatory response is triggered with leukocytes flooding into the infarcted area as they try 
to clear necrotic tissue and extracellular matrix debris [24]. This is followed by a proliferative 
phase defined by activation of fibroblasts to myofibroblasts. Myofibroblasts, usually absent in 
healthy myocardium, are phenotypically between smooth muscle cells and fibroblasts, and 
secrete large amounts of extra cellular matrix (ECM) proteins such as collagen into the 
interstitial space. This leads to expansion of tissue that has reduced contractile ability at the 




undergo hypertrophy (an increase in size, rather than number, of cardiomyocytes). This 
increases the volume of the left ventricle (LV), an initial compensatory process that improves 
stroke volume and cardiac output but over time further overloads the heart [26, 27].   
 
Reperfusion  (reoxygenation) after MI can save further loss of cardiomyocytes but can also 
cause more injury (up to 50% of MI injury) by damaging the microvasculature via oxidative 
stress [28].  
Together, these processes influence the size of the infarct, the degree of cardiac function and 
the amount of compensatory cardiac remodelling. After the initial compensatory response, 
ongoing cardiomyocyte hypertrophy in the non-infarcted border zone increases ventricular 
wall thickness and further enlarges the ventricular chamber, and there is a shift in the 
geometry of the ventricle from a normal elliptical shape to a spherical one [29].   
The remodelling process continues in an effort to compensate for reduced cardiac output, but 
eventually becomes detrimental. Ultimately, hypertrophy and scarring decrease cardiac 
contractility to the point where the heart cannot pump the blood sufficiently to meet the 
body’s demands and enters HF. [30]. The transition from compensatory to adverse 
remodelling is poorly understood, as is the biological reason why some people regain 
ventricular function whilst others do not [31].  
HF can be broadly classified into two groups depending on the volume of blood pumped from 
the left ventricle with each contraction (left ventricular ejection fraction, LVEF); HF with 
reduced ejection fraction (HFrEF, LVEF< 40%) or HF with preserved ejection fraction 
(HFpEF, LVEF ≥ 40%). LVEF is calculated by the:  
volume of blood pumped from the left ventricle per beat (stroke volume)  





Although HFrEF and HFpEF share the same clinical classification, they should be considered 
as two distinct subtypes of HF as they differ in terms of pathophysiology and aetiology, as 
well as treatment responses [32].  Because this thesis focuses on the progression of ischaemic 
heart disease and IHD and MI are more strongly associated with HFrEF than HFpEF, the 
following section on neurohormonal compensatory mechanisms will focus on HFrEF alone 
[33, 34].  
2.1.3 Neurohormonal compensatory mechanisms of HFrEF 
Cardiac output is a combination of heart rate and stroke volume (the volume of blood pumped 
at each contraction). In a healthy heart, if left ventricular contraction decreases there will be 
an incomplete emptying of the chamber. This leads to an increase in end diastolic volume (the 
volume of the blood in the ventricles just prior to contraction), an increased stretch of 
myocardial fibres and consequently an increase in force on the subsequent contraction (part of 
the mechanism known as the Frank-Starling law) [20]. This is not the case in the HFrEF heart, 
where there is ventricular impairment and a diminished contraction capability. In HFrEF, the 
heart cannot achieve the required stroke volume and cardiac output is reduced. To increase 
stroke volume, the ventricle responds by remodelling resulting in ventricular dilation.  The 
consequences of these factors are an increased end diastolic volume which leads to increased 
left atrial pressure and pulmonary venous pressure. These can cause a build-up of pressure 
behind the heart, which can force fluid into the lungs and result in shortness of breath and 
other congestive symptoms [35].    
Structural remodelling, a decrease in cardiac output and falling blood pressure all trigger 
compensatory neurohormonal mechanisms. These include the sympathetic nervous system 
(SNS), renin-angiotensin-aldosterone system (RAAS), natriuretic peptides and arginine 
vasopressin (AVP) [34, 36].  Activation of the SNS increases blood pressure by 
vasoconstriction (narrowing the blood vessels) and increases contractility and heart rate by 




SNS activation, the kidney releases the hormone renin into the bloodstream to activate the 
renin-angiotensin-aldosterone system (RAAS) in an attempt to raise blood pressure and blood 
volume [36]. Renin converts angiotensinogen to angiotensin I which is then processed to 
angiotensin II by the angiotensin-converting enzyme (ACE). Angiotensin II induces 
vasoconstriction and activates the antidiuretic hormones AVP and aldosterone. Both AVP and 
aldosterone regulate blood volume: AVP is both a potent vasoconstrictor and antidiuretic 
hormone (acts on the kidneys to decrease urine formation), whereas aldosterone causes an 
increase in reabsorption of sodium and water from the kidneys [36].   
Again, there is a temporary reprieve from the declining cardiac output however, prolonged 
exposure to these hormones leads to ever-increasing fluid and salt in the body and eventually 
into HF. Chronic SNS activity can lead to desensitising of cardiomyocytes to catecholamines 
(the hormones adrenaline and noradrenaline) leading to reduced contractility as well as 
cardiac arrhythmias [34]. Chronic exposure to the RAAS can lead to further myocyte 
hypertrophy and interstitial fibrosis thereby increasing detrimental remodelling [34]. To 
counteract the renin and aldosterone secretion, the heart releases the natriuretic peptides, atrial 
natriuretic peptide (ANP, released by the atria) and B-type natriuretic peptide (BNP, released 
primarily by the cardiac ventricles). These natriuretic peptides promote diuresis (increased 
production of urine), natriuresis (excretion of sodium in the urine) and vasodilation. 
Unfortunately, their effects soon become diminished as their target organs become less 
responsive through receptor desensitisation and/or further release of counter-regulatory 
hormones from the RAAS and SNS [37].  
The two cardiac natriuretic peptide hormones are worth introducing here as they are of 
considerable importance in HF. ANP is encoded by the gene NPPA, which is translated into a 
151 amino acid pre-prohormone (pre-proANP), and subsequently cleaved to produce the 
prohormone proANP1-126. A second cleavage of this prohormone produces the biologically 




circulation is approximately two minutes although proANP is more stable. Assays have been 
developed to detect the mid region of proANP (MR-proANP) which show it provides similar 
diagnostic (and prognostic) information as NT-proBNP (described in the following section, 
1.1.5) in patients with acute HF [38]. 
The gene encoding BNP, NPPB is transcribed and translated in response to cardiac ventricular 
myocyte stretch in the form of pre-proBNP, a 134 amino acid peptide [39]. This peptide is 
cleaved to remove a 26 amino acid signalling peptide leaving the prohormone proBNP1-108. A 
second cleavage of this prohormone produces the biologically active C-terminal peptide 
BNP1-32 and the inactive (N-terminal) NT-proBNP which are both released into circulation.  
Whereas BNP is cleared from plasma by the natriuretic peptide clearance receptor type-C and 
proteolysis, NT-proBNP is thought to be cleared from plasma by renal excretion. BNP has a 
half-life of 20 minutes in circulation whereas NT-proBNP has a half-life of 120 minutes 
which has considerable advantages for use as a biomarker [40-42].  
2.1.4 Biomarkers for heart failure 
For patients presenting to the emergency department with breathlessness, there needs to be a 
fast and accurate test to distinguish between HF or pulmonary disease. Traditionally HF 
diagnosis consisted of taking a clinical history, along with a chest X-ray or echocardiogram.  
However, X-rays have low sensitivity and specificity for making a clinical diagnosis of HF 
[40] and both X-rays and echocardiograms may be difficult to obtain out of the normal 
working hours in the acute setting. In the last 20 years, the natriuretic peptides have emerged 
as the international gold standard for HF diagnosis [9].  In the early 2000’s, the Breathing Not 
Properly Study (B.N.P. Study) was the first major study (1586 patients) to look at circulating 
BNP levels in patients presenting to the emergency department with acute breathlessness [43] 
(the very first study to measure ANP and BNP to assess their effectiveness at diagnosing HF 
was from the Christchurch Heart Institute [44]). Not only were higher BNP levels seen in 




± 450 pg/mL versus 110 ± 225 pg/mL, respectively; p=0.001) but the levels of BNP 
correlated with increasing severity of HF. Using a BNP cut-off of 100 pg/mL, BNP 
concentration had a 90% sensitivity and 76% specificity for HF and using a cut off of 50 
pg/mL, BNP had a negative predictive value of 96%. 
Building on this work, the ICON (International Collaborative of NT-proBNP) clinical trial 
investigated NT-proBNP (the amino terminal fragment of BNP) in 1,256 patients presenting 
with new-onset shortness of breath at emergency departments in New Zealand, the United 
States, Spain, and the Netherlands [45]  The trial reported much higher circulating levels of 
NT-proBNP in patients with HF compared to those without (4,639 pg/ml versus 108 pg/ml, 
respectively; p<0.001) and again, plasma concentrations increased with HF severity. Using a 
cut-off of 300 pg/mL of NT-proBNP was sufficient to rule out acute HF with a sensitivity of 
99% and a specificity of 60%. Because circulating concentrations of the natriuretic peptides 
increase with age, the investigators also developed age stratified cut-off points to improve 
specificity of a rule-in test (Table 2-1) [45]. These cut-off levels are now used in international 
guidelines for the diagnosis of HF [9].  
Table 2-1 Adapted from Januzzi et al 2006 [45]. Rule-out and age stratified ‘rule-in’ cut off levels of 
NT-proBNP for diagnosis of acute heart failure.  
Category Optimal cut off (pg/mL) Sensitivity (%) Specificity (%) 
Rule out (n=1256) 300 99 60 
      Rule in 
<50 years old (n = 184) 450 97 93 
50-75 years old (n = 537) 900 90 82 
> 75 years old (n=535) 1800 85 73 
pg/mL = picogram per millilitre 
While the ICON study primarily looked at diagnostic capabilities, they also demonstrated 
levels of NT-proBNP as a prognostic biomarker for survival in patients with acute HF during 




NT-proBNP as independent predictors of all-cause death and of readmission for chronic 
HFrEF [46-48]  Again, of note, both BNP and NT-pro BNP are also strong predictors of 
adverse events (death, HF, and new myocardial infarction) after MI. [49, 50] 
2.1.5 Limitations of natriuretic peptides 
Unfortunately, circulating concentrations of the natriuretic peptides can vary in response to a 
range of physiological factors, in addition to HF.  These include age, gender, obesity, atrial 
fibrillation, renal failure, anaemia, or inflammation of the heart muscle (myocarditis) [9]. 
Further, most studies have been carried out on patients of European ancestry and do not 
account for differences in natriuretic peptide levels across ethnic groups. A meta-analysis 
looking at BNP levels in 92,072 HF patients from white, black, Hispanic and Asian 
populations showed that despite having similar severity of disease Asian and black patients 
had higher BNP levels at admission compared with white and Hispanic patients, although 
BNP provided prognostic value regardless of ethnicity [51]  Another complication is that the 
natriuretic peptides are excreted by the kidneys and so concentrations can potentially be 
elevated in patients with renal failure without HF [52].  
These potential confounding factors are compounded by the considerable variation can be 
apparent between patients in the extent of the initial myocardial insult, prior medical history 
and lifestyle factors. Variability of BNP levels are due to several factors including age, 
gender, kidney function, atrial fibrillation and BMI. Certain confounders also seem to cluster 
in certain ethnic groups with Maori and Pasifika having higher BMI than Pakahe. A recent 
paper suggests that the pro-BNP precursor is glycosylated  (affecting both cleavage to form 
BNP / NT-proBNP and antibody binding in the laboratory assays). Also, there seems to be 
higher glycosylation with a higher BMI. It may be the case that a different class of biomarker 
(RNA and not protein) would avoid this issue of glycosylation but there could also be an 
underlying genetic component even after adjusting for confounders. If this is the case then this 




Thus, despite the utility of the natriuretic peptides in diagnosis and prognosis in HF and in 
prognosis post MI, it remains difficult to identify patients at risk of progression from 
myocardial ischaemia/infarction to ischaemic HF. 
2.1.6 Other cardiac biomarkers and their limitations 
Troponin is a protein made up of three subunits (troponin C, troponin I and troponin T) and is 
found in both cardiac and skeletal muscle. Because the I and T subunits are structurally 
different in the heart compared to skeletal muscle, this makes them specific to cardiac 
myocyte injury [53]. Cardiac specific troponin T (cTnT) and troponin I (cTnI) are released 
into the circulation by cardiomyocytes after cardiac injury and remain elevated for multiple 
days afterwards.  High sensitivity assays for cTnT and cTnI have significantly improved the 
diagnostic accuracy of MI as they detect troponin at much lower concentrations [54]. The 
European Society and American College of Cardiology define acute MI as an increase in 
serum troponin greater than the 99 percentile of a healthy reference population (with other 
signs of cardiac ischaemia [53]. 
Troponin levels are also elevated in patients with HF [55]; however, they are a marker for 
myocardial injury rather than a specific marker for HF and are useful in risk stratification [9].  
C-reactive protein (CRP) is synthesised by hepatocytes and is part of the immune response.  
Early studies demonstrated increased CRP levels in individuals with ongoing ischaemia, 
unstable angina and chronic atherosclerotic disease [56]. The Physicians Health Study (PHS) 
demonstrated that high-sensitivity C-reactive protein (hsCRP) is elevated decades before the 
first acute ischaemic event and is a strong predictor of risk of acute MI [57, 58].  HsCRP is a 
clinically useful biomarker however, there is doubt as to whether CRP is itself a target for 
intervention and upstream cytokines in the inflammatory response such as interleukin-6and 




marker and could be elevated by a number of diseases or injuries and needs to be interpreted 
in a clinical context.  
Elevated hsCRP levels are also associated with HF [60].  However, a meta-analysis showed 
that there were discrepancies of hsCRP cut-off values when used for stratifying patients for 
HF development between studies; most studies included only subjects older than 65 years and 
sex differences were apparent [61]. In addition to the natriuretic peptides, Galectin-3 
(expressed during tissue inflammation, repair and fibrosis) [62] and ST2 (Soluble Interleukin 
1 receptor-like 1,expressed by cardiomyocytes in response to mechanical stress) have also 
been proposed for HF [63]. However, because they lack specificity for HF the American 
College of Cardiology (ACC) and American Heart Association (AHA) currently recommend 
they be for additive risk stratification to the natriuretic peptides [64]. 
2.1.7 Future Biomarkers? 
Until recently biomarkers have generally been proteins or peptide neurohormones. The 
cardiac troponins and the natriuretic peptides are currently the gold standard markers for 
diagnosis of MI and HF respectively, but they have their limitations discussed above. 
Cardiovascular disease is complex; many factors influence the speed and route from sub-
clinical atherosclerosis to MI to ischaemic HF and how severely an individual will be 
affected. The aim of this thesis is to identify new candidate markers to improve detection of 
ischaemia, MI, and prediction of progression from ischaemic heart disease to ischaemic HF. 
This thesis investigates potential RNA biomarkers an alternative molecular class to proteins, 
neurohormones and DNA. 
There is relatively new field of genomics which focusses on the non-coding genes of the 
genome. Only 2-3% of the human genome codes for proteins and around 80% is transcribed 
into non-coding RNA [65]. While a considerable proportion of non-coding RNAs represent 




ribosomal RNAs (rRNAS), over the last 20 years discoveries in the fields of lncRNAs, 
circRNAs and microRNAs (miRNAs) suggest important roles for these newer classes of non-
coding of RNAs in almost all cellular processes. Non-coding RNAs of all three classes have 
been implicated in many disease states and their roles as biomarkers are beginning to be 
established [66-68]. Although miRNAs are a group of non-coding RNAs they are beyond the 
remit of this thesis. miRNAs are well studies as biomarkers in comparison to lncRNAs and 
circRNAs. This thesis focusses on the more understudied class of noncoding RNAs. The 
following sections discuss lncRNAs and circRNAs in detail, their biogenesis, functions, and 
finally their role in cardiovascular disease. 
2.2 The Long Non-Coding Genome 
2.2.1 LncRNAs – An overview 
The rather protein-centric view of molecular biology, with its central dogma of DNA being 
transcribed to RNA and then translated into protein, is having to be rethought. One of the 
biggest misnomers in genetics has been the term ‘junk DNA’ [69]. A belief in a vast 
transcriptional wasteland residing in our genome was encouraged by the C-paradox (Swift, 
1950). This term was coined in the 1950s to describe the puzzling disparity between the size 
of an organism’s genome and its complexity. It was assumed that the complexity of an 
organism would be correlated with the amount of cellular DNA content, but this was not the 
case - the single-celled amoebae has a genome up to 100-fold larger than the human genome 
[70].  The Human Genome Project, completed in 2004, added a second paradox - the G-value 
paradox which assumes a relationship between an organism’s complexity and its number of 
protein-coding genes [71]. Instead of the original prediction of around 100,000 protein-coding 
genes, humans had a mere 31,000 (which was later re-estimated to be around 21,000).  More 
than 97% of our genome does not code for protein [72] thus, rather than the size of the 
genome or the number of protein-coding genes, it is the relative abundance of non-protein-




with an organism’s complexity [73]. Many of these non-coding regions are conserved across 
mammalian species suggesting their biological importance [74]. 
In the mid 2000’s, two large scale projects from the FANTOM (Functional Annotation of 
Mammals) and ENCODE (Encyclopedia of DNA Elements) consortia set out to provide a 
comprehensive catalogue of mammalian transcription. In 2005, the FANTOM Consortium 
concluded that there were more non-coding genes than coding genes in the mouse genome 
[75] and, in 2007, the ENCODE Consortium began a pilot project to delineate all functional 
elements encoded in the human genome [76]. Their seminal paper which comprised 32 
institutions studying 147 cells types was published five years later [77]. From this study they 
assigned 80% of the genome to be biochemically active (in other words transcribed or 
potentially functional), most of which is not translated into protein and is termed non-coding 
RNA. The rapid pace of discovery in this non-coding world can be attributed to the 
development of RNA-Seq technologies that have allowed the transcriptome to be sequenced 
to greater depths with greater precision enabling the discovery of rare transcripts. This is 
especially pertinent to certain classes of non-coding RNAs, such as lncRNAs, as these 
transcripts are typically less abundant than protein-coding transcripts [78].  
Non-coding RNAs are rather arbitrarily separated into two groups depending on their length. 
Any transcripts shorter than 200 nucleotides are categorised as ‘small non-coding RNA’. This 
group is heterogeneous and contains the well-known  RNAs such as rRNAs and transfer 
RNAs (tRNAs), both essential for messenger RNA (mRNA) translation, as well as small 
nuclear RNAs (snRNAs), involved with RNA splicing; small nucleolar RNAs (snoRNAs), 
which guide chemical modifications of other RNAs; miRNAs and short interfering RNAs 
(siRNAs), both involved with transcriptional and post-transcriptional silencing; piwi-
interacting RNAs (piRNAs), which act to silence transposons in germ cells, and more 
recently; transcription initiation RNAs (tiRNAs) and splice site RNAs (spliRNAs) which are 




LncRNAs are transcripts longer than 200 nucleotides that lack protein-coding potential [78]. 
Over the last decade there has been an explosion of novel lncRNAs being discovered due to 
the rapid development of accurate, high-throughput sequencing technologies, as well as 
decreasing costs and enhancements in bioinformatic analysis tools [80, 81].  The arrival of 
third generation sequencing technologies, bypassing the need for PCR amplification steps, 
generate much longer read lengths. With these advantages in mind, it is tempting to think that 
the list will continue to grow or, at the very least increase the accuracy and completeness of 
lncRNA annotations [82]. Although the functional roles of many lncRNAs have yet to be 
determined, numerous lncRNAs have already been implicated in diseases ranging from cancer 
[83], neurological disorders [84], diabetes [85] and DNA imprinting [86]. In the coming 
years, many more lncRNAs may be implicated in disease as a result of large-scale searches 
for genetic variants that differ in frequency between healthy and diseased individuals 
(genome-wide association studies GWAS), which have concluded that >90% of our inherited 
susceptibility for disease comes from these non-coding regions [87]. 
The following sections of the literature review discusses lncRNA annotation which leads on 
to lncRNA classification. The next part discusses their functions within the nucleus and then 
the cytoplasm. The final part discusses our current understanding of their role as biomarkers 
in cardiovascular disease and their roles in atherosclerosis, MI and cardiac remodelling/HF.  
2.2.2 Annotation – the state of play 
Perhaps the largest challenge facing the non-coding RNA field at present is to collate a 
thorough and comprehensive ‘gold standard’ annotation resource. Numerous lncRNA 
annotation resources exist [88-96]; however, with differing techniques and cell/tissue types 
used for discovery of lncRNAs, there are inconsistencies and variation amongst them. The 
predicted number of human lncRNA genes ranges from 15,787 to 144,134 (from GENCODE 
version 26 [88] and NONCODE 2016 [91] respectively) with human lncRNA transcripts 




lncRNA annotation resources and found that 88% of lncRNA transcripts were unique to one 
resource with only 8 transcripts showing the same exon structure in 5 resources. This figure is 
even more disappointing when looking at the subset of long intergenic non-coding RNAs 
(lincRNAs) with 91% of transcripts being unique to one resource and the remaining 9% 
occurring in only 2 resources [97]. The task of mapping millions of short reads correctly onto 
the current reference genome annotation and then assembling these into novel transcripts is 
not a trivial one, and bioinformatic software has not yet achieved 100% specificity and 
sensitivity. Added to this, potential technical issues such as the methods of preparation of the 
RNA before sequencing may introduce bias in coverage of the transcriptome [98]. This could 
potentially introduce errors in recognising all constituent exons, which may lead to 
assembling incomplete isoforms. As mentioned earlier, this problem should be improved with 
the advent of much longer reads generated with third generation sequencing technologies. The 
GENCODE consortium within the ENCODE project has for several years been manually 
annotating a comprehensive set of human lncRNAs [78]. This constitutes the largest manually 
curated catalogue of human lncRNAs, making it a good reference point. There are also 
several databases attempting to provide accurate, manually curated, online repositories from 
various sources of annotations [90, 97, 99, 100]. A recent database has been established which 
integrated several previous databases to provide a repository of experimentally validated 
lncRNAs [101]. This is an important next step in accurately classifying this relatively new 
class of non-coding RNA. Indeed, current annotation may overestimate the numbers of 
lncRNAs. A growing number of transcripts that have been mistakenly classified as lncRNAs 
have been shown to have short open reading frames (sORFs) that encode functional peptides 
known as micro peptides [102-105]. As bioinformatic and functional techniques evolve to 
identify these micro peptides and potentially other forms of coding RNAs, it will be a 




2.2.3 Characteristics of lncRNAs 
On first glance it appears that lncRNAs are mRNAs that lack an open reading frame (ORF); 
they are both transcribed by RNA polymerase II (RNAPII) from loci with similar epigenetic 
marks at their promoter regions [74]. LncRNAs are present in the nucleus and/or the 
cytoplasm and are mostly thought to be 5’-capped (7-Methyl guanosine (m7G) capping at the 
5′ end occurs during the initiation phase of Pol II transcription), spliced and polyadenylated 
(poly-A) [106]. However, there are also distinctions: lncRNAs generally have fewer exons 
(on average 2.8 exons in lncRNAs compared to 11 exons in protein-coding genes [107], with 
nearly half having just two exons (42% of lncRNAs have two exons compared to 6% of 
protein-coding genes [78]). LncRNAs typically have lower expression levels (10-fold lower) 
and appear to show a high degree of cell type-, tissue-, developmental stage or disease state-
specificity [107, 108]. They have fewer conserved primary sequences, [106], although the 
level of conservation is higher at lncRNA exon splice sites and much higher at their promoters 
[109]. This reduced conservation at primary sequence level compared to mRNAs is perhaps 
unsurprising given the fact that lncRNAs do not have to maintain stringent amino acid coding 
sequences.  LncRNAs can form complex secondary and tertiary structures [110] and the 
functional domains formed from this 3-dimensional folding are thought to be more strictly 
conserved than their primary sequence. Reports have shown cross-species, tissue-specific 
conservation of expression in equivalent genomic loci despite no nucleotide sequence 
conservation [111]. Early predictions were that 40% of lncRNAs are polyadenylated [112], 
but as the majority of studies may have been biased towards detecting poly-A transcripts (by 
using oligo dT primers) for cDNA synthesis in library preparation for transcriptome analysis), 
this figure may be an overestimate. A study by Zhang et al (2014) demonstrated that lncRNAs 
can be processed into mature transcripts and stabilised through non-canonical pathways such 




3’end, or capped by snoRNP complexes at both ends [113]. Consequently, this group of 
lncRNAs do not have poly-A tails.  
In general, lncRNAs are sub-divided by their location with respect to protein-coding genes, 
[97, 114, 115]. To date the subclasses are promoter upstream transcripts (PROMPTs), 
enhancer RNAs (eRNAs, described in detail below), natural antisense transcripts (NATs), 
intronic lncRNAs and long intervening/intergenic ncRNAs (lincRNAs), (Figure 2-2). 
The definition of promoter-upstream transcripts (PROMPTs) is somewhat arbitrary and 
depends on the distance between the transcription start sites of a protein-coding gene and the 
lncRNA. If they share the same start site, they are technically bidirectional, but this term has 
been used for lncRNA and protein-coding gene pairs with up to 100 base pairs separating 
their divergent start sites [116]. Wu et al, 2017 define this subclass as lncRNAs transcribed in 
the antisense orientation, approximately 0.5-2.5kb upstream of the active transcription start 
sites (TSSs) of protein-coding genes [117]. 
Enhancer RNAs (eRNAs) are bidirectionally transcribed from enhancers with the two 
directions producing equivalent levels of RNA [118]. Along with PROMPT lncRNAs this 
subclass has rapid turnover rates as they are targeted by nuclear RNA exosomes (a multi-





Figure 2-2 Classification of lncRNAs based on their genomic location. 
A) promoter associated lncRNAs (PROMPTS) are transcribed from the sense (not shown) or 
antisense strand from sequence within the promoter sequence B) Enhancer lncRNA from 
direct, bi-directional transcription of enhancer elements C) Natural antisense (NATs) 
lncRNAs are transcribed from the antisense strand and may share complementary sequence 
with the protein coding gene D) Intronic lncRNAs are located within intron(s) of a protein 
coding gene E) Long intergenic (Linc)RNAs are transcribed between genes. Blue lines 
represent the RNA sequence, blue boxes represent protein coding exons, red boxes represent 
lncRNA exons, red and blue arrows show the direction of transcription start sites, black lines 
represent gaps in the DNA sequence up to mega bases long. 
Natural antisense lncRNAs overlap any exon of a protein-coding gene but on the opposite 
strand and contain complementary sequences to the mature mRNA. It is thought that up to 
63% of transcripts have an associated antisense transcript, many of which are not protein-
coding [119]. The FANTOM consortium suggest that these sense/antisense pairs can either 
directly interact or that they are separately regulated, the difference suggesting whether the 
antisense transcript is acting in cis or trans [120] 
Intronic/Overlapping lncRNAs are encoded within an intron of a protein-coding gene and can 




thought to represent transcriptional noise (i.e. unprocessed pre-mRNAs) but has now been 
shown to be transcribed independently of exonic mRNAs, suggesting they are functionally 
independent [121]. This transcriptional autonomy is also strengthened by studies that show 
they can be transcribed from either the sense or antisense strand [122, 123].Long Intergenic 
RNAs (lincRNAs) do not overlap with protein-coding genes and are distant from any 
promoter regions or from neighbouring genes.  
There are conflicting reports as to which group of lncRNAs is most actively transcribed. The 
GENCODE study [78] suggested that the majority of transcripts (64%) are long intergenic 
RNAs (lincRNAs) whereas a later study by St Laurent et al. (2012) suggested that intronic 
RNAs form the largest single class of lncRNAs, making up 35% of all lncRNAs [121]. Again, 
this discrepancy highlights the need for a more complete and robust annotation for lncRNA.  
2.2.4 Functions of lncRNAs 
It is now accepted that lncRNAs regulate gene expression in the nucleus and the cytoplasm 
[115], where they operate at both transcriptional and translational levels [124]. Their modes of 
operation are diverse, which reflects the versatility of the RNA molecule itself – it can form 
numerous secondary structures and bind specifically to RNA, DNA and proteins [125]. 
Because lncRNAs are not translated as their mRNA counterparts are, they can function as 
soon as they are transcribed within the nucleus and so act upon their targets much quicker. 
They can also be rapidly up- or down-regulated making them effective regulators of gene 
expression [126].  
2.2.5 Functional mechanisms of lncRNA within the nucleus 
Within the nucleus, lncRNAs can act in cis or trans. The cis transcripts act upon a nearby 
gene on the same allele (typically within 1Mb of the gene TSS); the trans transcripts interact 




A growing evidence-base from functional studies suggest mechanisms as to how lncRNAs 
within the nucleus regulate gene expression. These include identifying and targeting specific 
sites on DNA to influence gene expression, tethering themselves to chromatin and acting as 
scaffolds for regulatory protein complexes and regulating compartmentalisation of the nucleus 
to sequester regulatory elements.  
2.2.5.1 Localisation to DNA 
Some lncRNAs exert their function by identifying and targeting specific sites on DNA. 
Engreitz et al, 2016 suggest two main strategies: firstly, via high affinity interactions with 
chromatin by binding to chromatin directly or via chromatin bound proteins, and secondly by 
three-dimensional (3D) proximity from their site of transcription (chromosomal 3D 
organisation is evolutionary conserved and looping of the DNA brings into proximity 
distantly related regulatory elements [128]).  Examples of lncRNAs binding DNA using these 
strategies include MALAT1, HOTTIP and XIST. 
MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), an abundant and 
stable lncRNA, solely uses affinity interactions to localise to its targets at distant sites. 
MALAT1 is a highly conserved lncRNA and a regulator of mRNA splicing, and appears to be 
recruited to sites of actively transcribed mRNA, many of which are at sites distant to its own 
transcription site [129, 130].  
In contrast, chromosomal looping brings the lncRNA HOTTIP (HOXA transcript at the distal 
tip) into proximity to its target homeobox genes. The homeobox (HOX) gene cluster are a 
group of related genes that control the body plan of the embryo along the anterior-posterior 
axis. HOTTIP is a lncRNA expressed at the 5’ end of the HOXA group on chromosome 7 and 
regulates activation of several of the downstream HOXA genes. HOTTIP directly binds the 
chromatin modifying WD Repeat Domain 5 (WDR5) and mixed-lineage leukemia 1 (MLL1) 




modifications for gene transcription [131]. When Wang et al knocked out HOTTIP, the 
WDR5 and MLL proteins were not observed at their usual locations at the transcription start 
sites. Expressing HOTTIP from another region of the genome was not able to rescue these 
effects indicating that HOTTIP must work from the chromosome it is transcribed from. 
Indeed, by using chromosome conformation capture techniques (a method to analyse the 3D 
spatial organisation of chromatin within the nucleus) the authors were able to show chromatin 
looping, demonstrating HOTTIP in physical proximity to its target genes (Figure 2-3). 
Lastly, X-inactive specific transcript (XIST) is an example of a lncRNA that utilises both 
strategies to exert its function of silencing one of the X chromosomes in female somatic cells. 
XIST uses a high affinity mechanism to bind to chromatin via scaffold attachment factor A 
(SAFA).  Knockdown of SAFA leads to dispersed localisation of XIST and the loss of X 
chromosome inactivation [132-134].  However, this affinity interaction cannot fully explain 
the mechanism by which XIST exerts its function, as SAFA is apparent across the autosomes 
as well as the other X chromosome.   
High resolution studies show that XIST localises to DNA regions that are in close three 
dimensional proximity to its transcription site; by moving XIST to another part of the X 
chromosome (using a cell line that expresses XIST from a transgene at a locus ~ 50 Mb 
proximal to the endogenous XIST locus) a new localisation pattern occurred which reflected 






Figure 2-3 An example of a lncRNA using a proximity mechanism to exert its function of recruiting 
mediator proteins to influence gene transcription. 
HOTTIP lncRNA stimulates the transcription of HOXA genes by enforcing H3K4me3 chromatin 
modifications via the chromatin modifying proteins WDR5 and MLL1.  This function is enabled by the 
DNA looping bringing the HOXA genes into the vicinity of HOTTIP lncRNA Red boxes indicate the 
HOX genes, the blue box represents the HOTTIP locus, the red line represents HOTTIP lncRNA and 
green circles show H3K4me3 chromatin modifications.(Modified from [137]) 
It seems that highly abundant and stable lncRNAs such as MALAT1 can use affinity 
mechanisms alone, whereas low abundance lncRNAs such as HOTTIP, which is present at <1 
copy per cell, regulates genes in very close proximity [138]. XIST sits somewhere in between 
and uses a combination of both mechanisms.  
2.2.5.2 LncRNAs as scaffolds 
LncRNAs have discrete domains within their secondary structure that can interact specifically 
with different proteins as well as DNA and RNA [127, 138]. These functional domains appear 
to have a high level of conservation and act to recruit various regulatory factors in a co-
ordinated way to regulate transcription [139]. A good example of this is XIST, which 
physically interacts with protein and DNA at the same time (described above). Once tethered, 
discrete regions of the XIST transcript can bind specific protein complexes independently of 
one another. In doing so, XIST co-ordinates chromatin modification and chromatin 




action involves a different homeobox (HOX) gene cluster to that described above, on 
chromosome 12 (Figure 2-4). The timing of expression of the HOX genes is precisely 
controlled by the lncRNA HOX transcript antisense RNA (HOTAIR) through simultaneous 
binding of regulatory proteins. HOTAIR acts as a scaffold to the histone modifying 
complexes polycomb repressive complex 2 (PRC2) at its 5’ domain and lysine (K)-specific 
demethylase 1A (LSD1) complex at its 3’ domain. Both proteins are involved with epigenetic 
DNA methylation to repress gene expression.  In acting as a scaffold to these two repressive 
protein complexes and guiding them to their target genes the lncRNA HOTAIR co-ordinates 
and maintains epigenetic repression over a 40-kb region of the chromosome [125, 142, 143].  
 
Figure 2-4 LncRNAs can act as scaffolds  
HOTAIR is transcribed from the HOXC cluster on chromosome 12. It acts as a scaffold to 
histone modification complexes PCR2 and LSD1 to regulate gene expression in a trans acting 
manner 40kb away on chromosome 2 (modified from [144]). 
2.2.5.3 LncRNAs and the 3D structure of the nucleus 
LncRNAs are also involved with organising the 3D conformation of the nucleus.  The 
lncRNA FIRRE (functional intergenic repeating RNA element), which is transcribed from the 
X chromosome, can influence the nuclear architecture across chromosomes by interacting 
with Heterogeneous nuclear ribonucleoprotein U (hnRNPU) and DNA on chromosomes 




When FIRRE is knocked out, this trans-chromosomal co-localisation is lost and there are 
transcriptional changes in the genes within these DNA regions. These genes are involved in 
energy metabolism/adipogenesis [146], suggesting that FIRRE coordinates expression of 
energy metabolism/adipogenesis by orchestrating this compartmentalisation of the genes 
involved in this biological process. 
 
Figure 2-5 LncRNAs can modulate the 3D chromatin structure 
The lncRNA FIRRE is transcribed form chromosome X and binds hnRNPU to interact with 
and regulate genes on other chromosomes forming its own subcellular compartment. Red 
lines represent FIRRE lncRNA, yellow hexagons represent hnRNPU (Modified from [145] 
Another notable example of a lncRNA modulating the 3D structure of the nucleus is NEAT1 
(nuclear enriched abundant transcript 1), which regulates the formation and maintenance of 
paraspeckles within the nucleus [147]. Paraspeckles are compartments within the nucleus that  
are thought to sequester mRNA and RNA-binding proteins (RBPs) to limit their function 
[148]. Knockdown of NEAT1 results in the loss of the paraspeckles and expressing it 
elsewhere in the genome results in ectopic paraspeckles formation [147, 149]. 
2.2.6 Functional mechanisms of lncRNA within the cytoplasm 
The subcellular location of a lncRNA is key to determining its function and there are 




cytoplasm [78, 150, 151].  Quinn and Chang make the interesting case that rather than debate 
their predominant location, it should be accepted that lncRNAs are ubiquitous throughout the 
cell. [106].  
Following export to the nucleus, mRNAs can be regulated by several post-transcriptional 
mechanisms. Implicated in these different mechanisms are lncRNAs, which influence mRNA 
stability, mRNA translation rates and levels of miRNAs within the cytoplasm that in turn 
have an effect on post-transcriptional regulation. 
2.2.6.1 The stability of mRNAs 
LncRNAs have been shown to both increase and decrease the stability of mRNAs. One 
mechanism by which lncRNAs decrease mRNA stability is by STAU1-mediated mRNA 
decay (SMD). STAU1 is a double-stranded RNA binding protein that binds to 
transcriptionally active mRNA at its 3’ untranslated region (3’UTR) [152] (Figure 2-6A).   
 
Figure 2-6 Mechanisms of lncRNAs in the cytoplasm 
In the cytoplasm lncRNAs can influence mRNA stability, mRNA translation and levels of 
miRNAs A) 1/2-sbsRNA is an example of a lncRNAs that can decrease stability of its target 
mRNA B) In contrast, BACe1-AS increases stability of mRNA C) LncRNAs can modulate 
mRNA translation by either inhibiting translation e.g. lincRNA-p21 which can interact with 




targets Uchl mRNA to active polysomes for translation E) Some lncRNAs such as H19 can 
give rise to miRNAs, in this case miR-675 F) LncRNAs can act as competing endogenous 
RNAs (ceRNAs) and in this way modulate gene expression.  LncRNAs bind miRNAs which 
sequester them and prevent them from degrading their target mRNA. 
The authors showed binding of STAU1 to mRNA is regulated by a group of lncRNAs which 
the authors name ½- Staufen 1-binding site lncRNAs (½-sbsRNAs). Binding occurs through 
Alu elements (a repetitive sequence common throughout the human genome) at the 3’ UTR of 
the targeted mRNA and another Alu element on the lncRNA. STAU1 then recruits the RNA 
helicase UPF1 which promotes decay. Conversely, other lncRNAs increase mRNA stability, 
through sense/antisense binding with their complementary mRNA. For example, base pairing 
between human β-site APP-cleaving enzyme 1 (BACE1) and its antisense lncRNA BACE1-
AS increases BACE mRNA stability and consequently BACE1 protein abundance [153]. The 
formation of this duplex masks a binding site for miRNA miR-485-5p and consequently 
prevents its degradation (Figure 2-6B). 
2.2.6.2 The translation of mRNAs 
In addition to altering mRNA stability, lncRNAs can alter protein expression by controlling 
the rate at which their target mRNAs are translated into protein. LincRNA-p21 inhibits 
translation by base pairing with complementary mRNA transcripts and enhancing the 
interaction between the mRNA and translational repressors RCK/DDX6 (DEAD-Box 
Helicase 6). RCK/DDX6 interacts with argonaute proteins which are a class of proteins that 
act as repressors of translation [154] (Figure 2-6C).  In contrast, the antisense Uchl1 (ubiquitin 
carboxy-terminal hydrolase L1) lncRNA forms a duplex with the 5’ end of Uchl mRNA and 
targets the mRNA to polysomes for translation (Figure 2-6D) [155].  
2.2.6.3 LncRNAs and miRNAs 
Lastly, some lncRNAs, such as H19, modulate gene expression through miRNA mechanisms. 
H19 RNA primarily exists in the cytoplasm and functions as RNA regulators [156], its first 




induced during skeletal muscle differentiation.  In myoblasts, knockdown of H19 reduced 
skeletal muscle differentiation, a phenotype that could be rescued by expression of miR-675-
3p and miR-675-5p [157] (Figure 2-6E). Other lncRNAs act as miRNA ‘sponges’, to 
sequester them and prevent their action on mRNAs. Within the cytoplasm a complex 
regulatory circuitry exists that is mediated by crosstalk among miRNAs, mRNAs and 
lncRNAs. Downregulation of miRNA interacting lncRNAs leads to an increase in the 
availability of miRNAs and a decrease in mRNA translation; conversely overexpression of 
lncRNAs leads to fewer miRNAs and an increase in mRNA translation (Figure 2-6F). 
2.2.7 Enhancer RNAs (eRNAs) 
There is another class of non-coding RNA within the nucleus called enhancer RNAs 
(eRNAs), although the classification of eRNAs and lncRNAs is a little blurry [158]  
Enhancers are regulatory DNA elements that bind proteins to promote gene expression [159]. 
Two studies in 2010 demonstrated the expression of stimulus-dependent RNAPII 
transcription of bi-directional, non-polyadenylated non-coding RNAs at enhancer sites which 
were termed enhancer-derived ncRNAs or eRNAs [109, 160]. These studies showed that the 
level of eRNA expression at enhancers positively correlated with the level of mRNA 
synthesis at nearby genes. This suggested that this stimulus-dependent eRNA transcription 
was specifically occurring at enhancers that were actively involved in downstream mRNA 
synthesis [160]. Since 2010 eRNAs transcription has been confirmed in many cell types and 
tissues by FANTOM and ENCODE [118, 161] and estimations of 40,000 to 65,000 different 
eRNAs throughout the genome demonstrates their biological importance [118, 162].   
Two potential functional mechanisms of eRNAs involve acting as decoys to RNA Pol II 
repressors and regulating conformational change in DNA.  eRNAs can regulate transcription 
by acting as decoys to complexes that are involved in RNAPII activity. The negative 




stimulus-responsive genes in higher eukaryotes [163]. The authors demonstrated activity-
regulated cytoskeletal protein (Arc) eRNA acts as an RNA decoy to bind NELF which 
facilitates NELF mediated RNAPII pausing back to RNAPII elongation (Figure 2-7A). 
In addition, eRNAs can facilitate looping of DNA enabling enhancer-bound regulatory 
proteins to interact with RNA Pol II transcriptional machinery and activate gene transcription. 
This is demonstrated by the Kallikrein-related peptidase 3 (KLK3) and the Nuclear Receptor 
Interacting Protein 1 (NRIP1) genes.  These were shown to interact with the Mediator 
complex (a multiprotein complex required for regulating transcription [164]) and Cohesin to 
promote DNA looping. Knockdown of NRIP1 eRNA showed reduced promoter: enhancer 
interaction [165] (Figure 2-7B). 
 
Figure 2-7 Example functions of Enhancer RNAs (eRNAs) 
A) Due to chromatin looping the ARC gene and enhancer are in proximity. Upon stimulation, 
transcription from both the ARC gene and enhancer element is initiated.  ARC Enhancer 
RNAs (eRNAs) can then mediate the exit from RNA polymerase II (RNA Pol II) pausing by 
acting as a decoy to the negative elongation factor (NELF) complex.  B) The Kallikrein-




facilitates the interaction enhancer and promoter regions to activate transcription. eRNAs 
like NRIP1 can also interact with Cohesin which acts as a ring to connect two regions of 
DNA 
2.2.8 LncRNAs, Ischaemic Heart Disease (IHD) and Heart Failure (HF) 
There is a growing literature supporting the role of lncRNAs in a wide spectrum of biological 
processes and diseases. In 2013, Cheng et al created the ‘LncRNA and disease database’  
(http://www.cuilab.cn/lncrnadisease), which at the last update linked over 1,000 lncRNAs 
with 221 diseases. The following sections will focus on the roles of lncRNAs involved with 
cardiovascular disease and, in particular, ischaemic heart disease. 
In 2007 the Welcome Trust Case Control Consortium carried out GWAS on 14,000 cases of 
seven common diseases (with 3000 controls) [166]. This and other studies identified a 
powerful association between CAD and MI and the chromosome 9p21.3 locus [167-169].  
Chromosome 9p21.3 spans a non-coding region of 50 kb that includes several single 
nucleotide polymorphisms (SNPs) associated with risk of CAD and a lncRNA known as 
ANRIL (antisense non-coding RNA in the INK4 locus, also known as CDKN2B Antisense 
RNA). ANRIL has subsequently been shown to be associated with coronary atherosclerosis 
[170], carotid arteriosclerosis [171], peripheral artery disease [172] and other vascular 
diseases [173]. There are several isoforms of ANRIL each with tissue-specific expression 
patterns in endothelial, smooth muscle and inflammatory cells [170]. Carriers of risk alleles at 
9p21.3 had higher levels of the two isoforms of ANRIL, EU741058 and NR_003529, but not 
the isoform, DQ485454, in whole blood and atherosclerotic plaque tissue, compared with 
other patients. Moreover, these two variants were correlated with the severity of 
atherosclerosis [170].  Holdt et al, [170] generated ANRIL over-expressing cell lines which 
led to significant changes of expression in genes enriched for cell adhesion, proliferation and 
apoptosis which are all central mechanisms of atherogenesis. These gene expression networks 




regulate genes in trans by acting as a scaffold and binding the PRC1 and PRC2 complexes 
(Polycomb repressive complexes 1 & 2 – protein complexes that can remodel chromatin).  An 
ALU repeat element expressed in both ANRIL and the promoters of target genes is thought to 
regulate this ANRIL-mediated trans regulation [174]. 
In the literature, much of the lncRNA data in heart comes from mice due to the lack of 
availability of human heart tissue.  However, in the last five years there have been 
accumulating transcriptome studies using human blood and, to a lesser extent heart tissue, 
providing insight into the lncRNAs associated with vascular and cardiac disease.  
Deep sequencing of the transcriptome of ischaemic and non-ischaemic human hearts by Yang 
et al showed that the expression profiles of lncRNAs differ between failing hearts before and 
after implantation of a left ventricular assist device. These findings suggest a role of lncRNAs 
in either the pathogenesis of HF or in the response to the restoration of cardiac function [95], 
but the functions of these lncRNAs were not investigated. Another study by Saddic et al 
investigated expression profiles of lncRNAs with RNA-Seq before and after ischaemic insult 
of cardiopulmonary bypass in 85 patients [175]. For the differentially expressed lncRNAs the 
authors looked at gene ontology of neighbouring genes and found significant enrichment for 
pathways involved in hydrogen peroxide metabolic processes, response to stress, response to 
stimulus and immune system processes. Four of the 15 most abundantly expressed lncRNAs 
in the heart (independent of ischaemia) were the well-known lncRNAs H19, MALAT1, 
NEAT1 and DANCR. H19 is upregulated in CAD patients [176] and is a regulator of 
cardiomyocyte hypertrophy [177]. MALAT1 regulates endothelial cell function and 
angiogenesis, with its inhibition reducing endothelial cell proliferation and vascular 
inflammation [178-180]. NEAT1 is involved with paraspeckle formation within the nucleus 
(described above) [181]. The role of Differentiation Antagonizing Non-Protein Coding RNA 
(DANCR) and cardiac disease is less clear but it has been implicated in reduced cell 




A study by Zangrando et al demonstrated that expression levels of lncRNAs are regulated in 
cardiac tissue after MI in mice, [183] and a related group went on to look at a panel of five 
lncRNAs that were suspected to be involved in cardiac pathology in humans. The group 
looked at ANRIL, hypoxia inducible factor 1a antisense RNA 2 (aHIF 1A antisense RNA 2), 
potassium voltage-gated channel, KQT-like subfamily, member 1 opposite strand/antisense 
transcript 1 (KCNQ1OT1), MI-associated transcript 1 (MIAT) MALAT1 in peripheral blood 
by quantitative polymerase chain reaction [184]. Levels of aHIF 1A antisense RNA 2, 
KCNQ1OT1, and MALAT1 were higher in patients after MI than in healthy volunteers, while 
levels of ANRIL were lower in patients after MI. The study demonstrates altered expression 
profiles of several lncRNAs in patients with acute MI and suggests that these may be useful 
for prognosis.  Interestingly, other studies which have used cardiac tissue, link MIAT 
upregulation to a higher risk of MI, microvascular dysfunction, cardiac hypertrophy and 
cardiac fibrosis [185-188], while KCNQ1OT1 may protect against ischemia/reperfusion (I/R) 
injury following acute MI [189].  
These studies provide a list of potential candidates of differentially expressed lncRNAs 
involved in cardiac disease, but until we understand the functional relevance of these 
lncRNAs, the story will not be complete. Various strategies to up- or down-regulate 
expression of candidate lncRNAs are now being applied to tease out the functional effects of 
these lncRNAs on cardiac disease processes. These include RNA interference (RNAi), small 
hairpin RNAs (shRNAs), modified antisense oligonucleotides (ASOs) and gapmers (a 
chimeric antisense oligonucleotide that contains a central stretch of DNA monomers that 
induces RNase H cleavage), aptamers (single stranded oligonucleotides that target the 
lncRNA) small-molecule drugs (chemical compounds that block the activity of the target 
lncRNA [190, 191] and clustered regularly interspaced short palindromic repeats 




Techniques of up- or down-regulating expression levels have provided clues as to which 
mRNAs, proteins and pathways lncRNAs regulate. As shown in Table 2-2, this regulation 
occurs at all stages of disease, spanning at-risk individuals with atherosclerosis and vascular 
dysfunction, to before, during and after MI, to cardiac remodelling and HF, thus providing 
potential biomarkers and drug targets for each stage along the spectrum of heart disease. The 
rodent lncRNAs didn’t appear to have a human equivalent which could be a naming issue. To 
interrogate this further the gene would have to be looked at in the gene annotation to see if 
surrounding genes are equivalent. Given that rodent cardiovascular models poorly replicate in 
the human condition then if these genes are in fact rodent specific then they do not give us a 
clear insight into human disease.  
2.2.9 LncRNA biomarkers  
Early diagnosis of cardiovascular disease can improve clinical management and reduce 
morbidity and mortality rates. Ideal biomarkers are low cost, non-invasive, accurate, stable 
and strongly predictive. However, none of the cardiovascular biomarkers have 100% 
sensitivity or specificity (described above) and there remains a critical need for new markers 
to further improve accuracy in diagnosis and prognosis in cardiovascular disease. 
It is clear that lncRNAs play an integral part in various cardiac and vascular diseases and have 
the potential to become powerful biomarkers. There are technical challenges to their utility as 
biomarkers, since lncRNAs are expressed at lower levels than mRNAs and miRNAs in the 
circulation and are prone to degradation by ribonucleases. However, within the circulation, 
they can be bound by extracellular vesicles known as exosomes which are thought to increase 
their stability [193, 194].  Although the tissue of origin of the circulating lncRNA is not 
known, measuring lncRNAs in peripheral blood provides a non-invasive, readily accessible 
and potentially relatively cheap source of novel biomarkers. Their potential is already being 
realised in the cancer field where a lncRNA with high specificity and sensitivity for bladder 




this success may be possible for cardiac disease. In 2014, Kumarswamy et al investigated 
lncRNAs as potential biomarkers for HF. They used human plasma-derived RNA for 
microarray-based global transcriptome analysis to look at lncRNAs in 246 patients with or 




Table 2-2 LncRNAs involved in Atherosclerosis, Myocardial Infarction and Cardiac Remodelling/Heart Failure 
Atherosclerosis 
LncRNA Location Phenotype Mechanism/Target Genes Reference 
ANRIL (antisense non-coding RNA in the INK4 
locus) 
Human Increased atherosclerosis 
risk 
Impairs ribosome biogenesis, activates p53 
promotes apoptosis 
[170, 174, 196] 
ANRIL (antisense non-coding RNA in the INK4 
locus) 
Human Inflammatory factors 
linked to endothelial 
activation and 
atherosclerosis 
Downstream of NF-κB pathway [197] 
SMILR (Smooth Muscle Enriched LncRNA) Human Atherosclerotic plaques HAS2 (a critical component of the 
extracellular matrix that accumulates in 
human atherosclerotic lesions) 
[198] 
Biomarker 




H19/LIPCAR (long intergenic non-coding RNA 
predicting cardiac remodelling) 
Human Increased risk of CAD 
 
[176] 
novlnc6 Mouse/Human Downregulated in AMI Bmp10/Nkx2.5 (Cardiac transcription 
factors) 
[200] 
NRON (ncRNA repressor of the nuclear factor of 
activated T cells) 




MHRT (Myosin Heavy Chain Associated RNA 
Transcripts) 




UCA1 (Urothelial Cancer Associated 1) Human Lower plasma levels 12 
hours post MI, elevated 




LncRNA Location Phenotype Mechanism/Target Genes Reference 






CARL (cardiac apoptosis-related lncRNA) Mouse inhibits anoxia-induced 
mitochondrial fission and 
apoptosis in 
cardiomyocytes 
Sequesters miR-539 maintaining 
mitochondrial homeostasis 
[204] 
MIAT (myocardial infarction associated transcript) Human SNPs linked to increased 
risk of  MI 
 
[185] 
MIRT1/MIRT2 (myocardial infarction associated 
transcript) 





Inhibition of NF-kB pathway [205] 
NRF (necrosis-related factor) Mouse Necrosis during MI NRF↑ → miR-873↓ →  RIPK1/3 
↑ → cardiac necrosis 
[206] 
ANRIL (antisense non-coding RNA in the INK4 
locus)/HIF-1α-AS2 (hypoxia inducible factor 1A 
antisense RNA) 2 ()/KCNQ1OT1 (KQT-like 
subfamily, member 1 opposite strand/antisense 
transcript 1)/ MALAT1 (metastasis-associated lung 
adenocarcinoma transcription 1) 
Human May improve prediction 
of left ventricular 
dysfunction 
↑ HIF-1α-AS2/KCNQ1OT1/ MALAT1 levels, 




LncRNA Location Phenotype Mechanism/Target Genes Reference 
Chaer (cardiac-hypertrophy-associated epigenetic 
regulator) 
Mouse/Human Cardiac Hypertrophy PRC2/ mTORC1 [207] 
Chast (cardiac hypertrophy-associated transcript) Mouse/Human Cardiac Remodelling Pleckstrin - autophagic inhibition and 
cardiomyocyte hypertrophy 
[208] 
CHRF (cardiac hypertrophy related factor) Mouse Cardiac Hypertrophy CGRF↑ → miR-489↓ → Myd88↑ → cardiac 
hypertrophy↑ 
[209] 






H19 Mouse Upregulated in 
pathological cardiac 
hypertrophy 
miR-675/CaMKIIδ pathway (CaMKIIδ is a 
multifunctional serine/threonine protein 
kinase) 
[177] 
H19 Human/Mouse Upregulated in human 
failing and mouse 
hypertrophic hearts 
Cathepsin D [211] 
MHRT (myosin heavy chain associated RNA 
transcript) 
Mouse Protects heart from 
pathological hypertrophy 
MYH6/MYH7 via Brahma Related Gene 1 
(BRG1) 
[212] 
MIAT (myocardial infarction associated transcript) Mouse Cardiac Hypertrophy competing endogenous RNA for miR-150 [188] 
MIAT (myocardial infarction associated transcript) Mouse Cardiac fibrosis competing endogenous RNA for miR-24 [187] 
MIRT1/MIRT2 
(myocardial infarction associated transcript) 
Mouse Left Ventricular 
remodelling after MI 
List of upregulated genes including Nppb, 
TNF, MMP9, TGFB1, lectin galactoside-
binding soluble 3 (lgal3), p53 
[183] 




WISPER (Wisp2 super-enhancer–associated RNA) Mouse/Human Cardiac Fibrosis TIA1/PLOD2 [214] 
Vascular 
    
MALAT1 (metastasis-associated lung 
adenocarcinoma transcription 1) 
Human Endothelial cell function 
and vessel growth 




MALAT1 (metastasis-associated lung 
adenocarcinoma transcription 1) 
Human Protects against 
endothelial dysfunction & 
upregulated in unstable 
angina 
competing endogenous RNA for miR-22-
3p/CXCR2(Interleukin-8 receptor) 
[179] 
MIAT (myocardial infarction associated transcript) Human Microvascular dysfunction competing endogenous RNA for miR-150-
5p/VEGF 
[186] 
SENCR (Smooth Muscle And Endothelial Cell 
Enriched Migration/Differentiation-Associated) 
Human Stabilizes smooth muscle 
cell contractility 
MyoCD (a key transcriptional regulator of 






One lncRNA, LIPCAR (long intergenic non coding RNA predicting cardiac remodelling) 
increased significantly with post-MI left ventricular remodelling during chronic HF and could 
potentially be used to predict future deaths in patients with HF [215].  
Further evidence for association of circulating lncRNAs with CAD, MI and HF comes from 
two recent studies. Higher levels of two lncRNAs, non-coding repressor of NFAT (NRON) 
and myosin heavy-chain-associated RNA transcripts (MHRT), were detected in HF versus 
non HF patients using quantitative reverse transcription-polymerase chain reaction (RT-
qPCR) [201]. 
Additionally, levels of a lncRNA named urothelial carcinoma-associated 1 (UCA1) were 
reduced in early state acute MI patients and then increased at day three after acute MI [202]. 
Finally, Yang et al (2014) used microarray analysis to screen for differentially expressed 
plasma lncRNAs in CAD patients compared to controls. They found 265 differentially 
expressed lncRNAs and filtered these down to four candidates based on levels of expression, 
fold-change, and p values. Of the four candidates, the best candidate was the lncRNA 
AC100865.1 (Coromarker), which they suggested could be used as a biomarker for CAD 
[199]. 
2.2.10 Summary 
These studies demonstrate that lncRNAs can be detected in human plasma. RNA-Sequencing 
(RNA-Seq) is a superior technology for biomarker discovery compared to microarrays in that 
it does not need pre-determined probes and therefore has an unbiased detection of transcripts. 
RNA-Seq has a broader dynamic range (not being hampered by background hybridisation and 
signal saturation), it has increased specificity and, arguably most important for lncRNAs, has 
increased sensitivity and superior detection of low abundance transcripts. As both studies by 




be many more lncRNAs involved in CAD still to be discovered with RNA-Seq that could 
potentially be used as biomarkers. 
2.3 Insights into circRNAs: their biogenesis, detection, and 
emerging role in cardiovascular disease 
The material in the following sections formed the basis of a review article which has been 
submitted for peer review  in RNA Biology. 
2.3.1 Circular RNAs – an Overview 
CircRNAs are an evolutionarily conserved form of non-coding RNA with covalently closed 
loop structures. The first studies to establish a functional role for circRNAs showed they can 
act as potent miRNA sponges and many other studies have focussed solely on this role. 
However, the biological functions of most circRNAs are still undetermined and other 
functional roles are gaining traction, including as protein sponges and regulators, and coding 
for proteins with an alternative mechanism of translation potentially opening up a whole new 
transcriptome. The first step to gaining insight into circRNA function is accurate 
identification and various software platforms have been developed for this purpose. What 
started out as specialised detection software has now evolved into whole bioinformatics 
pipelines that can be used for detection, de novo identification, functional prediction, and 
validation of circRNAs.  However, few cardiovascular circRNA studies have utilised these 
tools. This section of the literature review summarises current knowledge of circRNA 
biogenesis, bioinformatic detection tools and the emerging role of circRNAs in cardiovascular 
disease. 
The first endogenous circRNAs in humans were reported in the early 1990’s as non-
polyadenylated transcripts with a ‘scrambled’ exon structure (i.e. exons joined at consensus 
splice sites but in a different order to the primary pre-mRNA transcript) [216, 217]. As most 
early transcriptomic studies used isolation methods that enriched for poly-A transcripts, 




next generation sequencing kits that interrogated ribosomal depleted total RNA (rather than 
poly-adenylated RNA), along with RNAse R digestion to enrich for circRNAs, studies 
identifying and functionally characterising circRNAs quickly proliferated.  Fast forward thirty 
years and we now know that circRNAs can contain a single exon or multiple exons, can 
contain exonic or intronic sequences or a combination of both (although most are thought to 
originate from middle exons and most commonly contain two to three exons [113, 218]), are 
conserved across species and are associated with many different disease states, including 
cardiovascular disease [219-222]. Despite these advances, our understanding of their 
functional roles is still in its infancy and for many circRNAs the functional mechanism has 
not been assigned. 
CircRNA transcripts may be located in either the nucleus or the cytoplasm. Whereas exon-
intron and intronic circRNAs remain in the nucleus and often appear to regulate the 
expression of the gene encoding them (parental gene) [223, 224], exonic circRNAs are more 
commonly exported to the cytoplasm where they exert multiple functions [218]. CircRNAs 
are highly stable due to a lack of free ends that are vulnerable to exonuclease activity, and can 
accumulate in non-proliferating tissues [225] and biofluids including plasma, saliva and urine 
[226-228] 
This part of the literature review is divided into four sections. The first section summarises 
current knowledge of circRNA biogenesis, focussing on the most recent developments in the 
field. The second section provides a comprehensive list of current bioinformatic detection and 
downstream in silico functional annotation tools.  The third section describes circRNA 
functions, including roles as miRNA sponges, protein sponges, protein scaffolds and protein-
coding transcripts. The final section discusses the emerging roles of circRNAs in 
cardiovascular disease, including as biomarkers and regulatory molecules in atherosclerosis, 






A single gene locus can produce multiple circularised transcripts, a process termed alternative 
circularisation [113, 218]. For example, Titin, the longest gene in the human genome, gives 
rise to 415 different exonic circRNA isoforms [229], compared with a median of three 
circRNAs per gene in human brain samples [222]. 
Canonical splicing of pre-mRNA to linear mRNA involves removing intervening sequences 
(introns) to join exons in a 5’-3’ direction, creating a mature mRNA transcript ready for 
translation to a protein. This editing is carried out by a complex molecular machine termed 
the spliceosome which recognises cis-regulatory elements such as a GT/U dinucleotide (the 
donor site at the 5’ end of the intron), an AG dinucleotide (the acceptor site at the 3’ end of 
the intron) and a branch point near the 3’ end of the intron. Exon-containing circRNAs are 
formed from non-canonical splicing of linear pre-mRNA where a downstream 5’ splice site is 
joined to an upstream 3’ splice site in what is known as ‘back-splicing’.  This results in a 3’, 
5’ phosphodiester bond at the back-splicing junction forming a covalently closed circular 
transcript and a linear transcript with a skipped exon [230] (Figure 2-8A). Mutation of the 
canonical splice sites or inhibition of splicing by isoginkgetin (a general inhibitor of both the 
major and minor spliceosomes) diminishes circRNA production [231, 232], suggesting that 
back-splicing of circRNAs utilises the canonical spliceosome and the same splice sites as 
linear splicing.  
A number of factors govern the formation of circRNAs and certain genomic features appear 
to favour circRNA biogenesis. First, for single exon circRNAs, the exon is, on average, 3-fold 
longer than other expressed exons [233]. This is in contrast with multi-exon circRNAs, where 
the exons are of more usual length. Second, exceptionally long introns that contain inverted 
repeat elements, such as inverted Alu repeat elements are significantly enriched in circRNA 
loci compared to linear controls, with nearly 90% of circRNAs in humans having ALU 




binding proteins (RBPs) in flanking introns also promote circularisation by allowing for RBP-
associated intronic base pairing. Notable examples of RBPs include the protein Quaking 
(QKI), which regulates the human epithelial–mesenchymal transition [235], the fused in 
Sarcoma (FUS) protein in motor neurons [236] and Muscleblind-like splicing regulator 1 
(MBNL1) in neuronal tissues [232]. Conversely, the RNA-editing enzyme, adenosine 
deaminases acting on RNA (ADAR) appears to inhibit circularisation and promote formation 
of linear transcripts. ADARs convert adenosine-to-inosine in double-stranded RNA which 
disrupts intronic base pairing thus ‘melting’ the secondary structures within the introns that 
facilitate circRNA biogenesis (Figure 2-8A). Accordingly, knockdown of ADAR1 
significantly upregulates circRNA expression [234]. Fourth, the complementary binding of 
inverted repeat sequences or the binding of RBP proteins bring the back-splice junctions into 
close proximity. This allows circularisation of either the exon(s) only or, to a lesser extent, the 
exon with a retained intron (termed circRNAs containing exonic and intronic sequences, 
EIciRNAs, Figure 2-8A). Along with EIciRNAs, ciRNAs (circRNAs containing exclusively 
intronic sequences) are thought to reside in the nucleus and are involved with regulation of 
their parental gene [223, 224].  
In contrast to exon-containing circRNAs, ciRNAs are generated during linear splicing when 
the 5’ splice site of the excised intron joins to an adenosine at the branch point, forming a 
lariat structure (Figure 2-8B). Lariat structures are usually removed by a debranching enzyme 
that hydrolyses the 2’-5’ phosphodiester bond at the branch point to produce linear molecules. 
ciRNAs are lariats that escape the debranching process. They contain consensus RNA motifs 
– a GU rich sequence near the 5’ splice site and a C rich sequence near the branchpoint 
(Figure 2-8B), although it is not yet known how these consensus sequences work or what 






Figure 2-8 Components involved in linear mRNA or circRNA biogenesis 
A) The top panel shows a pre-mRNA transcript with 4 exons. Long flanking introns containing 
inverted repeat elements such as Alu elements or trans- acting RBP proteins bring the downstream 
splice site into close proximity with the upstream splice site to favour back splicing and thus circRNA 
production. Conversely, introns bound by ADAR1 ‘melt’ RNA secondary structures by disrupting 
intronic base disrupting circularisation. B) Intronic circRNA biogenesis: Linear splicing produces 
lariat structures that are usually debranched and hydrolysed. However, GU rich and C rich intronic 
motifs escape debranching to form ciRNAs (intronic circRNAs). ADAR adenosine deaminases acting 
on RNA, BP: Branch points. RBP: RNA binding proteins. ALU: Alu repeat elements, mRNA messenger 
RNA 
Most circRNAs are generated from pre-mRNA transcripts that also produce linear mRNA 




counterparts. Given that the same spliceosome and splice sites are used and that many 
circRNAs consist of exons, it may be tempting to speculate that circRNA biogenesis could be 
a regulator of mRNA production. However, accumulating evidence show that circRNAs have 
their own function independent to that of the linear transcript.  
In summary, the current model of circRNA biogenesis is that back splicing is promoted by a 
looping of the intron(s) bringing the (back) splice sites into close proximity. This ‘looping’ 
appears to be facilitated by longer introns, inverted repeat sequences and RNA binding 
proteins [113, 218, 235].  
2.3.3 CircRNA detection. 
Due to exclusion of non-polyadenylated transcripts in standard RNA-Seq protocols, 
circRNAs went undetected for years. As libraries evolved from poly-A enriched to (rRNA 
depleted) total RNA, circRNA detection became possible. Furthermore, addition of 3′-5′ 
exonuclease Ribonuclease R (RNAse R), which degrades linear RNA, enabled enrichment of 
circRNAs, although certain circRNAs are sensitive to RNAse R treatment including the well-
known circRNA, CDR1as [237, 238]. However, as RNAse R treatment doesn’t remove RNA 
with highly structured 3’ ends such as snRNAs, histone mRNAs, or RNAs with G-rich G-
quadruplex (G4) secondary structures, circRNA library preparation methods were further 
refined, using RNAse R treatment followed by polyadenylation of transcripts and then 
poly(A)+ RNA depletion [239-241]. 
Following RNA sequencing, bioinformatic detection of circRNAs remains challenging. For a 
list of current software for circRNA detection and potential functional prediction see Table 2-
3.  While numerous programmes are freely available, there appears to be limited overlap in 
the circRNAs identified between the different programs. This suggests that all programmes 




and taking the intersection of these combined results will give more reliable outputs than the 
use of a single algorithm.  
Table 2-3 Software for CircRNA detection and downstream applications 
Software for CircRNA detection 

























DCC Split alignment 
based 
STAR https://github.com/dieterich-lab/DCC [246] 










































BIQ No alignment kmers https://github.com/pmenzel/biq [253] 
CircDBG No alignment kmers https://github.com/lxwgcool/CircDBG [254] 
CircMarker No alignment kmers https://github.com/lxwgcool/CircMarker [255] 
Software for downstream of CircRNA detection 
ACValidator in silico validation of 
circRNAs 
https://github.com/tgen/ACValidator [256] 
CircCode identifying circRNA Coding 
Ability 
https://github.com/PSSUN/CircCode [257] 
CirComPara detect, quantify, and 
correlate expression of 






interactions of circRNAs 
with RBPs, design specific 
divergent primers to detect 
circRNAs, study tissue- and 
cell-specific circRNAs, 
identify gene-specific 
circRNAs, explore potential 
miRNAs interacting with 
circRNAs, and design 






CircPrimer a software for annotating 
circRNAs and determining 
specificity of circRNA 
primers 
http://www.bioinf.com.cn/ [259] 






CircRNAwrap circRNA identification, 
transcript prediction, and 
abundance estimation 
https://github.com/liaoscience/circRNAwrap [261] 
CircTools circRNA identification, RBP 
enrichment screenings, 
circRNA primer design, 
miRNA seed analysis and 











spliced, or fusion RNAs) for 
high confidence selection 
https://github.com/TreesLab/NCLcomparator [264] 
ReCirc prediction of circRNA 
expression and function 
through probe reannotation 
of non-circRNA microarrays 
http://licpathway.net:8080/ReCirc/ [265] 
Ularcirc circRNA detection 
independent of gene 
annotation, 
visualisation of forward AND 
backsplice junctions 
recover predicted circRNA 
sequence, 
recover sequence of 
backsplice junctions and 
forward splice junctions, 
detect miRNA binding sites, 
detect putative open 
reading frame of circRNA 
https://github.com/VCCRI/Ularcirc [266] 
The reader is directed to the following review for a detailed comparison between circRNA 
software programmes [267], although the field is rapidly evolving and several programmes 
have been updated and new ones have been developed since these articles were published.  
CircRNA detection software needs to distinguish between circRNAs and their linear 
counterparts as most circRNAs will contain the same exon(s) as the linear mRNA. To do this 
the software exploits the fact that circRNAs contain back-spliced junctions. The detection 
strategies can be split into three groups – those that use a multi-stage mapping approach, those 
that directly detect the back-spliced junction reads using split or chimeric reads and, lastly, 




stage mapping approach, there is an initial mapping step where reads that align continuously 
to the reference genome are filtered out and only unmapped reads are taken for further 
analysis. These ‘unmapped’ reads are then aligned to pseudo-sequences which are built 
around putative back spliced junctions (BSJs) [267] (Figure 2-9A)  The newer aligners are 
‘splice aware’ (software that split reads when aligning back to the reference to account for 
intronic sequences) such as STAR2, HISAT or TopHat2 [268-270], allowing for chimeric 
reads to be directly aligned to the human reference genome (Figure 2-9B). Care must be taken 
here as chimeric reads that are in the opposite order can also be generated from other 
instances in the genome such as intergenic or intragenic trans splicing to produce tandem 
duplications of exons [271]. To account for these potential false positives, one can select only 
those that occur in the same gene (to eradicate intergenic trans splicing) and use of biological 
replicates is recommended (to minimise false positives due to intragenic trans splicing). 
Lastly, the more recently developed software packages appear to be opting to forgo the 
mapping stage altogether and instead use the reference and annotation to assemble and store 
all kmers that are located near exon boundaries (Figure 2-9C). Each sequencing read is then 
examined for kmers and these are matched to the stored kmers. (Circ DBG builds a De Bruijn 
graph from the kmers). When two kmers from a single read are out of order to the reference 
then this suggests the presence of a circRNA. As this strategy assembles all possible kmers 
from the reference and annotation files only circs from annotated exons will be predicted, no 
de novo circRNAs will be detected. 
Although circRNAs may contain multiple exons that align with multiple reads in an RNA-Seq 
run, it is only the reads that align across this back splice that can be counted as 
unambiguously originating from the circRNA. The other reads may have originated from 
either the linear or circular forms. For this reason, the read counts for circRNAs are relatively 




functional predictions (such as miRNA and RBP binding sites) and this is only possible for 
single exon circRNAs. 
 
Figure 2-9  Three different strategies of identifying back-splice junction (BSJ) reads employed by 
circRNA detection software. 
A) Pseudo reference strategy: Reads are first aligned to the reference (grey boxes) any unmapped 
reads (red boxes) are taken forward and aligned against pseudo references which include all possible 
combinations of exon junctions. In this way, any reads that align identify the exons involved in the 
back-spliced junctions. B) Split alignment strategy: Splice-aware aligners split the sequencing reads 
which allows direct alignment to the reference. Reads can be selected to choose the BSJ reads C) 
Kmer strategy: The actual step of read alignment is forgone. Instead, all possible kmers (short 
stretches of sequence) are created from the exon boundaries. Kmers are then matched to the reads. 
Matched kmers that are in sequence with the reference are considered linear spliced reads (top 
exons). Matched kmers that are out of sequence to the reference are considered circRNA back spliced 
junction reads (bottom exons).   
Because only reads that align across the BSJ can be confidently assigned, it is hazardous to 
make assumptions as to which exons are, or are not, included in multi-exonic circRNAs. 
Unfortunately, this does not appear to be the case for several circRNA databases, which 
include many multi-exonic transcripts that have not been experimentally validated [272]. 
Lastly, as the number of studies using the various algorithms continues to grow so does the 




curated based on literature searches for empirically validated circRNAs). To date there are 
between 1953 - 1,223,114 noncurated or 249 -3181 curated circRNAs in databases, and there 
appears to be little overlap between them. For an excellent review of the current state of 
circRNA databases see Vromman et al. [272] 
2.3.4 CircRNA functions. 
2.3.4.1 CircRNAs as miRNA sponges 
The first papers to demonstrate functional roles for circRNAs found that the circRNAs miR-7 
(ciRS-7) and sex-determining region Y (circSRY) bound and sequestered miRNAs miR-7 and 
miR-138, via 70 and 16 conserved binding sites, respectively [247, 273]. Both circRNAs 
strongly supressed the ability of the miRNAs to bind to its target mRNA leading to increased 
expression of the mRNA, suggesting a competing endogenous RNA regulation of the mRNA. 
CircRNAs may bind one or more miRNAs and depending on whether there is partial or 
complete binding of the miRNA may result in different mechanisms of inhibition or 
degradation [274]. Piwecka et al [274] demonstrated that the circRNA Cdr1as has > 70 
biding sites for miRNA-7 that partially binds at the seed region, which they suggest alters the 
availability of this miRNA.  Cdr1as also has a binding site for miRNA-671 that has almost 
full complementarity and which could direct Argonaute protein mediated cleavage of the 
circRNA, as has been previously demonstrated [275]. 
This sponge like mechanism caused great excitement and anticipation of a general functional 
mechanism for circRNAs. However, bioinformatic analyses suggests that circRNA miRNA-
binding sites are no more enriched than would be expected by chance [276] and sequestering 






Figure 2-10 An overview of the various functions for circRNAs. 
Within the nucleus, intronic circRNAs (ciRNAs (i)) and exon and intron containing circRNAs 
(EIciRNAs (ii)) are involved in regulation of their parental gene. Exonic circRNAs(iii) are exported to 
the cytoplasm where they can either act as miRNA sponges (which also bind the Argonaute protein – 
an essential component of the RNA-induced silencing complex (RISC) which acts upon the targeted 
mRNA) , RBP sponges, protein scaffolds or are translated. RBP: RNA binding protein, Ago: 
Argonaute protein, Alu: Alu elements 
2.3.4.2 CircRNAs as protein sponges, regulators, and scaffolds 
As well as being involved in circRNA biogenesis, emerging evidence suggests that RBPs 
interact with circRNAs both within the nucleus and cytoplasm. CircRNAs can act as (i) 
protein sponges to block protein activity [196, 277], (ii) positive regulators of polymerase II 
to regulate the transcription of their parental genes in the nucleus (examples include 
circEIF3J, circPAIP2 and ci-ankrd52 [224, 278]), and (iii) protein scaffolds to colocalise 
enzymes and their substrates in the cytoplasm thereby facilitating recruitment [279] and 
enzyme activity [280, 281].  
2.3.4.3 CircRNAs as protein-coding transcripts 
The notion of an alternative circRNA transcriptome is appealing given that circRNAs are 
predominantly located in the cytoplasm, contain exonic (therefore potential coding) 
sequences, sometimes contain the canonical AUG initiator codon of the associated mRNA 




circular structure (if a stop codon is not encountered beyond the translational start site) [283].  
Early studies used ribosome profiling which identifies RNA fragments that are protected by 
the ribosome and escape ribonucleases.  Ribosome protected fragments indicate translation 
sites so if circRNA back spliced reads overlapped these then this would suggest that the 
circRNAs are being translated. However, the studies found no evidence of translation [218, 
276].  
For circRNA translation to occur, it would have to be via an alternative mechanism to linear 
translation.  In eukaryotic translation, the 5’cap of the mRNA transcript is recognised by the 
eukaryotic initiation factor 4E (eIF4E) complex, which recruits ribosomes to translate the 
transcript into protein. While circRNA transcripts lack a 5’ cap and cannot be translated into 
protein via this mechanism, there is growing evidence for their translation by alternative 
mechanisms. Work on viruses and cellular physiological stress responses identified an 
alternative, cap-independent translation mechanism involving RNA structures known as 
internal ribosome entry sites (IRESs) which recruit ribosomes to an internal start codon to 
initiate translation [284].  It has been shown that circRNAs synthesised in vitro carrying 
engineered IRESs can be translated in this manner [285, 286] but endogenous IRESs are rare. 
Recent bioinformatic analysis identified IRES-like AU-rich hexamers that bind trans-acting 
factors to drive circRNA cap-independent translation in a green fluorescent protein (GFP) 
cell-based reporter system [287]. The authors predicted that a nucleotide sequence longer than 
50 nucleotides would contain an IRES-like hexamer by chance. More than 99% of circRNAs 
are longer than 100 nucleotides, suggesting that most circRNAs could potentially be 
translated by this mechanism [287].   
In addition to IRESs, methylated adenosine residues (N6-methyladenosines (m6A), the most 
abundant base modification of RNA) in the 5’ UTR region can directly recruit the eukaryotic 
initiation factor 3 (eIF3) and initiate translation in the absence of the cap-binding factor eIF4E 




m6A site was found to be sufficient to drive translation in human cells [289]. For example, 
endogenous circ-ZNF609 is expressed in human and mouse myoblasts and contains a 753-nt 
open reading frame. Bozzoni et al used a CRISPR/Cas9 system in mouse embryonic stem 
cells to produce constructs expressing circular tagged transcripts which were translated into 
protein. The authors did not determine the molecular activity of the proteins, but Circ-
ZNF609 was found to control myogenic proliferation [290]. Other studies have demonstrated 
circRNA encoded proteins that suppressed the cell cycle and glioma cell proliferation [291-
293], promoting the growth and metastasis of colon cancer [294] and liver cancer cell growth 
[295]. 
From the literature it would appear that the predominant functional mechanism of circRNAs 
is to sequester cytoplasmic miRNAs and, in doing so, participate in regulation of their 
downstream mRNA targets.  However, this focus on miRNAs may reflect the finding that the 
first circRNAs to be discovered were potent sponges of miRNAs [247, 273] and the relative 
technical ease of demonstrating this in vitro.   
From the literature there are three in vitro methods to demonstrate circRNA/miRNA 
interaction. The first approach is a luciferase reporter assay which co-transfects the circRNA 
sequence along with the miRNA of interest downstream of the luciferase gene and measure 
luciferase activity. If the miRNA binds to the circRNA sequence, then luciferase activity is 
inhibited [296].  This demonstrates that the miRNA can bind to this circRNA mimic in vitro 
but not that actual circRNA in vivo.  The second approach uses a biotin labelled probe to co-
precipitate or ‘pull down’ the circRNA/miRNA. This is more compelling than the previous 
method in that the actual interaction of the circRNA/miRNA can be demonstrated in vivo 
[297] The third method is RNA immunoprecipitation (RIP) or crosslinking-
immunoprecipitation (CLIP) of circRNA by an argonaute 2 protein (AGO2) antibody. The 




complex (RISC) complex which contains the AGO2 protein. This method demonstrates both 
circRNA/miRNA interaction and the RNA silencing mechanism. 
Robust experimental validation should be the priority as non-specific binding can occur. This 
was illustrated in a study by Lim et al. [298], investigating circSlc8a1. Biotin pull down of 
circSlc8a1-bound miRNAs resulted in 14 miRNAs being detected which, after Benjamini–
Hochberg correction and filtering for a magnitude fold-change >3, led to prioritisation of five 
candidate miRNAs. Three of these showed significant and consistent inhibition of luciferase 
activity, with two having in silico prediction for several binding sites. The authors repeated 
the biotin-based pull-down assay using isolated mouse cardiomyocytes for these two miRNAs 
and saw a 180- and 18-fold enrichment, respectively. It was not until they performed an 
inverse pull-down assay to test for endogenous circSlc8a1 binding by using biotinylated 
miRNA mimics that they demonstrated only one of these miRNAs had a robust endogenous 
interaction between the circRNA and the miRNA. 
While circRNA-miRNA sponge mechanism studies are exposing important candidate targets 
for circRNAs, other gene regulatory mechanisms are now gaining traction and should be 
explored in parallel, when characterising circRNA function.   
2.3.5 CircRNAs in Cardiovascular Disease 
There is growing evidence that circRNAs have potential functional roles in cardiac 
pathologies including atherosclerosis, myocardial infarction, cardiac fibrosis, cardiac 
hypertrophy, and HF (as demonstrated by the tables below). As we unravel the role of 
circRNAs in the development and progression of CVD, their potential as therapeutic targets to 
reverse pathophysiological remodelling or enhance protective mechanisms will become 




2.3.5.1 CircRNAs as novel biomarkers  
CircRNAs have been reported in plasma, serum, saliva and urine [227, 300-302] and are 
enriched in biofluids compared to tissues [303]. In addition to their roles in the nucleus and 
cytoplasm, circRNAs are released from healthy, apoptotic and necrotic cells into biofluids and 
due to their closed structure are considerably more stable than linear mRNAs, making them 
excellent candidate biomarkers for the presence and progression of a range of cardiovascular 
diseases. 
Presently only a few studies have demonstrated the use of circRNAs as biomarkers for CAD 
and MI (summarised in Table 2-4). Although these studies highlight the potential of 
circRNAs as biomarkers, we should proceed with caution. Studies suffer from small cohort 
sizes, a lack of independent replication and lack of consideration for confounding medications 
commonly used for treatment of IHD and HF. Circulating circRNAs levels may change 
rapidly through disease development and progression, and so timing of collection needs to be 
considered. As yet, there is little consensus between the studies as to which circRNAs are the 
lead candidates and more work is needed to identify these.  Moreover, these studies have been 
carried out using targeted technologies of microarray or RT-qPCR highlighting the potential 
for more discoveries to come with the use of more sensitive RNA-Seq coupled with 
specialised library preparation protocols for circRNA enrichment. 
2.3.5.2 CircRNAs- miRNAs in Atherosclerosis (AS) 
Table 2-5 summarises current knowledge of the involvement of circRNAs in atherosclerosis. 
Of the 10 papers published to date, eight studies have identified the mechanism underlying 
the association between the circRNA and atherosclerosis, with seven studies identifying in 
vitro circRNA/miRNA associations and one showing a circRNA/protein interaction. Notably, 
for three circRNAs (circANRIL, circCHFR and circ_0003204), associations with 





Table 2-4  CircRNAs as potential biomarkers 




remarkably stable in plasma. 
Plasma levels of 
hsa_circ_0001445 were 
proportional to coronary 
atherosclerotic burden and 
improved detection of coronary 
artery atherosclerosis. 
RT-qPCR in 










CAD Both significantly upregulated in 
CAD patients. Overexpression of 
hsa_circ_0004104 in vitro 





from 24 CAD 





Hsa_circ_0124644 CAD First study to investigate the 
circRNA profile in the peripheral 
blood of CAD patients. 
Circulating levels of 
hsa_circ_0124644 improved 
detection of CAD. 
Microarray in 
peripheral blood 
from 12 CAD 
patients and 12 
healthy controls. 
Validation in 137 
CAD patients 
and 115 healthy 
controls 









Circulating levels of MICRA were 
lower in MI patients. MICRA was 
a strong predictor of left 
ventricle (LV) dysfunction; 
patients with lower levels of 




from 642 acute 
MI patients, 86 
heathy controls 
Vausort 








MICRA classified patients into 
ejection fraction (EF) groups. 












et al 2017 
[307] 
 
Of the seven circRNA/miRNA studies, only two used the more compelling RNA pulldown 
method to validate the circRNA/miRNA interaction, with the remaining studies using the less 
compelling luciferase method. In fact, two studies to use the luciferase method suggest two 









Protein target Findings of the study  Methods Reference 
CircRNA‑0044073 miR‑107 JAK/STAT circRNA‑0044073 is upregulated in atherosclerosis and promotes the 
proliferation and invasion of cells by targeting miR‑107 and activating 
the JAK/STAT signalling pathway 
RT-qPCR in blood cells from 
patients with atherosclerosis 
and healthy controls (n=20 
total). RNA pulldown for 
miRNA interaction. 
Shen et al 
2019 [308] 
Circ_CHFR miR-370 FOXO1 Knock down of circ_CHFR inhibits the proliferation and migration of 
VSMCs in vitro 
Microarray on human 
vascular smooth muscle cells 
(VSMCs). Luciferase reporter 
assay for miRNA interaction 






Circ_CHFR was up-regulated in atherosclerotic    serum and ox-LDL-
stimulated VSMC. Circ_CHFR regulated cell growth, migration, and 
inflammation via regulating the expression of Wnt3 as a competitive 
endogenous RNA (ceRNA) of miR-214 in ox-LDL-treated VSMCs 
RT-qPCR in atherosclerotic 
(n=32) and control patient’s 
serum (n=32). Cell model of 
atherosclerosis in (VSMCs) 
with oxidized low-density 
lipoprotein (ox-LDL). 
Luciferase reporter assay for 
miRNA interaction 
Zhuang et al 
2020 [310] 
Circ-SATB2 miR-939 Stromal Interaction 
Molecule 1 (STIM1) 
circ-SATB2 and STIM1 up-regulated in proliferative VSMCs, miR-939 
down-regulated. circ-SATB2 can regulate VSMC phenotypic 
differentiation, proliferation, apoptosis and migration by promoting 
the expression of STIM1 
RT-qPCR in VSMCs. Dual 
luciferase assay for miRNA 
interaction 






of activated B cells 
(NF-κB) 
circ-Sirt1 inhibits inflammatory phenotypic switching of VSMCs. circ-
Sirt1 controls NF-κB activation via enhancement of SIRT1 expression 
by binding to miR-132/212 in vascular smooth muscle cells 
RT-qPCR and microarray in 
human arterial tissues (11 
atherosclerotic, 14 control), 
human plasma (20 CAD, 20 
control) and rat VSMCs. RNA 
pulldown for miRNA 
interaction 






CircRNA circ_0003204 inhibits proliferation, migration and tube 
formation of endothelial cell in atherosclerosis via miR-370-
3p/TGFβR2/phosph-SMAD3 axis 
RT-qPCR in human aorta 
endothelial cells (HAECs).  
Luciferase activity assay 
Zhang et al 
2019 [313] 
Circ_RUSC2 miR-661 Tyrosine-protein 
kinase (SYK) 
Circ_RUSC2 can promote the expression of SYK, a target gene of miR-
661, and regulates VSMC proliferation, apoptosis, phenotypic 
modulation, and migration 
RT-qPCR in human coronary 
artery smooth muscle cells. 
Dual luciferase assay 






CircRNA Protein target Findings of the study Methods Reference 
circANRIL Pescadillo Homologue 1 (PES1) binds pescadillo homologue 1 (PES1) to prevent rRNA maturation.  
This induces nucleolar stress and p53 activation which leads to 
apoptosis and proliferation inhibition. Atheroprotection is achieved 
by culling over-proliferating cell types in atherosclerotic plaques. 
RT-qPCR for circRNA 
expression levels from 
peripheral blood 
mononuclear cell (PBMC), 
human primary tissues and 
cells. CAD patients (n=2,280) 
undergoing coronary 
angiography. Also, human 
endarterectomy specimens 
(n=218) collected in a cohort 
of patients undergoing 
vascular surgery. Genome-
wide expression arrays for 
cells overexpressing 
circANRIL. λN-Peptide-
mediated pull-down of 
circANRIL-bound proteins 
Holdt et al 
2016 [196] 
Mechanism unknown 
CircRNA Findings of the study Methods Reference 
circANRIL Reduced circANRIL expression could prevent coronary AS by reducing vascular EC apoptosis and 
inflammatory factor expression 
Atherosclerosis rat model 
(n=60) 5 groups: control, 
model, empty vector group, 
over-expressed circANRIL 
group and low-expressed 
circANRIL group. serum 
lipids, apoptosis, protein and 
mRNA levels analysed in the 
5 groups 
Song et al 
2017 [315] 
has_circ_0003204 Oxidized low-density lipoprotein (oxLDL) plays a vital part in the initiation of AS. hsa_circ_0003204 was 
notably upregulated in HUVECs treated with oxLDL indicating it may be involved in the pathogenesis of 
atherosclerosis. Knockdown boosted the proliferation, migration, and invasion of oxLDL-induced HUVECs, 
suggesting that hsa_circ_0003204 may slow down the repair of vascular endothelial cell injury.  
RT-PCR from (OxLDL) Human 
umbilical vein endothelial 
cells (HUVECs) 






CircANRIL investigated by Holdt et al [196] and Song et al [315] is interesting as it 
originates from chromosome 9p21 which houses a lncRNA called ANRIL (described above). 
Increased linear ANRIL is associated with increased atherosclerosis [170] and multiple linear 
isoforms as well as circular isoforms have been identified [196, 317].  circANRIL is 
expressed in human vascular tissue, smooth muscle cells and monocyte/macrophages, all of 
which play an important role in atherogenesis. The study by Holdt et al [196] suggests 
circANRIL confers atheroprotection. However, another study looking at the effect of 
circANRIL on the inflammatory response of vascular endothelial cells (ECs) in a rat model of 
coronary atherosclerosis suggests that expression of circANRIL was correlated with the 
expression of inflammatory factors in vascular ECs, and the over-expression of circANRIL 
could exacerbate vascular EC inflammation and promote atherosclerosis. Further studies are 
needed to confirm whether circANRIL has a protective or antagonistic role in atherosclerosis. 
[315]. 
Together these studies provide evidence to suggest circRNAs play a regulatory role in the 
development and progression of atherosclerosis. To date four studies [196, 226, 308, 310] 
have reported altered levels of circRNAs in biofluids in patients with atherosclerosis 
highlighting a potential role for these circRNAs (circRNA_0001445, circRNA-0044073, 
circCHFR, circANRIL) as potential biomarkers. 
2.3.5.3 Myocardial infarction / Ischaemia Reperfusion injury  
Accumulation of atherosclerotic plaque can lead to myocardial ischaemia, associated with a 
cascade of cellular, inflammatory and biochemical events [318] subclinical myocardial 
dysfunction and ultimately MI [319] Cardiomyocytes have limited regenerative capacity and 
restoration of blood supply or reperfusion is the current clinical procedure to limit death of 
cardiomyocytes but reperfusion itself can cause injury to the site [320]. There is growing 
evidence that circRNAs are involved cellular responses to MI and ischaemia reperfusion (IR), 




Of 18 circRNAs associated with MI/IR to date, 13 circRNAs have been suggested to regulate 
MI/IR induced apoptosis in cardiomyocytes via interaction with miRNAs in animal models or 
human cells in vitro (Table 2-6) and represent potential therapeutic targets in this setting. 
Geng et al  [296]were the first study to suggest this mechanism, suggesting CDR1as, acted as 
a sponge of miR-7 and led to an increase in apoptosis in cultured mouse cardiomyocytes. 
However, this study demonstrated no direct evidence for this interaction. Instead, 
overexpression of CDR1as through administration of an expression plasmid via intracardiac 
injection in a mouse model of MI led to an increase in infarct size which could be reversed by 
overexpression of miR-7a. A further three studies [321-323] provide no direct evidence for 
circRNA/miRNA interaction and instead provide evidence with overexpression of one 
affecting expression levels on the other. 
Conversely, the study by Wang et al [324] was the first to use the more compelling method of 
AGO2 pulldown to not only demonstrate direct evidence of circMFACR interaction with 
miR-652-3p but also the AGO2 protein in vivo.  A further three studies also provide evidence 
of circRNA/miRNA interaction with AGO2 pulldown [325-327].  In addition, four studies 
have demonstrated circRNA/protein binding mechanisms involved in MI/IR injury [328-331]. 
Interestingly and perhaps surprisingly, it was not until the Huang et al [330] study in 2019 
that RNA-Seq was used to identify CircNfix (albeit using RNA-Seq data provided from 
another study).  As yet, there is no confirmation of the same circRNA between studies with no 














Protein target Findings of the study Methods Reference 
CDR1as miR-7a poly(ADP-ribose) 
polymerase  (PRP) 
and SP/KLF family of 
transcription factors 
(SP1) 
Overexpression of CDR1 in vivo promoted 
apoptosis and increased cardiac infarct size; 
overexpression of miR-7a had the opposite effect 
RT-qPCR from mouse cardiomyocytes. 
No direct evidence of circRNA/miRNA 
interaction. CDR1as induced apoptosis 
could be reverse by miR-7 
overexpression 















Mouse cardiomyocytes. AGO2 
immunoprecipitation  







Increased in response to reactive oxygen species 
(ROS) and promotes cardiomyocyte apoptosis 
H9c2 cells and neonatal rat 
cardiomyocytes. Biotinylated pulldown 
of miRNA-133 and circMFACR. AGO2 
immunoprecipitation 










apoptotic Bax, and 
downregulated anti-
apoptotic Bcl-2 
Inhibited proliferative ability and induced 
apoptosis of cardiomyocytes after myocardial IR 
injury 
Mouse cardiomyocytes. Dual-Luciferase 
Reporter Gene Assay 
Bai et al 
2019 [332] 
Ttc3 miR-15b ADP ribosylation 
factor like 2 (Arl2) 
Played a cardioprotective role after myocardial 
infarction. Overexpression counteracted hypoxia-
induced ATP depletion and apoptotic death. 
Rat cardiomyocytes and cardiac 
fibroblasts. Dual-luciferase reporter 
assay  




mTOR and MEK/ERK 
pathways 
Silencing circRNA circ_0010729 protected human 
cardiomyocytes from oxygen-glucose 
deprivation-induced injury 
4h oxygen-glucose-deprivation (OGD) 
human cardiomyocytes. No direct 
evidence for circRNA/miRNA 
interaction. Expression studies after 
Overexpression of one against the 
other.  





protein 1 (EMP1) 
Attenuated Acute Myocardial Infarction Mouse cardiomyocytes. Dual Luciferase 
Reporter Gene Assay 





CircRNA_101237 let‑7a‑5p insulin-like-growth 
factor 2 mRNA-
binding protein 3 
(IGF2BP3) 
Mediated anoxia/reoxygenation injury 
 
Mouse cardiomyocytes 
Biotinylated miRNA pull-down. AGO2 
immunoprecipitation 
Gan et al 
2020 [326] 
Circ_LAS1L miR-125b secreted frizzled-
related protein 5  
(SFRP5) 
Down-regulated in acute myocardial infarction 
(AMI).  regulates cardiac fibroblast activation, 
growth, and migration and apoptosis 
Mouse cardiomyocytes. 
Luciferase reporter gene assay. 
Biotinylated RNA pull down. AGO2 
immunoprecipitation 
Sun et al 
2020 [327] 
circDLPAG4/HECTD1 miR-143 HECT Domain E3 
Ubiquitin Protein 
Ligase 1 (HECTD1) 
circDLPAG4/HECTD1 played a vital role in 
apoptosis and cell migration in endothelial cells 
through ER stress in response to 
ischaemia/reperfusion injury 
Primary Human Umbilical Vein 
Endothelial Cells (HUVEC)/mice. 
No direct evidence for circRNA/miRNA 
interaction. Expression studies after 
Overexpression of one against the 
other. 




quaking (QKI)  Silencing of miR-31-5p significantly alleviated the 
myocardial apoptosis induced by Doxorubicin 
(DOX) treatment. MiR-31-5p acts as a negative 
regulator of circPan3 by directly suppressing QKI 
both in vivo and in vitro 
Mouse cardiomyocytes. No direct 
evidence for circRNA/miRNA 
interaction.  Dual-luciferase reporter 
gene assay of QKI/ miR-31-5p  
interaction.  RNA immunoprecipitation 
of QKI/circPan3 interaction. Expression 
levels of circPan3 when miR-31-5p was 
inhibited   
Ji et al 2020 
[323] 
circ_0007623 miR-297 Vascular Endothelial 
Growth Factor A  
(VEGFA) 
hsa_circ_0007623 promoted cardiac repair after 
acute myocardial ischemia, and protect cardiac 
function 
hypoxia-induced human umbilical vein 
endothelial cells (HUVECs). Dual 
luciferase reporter gene assay of 
circ_0007623/miR-297 
Zhang et al 
2020 [335] 




Overexpression of circDENND2A enhanced cell 
viability and migration but declined apoptosis 
under oxygen glucose deprivation (OGD) 
Rat H9c2 cells. Luciferase activity assay 
For interaction of circDENND2A/ miR-
34a 
Shao et al 
2020 [336] 
circRNA/Protein interaction 




methyltransferase 3 beta 
(Dnmt3B) 
Inhibition of autophagy – a type of cell death 
protects cardiomyocytes during 
ischemia/reperfusion. circRNA ACR was able to 
inhibit autophagy and cell death in 
Microarray on Mouse cardiomyocytes 
to look at differential expression in 
autophagy induced mouse hearts by I/R 
injury. Transcriptome microarray after 





cardiomyocytes to protect the heart from 
reducing I/R induced infarct sizes. ARC activated 
PTEN-induced kinase 1 (PINK1) expression (an 
autophagy associated gene) by directly binding to 
and blocking Dnmt3B-mediated methylation of 
the Pink1 promoter. 
ACR knockdown. RNA-binding protein 
immunoprecipitation (RIP) of 
ACR/Dnmt3B association. Chromatin 
immunoprecipitation (ChIP) assay 
showing Dnmt3B/Pink1 association 
CircNfix Y-Box Binding Protein 1 (Ybx1) Ybx1 is a transcription factor that is involved with 
cardiomyocyte differentiation. Interaction 
between circNfix and Ybx1 prevented nuclear 
translocation of Ybx1, causing cytoplasmic 
retention and degradation. Nfix also bound to 
miR-214, which has been demonstrated to be 
essential for cardiomyocyte proliferation. Loss of 
circNfix induced cardiac regeneration and 
angiogenesis and inhibited cardiomyocyte 
apoptosis after MI, which significantly restored 
cardiac function and improved the prognosis 
Used RNA-Seq data from another study 
[337] to filter for circRNAs differentially 
expressed in human, mouse and rat MI 
vs control/sham. RT-qPCR of circNfix. 
RNA pulldown assays and mass 
spectrometry analysis for Nfix/Ybx1 
association. Luciferase, RNA pulldown 
for Nfix/mIR-214 association 
Huang et al 
2019 [330] 
circFndc3b Fused in Sarcoma (FUS) circFndc3b significantly downregulated in post 
MI mouse hearts and in human cardiac tissues of 
ischemic cardiomyopathy patients. 
Overexpression in cardiac endothelial cells 
increases vascular endothelial growth factor-A 
(VEGF-A) expression which enhances angiogenic 
activity and reduces cardiomyocytes and 
endothelial cell apoptosis. circFndc3b interacts 
with the RNA binding protein Fused in Sarcoma 
to regulate VEGF expression and signalling 
Microarrays on sham or MI mouse 
hearts (n = 2) and ischemic 
cardiomyopathy human heart tissue 
(n=7), normal heart tissue (n=4). RNA 
Immunoprecipitation (RIP) 
Garikipati 
et al 2019 
[329] 
circFoxo3 p21-CDK2 circ-Foxo3 highly expressed in the tissues of aged 
mice and patients. Ectopic expression of 
circFoxo3 induced cellular senescence of mouse 
embryonic fibroblasts (MEFs), where it interacted 
with the anti-senescence proteins ID1 and E2F1, 
and anti-stress proteins FAK and HIF1α. These 
interactions prevented nuclear translocation of 
these transcription factors, causing cytoplasmic 
retention and reduced function 
Primary cardiomyocytes isolated from 
neonatal and 12-week heart mouse 
tissues (n=20) RT-PCR for expression 
levels. Antibody pulldown for 
protein/circRNA association 






CircRNA Protein target Findings of the study Methods Reference 
CircRNA 010567 May be related to the inhibition 
on the TGF-β1 
signalling pathway 
Cardiac function and myocardial infarction (MI)-
induced myocardial fibrosis (MF) improved, 
myocardial apoptosis was ameliorated in circRNA 
010567 siRNA group compared with that in 
Model group. Regulatory mechanism 
may be related to the inhibition on the TGF-β1 
signalling pathway 
Rat MI model by ligation of the left 
anterior descending coronary artery. 
Model rats were randomly divided into 
circRNA 010567 siRNA group and Model 
group, with sham operation group as 
Control group (n=30). The effects of 
circRNA 010567 on myocardial 
infarction 
(MI)-induced myocardial fibrosis (MF), 
myocardial apoptosis, mRNA, and 
protein expression levels of TGF-β1 and 
Smad3 in heart tissues of MI rats were 
detected using the small animal 
ultrasound system, Masson staining, 
terminal deoxynucleotidyl transferase-
mediated dUTP nick end labelling 
(TUNEL) staining, reverse transcription-
polymerase chain reaction (RT-qPCR), 
and Western blotting 





2.3.5.4 CircRNAs- miRNAs in Heart Failure/Hypertrophy/Cardiac fibrosis 
Once damage has occurred through MI or chronic hypertension, the heart undergoes macro- 
and microscopic remodelling [339, 340] An early infiltrative inflammatory response is 
followed by replacement of infarcted myocardium by non-elastic fibrotic tissue. Diffuse 
interstitial fibrosis may also affect areas of the heart remote from the  
initial injury. The architecture of the left ventricle exhibits mechanically disadvantageous 
changes, including overall ventricular dilatation and alteration from an efficient elliptical 
shape to a spherical chamber morphology. In vulnerable patients, these processes can lead to 
subclinical myocardial dysfunction and subsequent symptomatic HF [339-341]. Cardiac 
fibrosis can be caused by abnormal deposition of extra cellular matrix in the myocardium. It 
can be the result of scarring after MI but can be more widespread and common in HF. The 
scarring is detrimental by either stiffening the myocardium thereby reducing the pumping 
ability of the heart by impairing  
electrical conductance [342]. 
Table 2-7 summarises nine studies on circRNAs that have been demonstrated regulate gene 
expression in HF, hypertrophy, and cardiac fibrosis. All 9 studies suggest a circRNA-miRNA-
protein axis. Only one study Han et al [343] was carried out in human with the remaining 
studies being carried out in mice. Two studies suggest a role of the circHIPK3 which has been 
demonstrated to be a key circRNA in a variety of cancers [344] and has been associated with 
several miRNAs. However, Ni et al [345] did not show direct evidence for a 
circHIPK3/miRNA interaction and only demonstrated cytoplasmic colocalisation by RNA 





Table 2-7 CircRNAs associated with Heart Failure/Hypertrophy and Cardiac Fibrosis 
CircRNA miRNA 
target 









miR-223 acted as a positive regulator of cardiac hypertrophy. 
Increased expression of HRCR sequesters free miR‐223 
RT-PCR of heart related circRNAs 
responsive to saline- vs. 
isoproterenol-infused mice. (n=7) 
and transverse aortic constriction 
or to sham treatment (n=8) 
Biotinylated RNA pulldown.  AGO2 
immunoprecipitation 











over-expression of circRNA_000203 could eliminate the anti-fibrosis 
effect of miR-26b-5p in cardiac fibroblasts 
CircRNA expression analysis with 
microarray from mouse 
myocardium (n=8 model, n=8 
control Biotinylated RNA pull-down 
of circRNA/miRNA. Luciferase assay 
for miRNA/mRNA targets 






TGF-β1 circRNA_010567 promoted myocardial fibrosis via suppressing miR-
141 by targeting TGF-β1 
Mouse cardiac fibroblasts. CircRNA 
expression with microarray 
confirmed with RT-PCR. Luciferase 
assay for circRNA/miRNA 
association.  





type 6 (ADCY6) 
Demonstrated an increase of Adenylate cyclase type 6 (ADCY6) 
caused by circ-HIPK3 which was ameliorated by miR-17-3p 
overexpression and vice versa, implicates a circ-HIPK3 - miR-17-3p - 
ADCY6 axis. Downregulation of circ-HIPK3 can alleviate fibrosis and 
maintain cardiac function post MI in mice 
24 mice divided into 4 groups - 
normal group (without surgery), 
control group (without ligation), NC 
(negative control) group and 
experiment group. Dual luciferase 
expression vectors with circ-HIPK3 
co-transfected with miR-17-3p  




 Adenovirus (AAV9)-mediated RNAi knockdown of circSlc8a1 
attenuates cardiac hypertrophy from pressure-overload, whereas 
forced cardiomyocyte specific overexpression of circSlc8a1 resulted 
in heart failure 
Mouse cardiomyocytes. Biotin-
based pull-down of circRNA/miRNA 
association then qPCR of miRNA 
and luciferase assay 







AZIN1 and JNK1 circNFIB overexpression reduced cardiac fibroblast proliferation (a 
process involved with fibrosis) based on TGF-β stimulation), while 
inhibition of circNFIB promoted fibroblast proliferation. Action via 
miR-433. 
RT-PCR of candidate circRNA 
expression levels in MI fibrosis 
mice (n=5 control, n=6 MI) and 
cardiac fibroblasts. miRNA 





association with dual luciferase 





Collagen type I 
alpha I (COL1A1, 
COL3A1 
circHIPK3 silencing reduced cardiac fibroblast proliferation, 
migration and the upregulation of a-SMA expression levels induced 
by Ang II in vitro 
Mouse cardiac fibroblasts (CFs).No 
direct evidence for 
circnRNA/miRNA interaction RT-
PCR for circRNA expression level. 
RNA FISH to determine whether 
circHIPK3 and miR-29b-3p 
colocalise in CFs.  








Gata4 CircRNA_000203 was found to be upregulated in the myocardium of 
cardiac hypertrophy induced mice.  Demonstrated that 
circRNA_000203 sponged miR-26b-5p, -140-3p, abolished the 
suppression of Gata4 by miR-26b-5p, -140-3p, resulting in the 
increase of GATA4 in NMVCs 
Neonatal mouse ventricular 
cardiomyocytes (NMVCs). Dual-
luciferase assays of 
circRNA_000203/miR-26b-5p, and 
miR-140-3p Biotinylated RNA pull-
down assay between 
circRNA_000203/ miR-26b-5p,and 
miR-140-3pincubated 















unknown Overexpression of circ_0097435 promoted cardiomyocyte 
apoptosis, Silencing hsa_circ_0097435 inhibited apoptosis 
RNA-Seq heart failure patients 
(n=5) vs control (n=4) Dysregulated 
expression confirmed with qPCR 40 
patients with heart failure. RNA-
pulldown experiments and AGO2-
immunoprecipitation experiments 
revealed that hsa_circ_0097435 
sponged multiple miRNAs 






Growing evidence supports an important role of circRNAs in normal physiology and a range 
of disease states, including cardiovascular disease. Most studies have focussed on the 
circRNA/miRNA/mRNA axis which may be due to the first circRNAs being demonstrated as 
potent miRNA sponges and the relative ease of the in vitro methods. However, caution must 
be applied as several studies suffer from low cohort numbers and some show no direct 
evidence of the circRNA/miRNA interaction and many other use luciferase assays which  
demonstrate an interaction with circRNA/miRNA mimics in vitro but these should be 
validated with further, more robust experimental methods such as circRNA/AGO2 
immunoprecipitation.  Several other mechanisms are now emerging and whilst translated 
circRNAs have not been associated with cardiovascular disease, evidence for this mechanism 
in cancer biology [294, 295] suggests it is only be a matter of time before protein-coding 
cardiovascular circRNAs are identified. As yet, there are few independent replications 
involving the same circRNA and consequently there is no overlap of circRNAs within or 
between cardiovascular aetiologies.  
It is surprising that so few studies have employed RNA-Seq for circRNA detection 
with most cardiovascular studies using microarray or RT-qPCR technologies, limiting 
detection of novel circRNAs. With the development of methods for circRNA enrichment in 
biofluids and more user-friendly software and bioinformatics pipelines future up take of 
RNA-Seq technologies for circRNA detection may be encouraged. 
2.4 RNA sequencing and bioinformatic analysis pipeline 
development  
As a large part of this thesis focuses on a bioinformatic pipeline developed to analyse these 
lncRNAs and circRNAs with RNA sequencing, the next section gives a brief introduction to 
RNA Seq and how it has developed over the past few decades. A later section (2-6) will guide 




2.4.1 First and second-generation sequencing 
Reducing costs have led to RNA Seq becoming the technique of choice for transcriptomics. 
RNA Seq is commonly used for quantifying gene expression and performing differential 
expression analysis of protein-coding genes [352]. However, with the development of new 
kits, we can now use RNA Seq to perform such techniques as targeted sequencing (to analyse 
a subset of genes of interest or specific regions of the genome) [353], RNA Seq from total 
RNA (including coding and non-coding RNA) [354], small RNA (small non-coding RNAs 
such as miRNAs) [355], ribosomal profiling (ribosome protected mRNAs to analyse which 
genes are being expressed at a specific time in a cell) [356], single cell RNA-Seq (analysing 
total RNA from a single cell) [357] and CLIP-Seq (allowing the generation of genome-wide 
maps of RNA binding protein – RNA interaction sites) [358]. 
The first manuscripts using RNA Seq started to appear in 2008 [359-362]. Prior to this, gene 
expression was analysed with probe-based microarrays and, before that, as expressed 
sequence tags (ESTs, ~200-500 nucleotide ‘tags’ of a transcript that were used for gene 
mapping) with Sanger sequencing. To date there have been three ‘generations’ of sequencing 
technology. The very first DNA sequencing method to be widely adopted was the Maxam and 
Gilbert chemical cleavage method, developed in 1976 [363] but this was superseded by 
Sanger Sequencing which, due to its very high accuracy rate and ease of use, has been the 
mainstay technique for low throughput sequencing since the late 1970s and is still used today. 
Collectively these methods are referred to as first generation sequencing. 
Second generation sequencing refers to the development of high throughput, short read or 
massively parallel sequencing, so named because the RNA/DNA is fragmented and amplified, 
and millions of fragments are sequenced in parallel. The second-generation market has been 
dominated by the Illumina ‘sequence by synthesis’ method used in this thesis for RNA-Seq in 
both human heart tissue and human plasma.  This method involves fragmenting the RNA to 




sequencing adapters to each end of each fragment, which are then PCR amplified and then 
passed over the flow cell – a glass slide with several channels or lanes in which millions of 
primers which are complementary to the adapters on either end of the fragments are bound. 
Next, there is an amplification step, which happens millions of times in parallel, termed 
bridge amplification for Illumina technology. In this step, the fragment is clonally amplified 
in a cluster on the flow cell so that image detection can take place. During a sequencing run 
there will be several million clusters in each lane of the flow cell.  
Illumina’s proprietary ‘sequencing by synthesis’ method uses these clonally amplified 
fragments as templates for sequencing. Fluorescently labelled nucleotides are added to extend 
the template one base at a time and, after each base addition, the imager captures the 
fluorescent signal. After addition of the last base, the synthesised strand is denatured and the 
fragment is ‘turned’ so that the fragment can be sequenced from the opposite direction – this 
is termed paired end sequencing [364]. This process generates millions of ‘reads’ of sequence, 
which then need to be aligned to the reference genome and quantified with bioinformatics the 
role of the pipeline developed in this project (discussed below). 
It is worth mentioning here that a big advance in the capabilities of RNA-Seq is due to the 
evolution of different library preparation methods.  RNA-Seq initially interrogated mRNA 
expression by selecting transcripts which have poly-A tails from total RNA. The purpose of 
this was to exclude rRNAs, which make up over 80% of the RNA in human cells [365], and 
avoid generating reads from transcripts not intended for analysis. Library preparation kits 
have since evolved to enrich for all RNAs from total RNA, not just those with poly-A tails, 
such as lncRNAs, circRNAs and miRNAs, while still excluding rRNA (by ribosomal 
depletion methods). Also, there are now stranded library kits which maintain information as 
to which DNA strand the RNA was transcribed from. In un-stranded libraries, strand of origin 
information is lost. In regions of the genome where genes overlap on sense and antisense 




align each fragment, and so which read belongs to which gene cannot be determined. As 
stranded libraries maintain strand of origin information, gene expression from overlapping 
genes can be quantified more accurately.  This is especially important for lncRNAs as many 
overlap mRNAs on the opposite DNA strand and hence has particular relevance for the 
current project. 
2.4.2 Third generation sequencing 
The throughput capabilities of sequencing increased again with the evolution of third 
generation sequencing, which improves on the read length capability up to >100kb [366] 
compared to the second generation technologies.  The two main players in the market 
currently are Pac Biosciences and Oxford Nanopore Technologies, with the latter used in this 
thesis and discussed below. For DNA applications, this has enabled sequencing of repetitive 
regions of the genome and has increased the accuracy of genome assembly. For RNA 
applications, it has allowed sequencing of whole transcripts from start to end and, with this, 
the ability to distinguish alternative isoforms. Long-read sequencing is achievable because the 
DNA or RNA does not have to be fragmented prior to sequencing and there is no need to 
amplify the transcript, as each transcript is read directly on the instrument (even direct RNA-
Seq without the need to convert to cDNA is possible). The trade-off is that the error rate is 
higher than that of Illumina’s <1% for short read sequencing (around 13% for both Pac 
Biosciences and Oxford Nanopore Technologies [367]), along with the need for a higher input 
of starting material. 
Briefly, the Nanopore library preparation takes the input RNA and reverse transcribes it to 
make cDNA. At the end of this reverse transcribed strand, an additional 3 non-templated 
cytosine bases are added, and a PCR primer annealed to the non-templated cytosine bases. In 
this way, the PCR priming sequence is added to the end of full-length cDNA transcripts. After 
PCR, sequencing adapters are added. Nanopore sequencing works by feeding a single DNA 




resistant membrane on the flow cell. A voltage is passed across this membrane which sets an 
ionic current across the nanopore.  When the DNA/RNA molecule passes through the pore 
each base or combination of several bases disrupts the current in a signature manner.  
Measurement of this signature allows identification of the bases and so the sequence of the 
whole fragment can be read [368]. 
2.5 Rational for Research 
Accumulation of atherosclerotic plaque in the coronary arteries, the major blood vessels to the 
heart muscle, can restrict blood supply to the heart. When the blood supply does not meet the 
demands of the myocardium, myocardial ischaemia occurs, associated with a cascade of 
cellular, inflammatory, and biochemical events.  Over time, these processes can lead to 
subclinical myocardial dysfunction and ultimately a MI, causing the death of heart muscle 
cells.  Once damage has occurred, the heart undergoes macro- and microscopic remodelling 
[331, 332] that can lead to subclinical myocardial dysfunction and subsequent symptomatic 
HF in vulnerable patients [331-333]. While the cardiac troponins and natriuretic peptides have 
emerged as vital biomarkers in the clinical diagnosis of MI and HF, we lack specific markers 
for early myocardial ischaemia that could help identify cell dysfunction before cell damage 
has become irreversible. We also lack markers to reliably predict progression to ischaemic HF 
before detrimental remodelling has occurred.  Such biomarkers would add substantially to 
current clinical tools and may help improve assessment of cardiovascular risk early in the 
disease trajectory, facilitating better monitoring and use of preventative strategies. 
This thesis is founded on the idea that novel non-coding RNA biomarkers may aid in 
cardiovascular diagnosis and prognosis. The following chapters describe the development of a 
bioinformatics pipeline and a series of RNA-Seq studies focussed on lncRNAs and circRNAs, 
aimed at identifying new candidate markers to improve detection of myocardial ischaemia 




     Chapter 3 
Materials and Methods 
3.1 Introduction 
This chapter describes the patient cohorts for the RNA-Seq and protocols for RNA extraction 
from plasma and tissue, Illumina short read RNA-Seq and Nanopore long read RNA- Seq.  
These studies formed the basis of three core bioinformatics analyses of: 
1. Illumina RNA-Seq data provided by Harvard Medical School from patients 
undergoing valve replacement to look ischaemia in heart tissue 
2. Nanopore RNA-Seq generated from Cleveland donor heart tissue to validate results 
from (1) 
3. Illumina RNA-Seq data generated from CDCS and HVOL cohort plasma to look at 
ischaemic heart disease and heart failure. 
As a number of methods were performed by colleagues, I would like to thank the following: 
• Dr Anna Pilbrow - RNA extraction from donor human heart to validate putative novel 
transcripts identified from the Harvard heart tissue  
• Dr Christine Moravec and Ms Wendy Sweet  - providing the Formalin-Fixed Paraffin-
Embedded (FFPE) left ventricle tissue glass slides 
• Ms Allison Miller – help with the Nanopore library and loading onto the Nanopore 
flow cell 
• Dr Arthur Morley-Bunker – for RNAscope expertise 
• Dr Aaron Jeffs – for the Illumina total RNA library preparation 
• Christchurch Heart Institute study coordinators – for plasma sample collection, 




3.2 Clinical Cohorts 
3.2.1 Human Heart Tissue Samples 
3.2.1.1 Ischaemic Heart Tissue cohort, Brigham and Women’s and Hospital, 
Harvard Medical School 
To identify mRNA, lncRNAs and novel lncRNAs involved in myocardial ischaemia, RNA-
Seq data from left ventricular tissue from 85 patients sampled before and after 
cardiopulmonary bypass for aortic valve replacement surgery [175] was analysed using the 
pipeline developed here.  RNA-Seq data were generously provided by Dr Danny 
Muelschlegeal and Prof Simon Body, Brigham and Women’s and Hospital, Harvard Medical 
School, Massachusetts, USA [175]. The findings from the analysis of these samples are 
presented in Chapter 5 along with validation using a second cohort (presented in the next 
Section) using Nanopore long read sequencing. 
Patients undergoing nonemergent aortic valve replacement surgery with cardiopulmonary 
bypass (n=85) were prospectively enrolled at Brigham and Women’s and Hospital, 
Massachusetts, USA. Procedures were performed in accordance with the ethical standards of 
The Partners HealthCare Institutional Review Board which approved this study, and written 
informed consent was obtained from each patient. Punch biopsies (≈3-5 μg total RNA 
content) were taken from the left ventricle apex immediately after the initiation of 
cardiopulmonary bypass at the time of routine placement of a surgical vent (pre-ischaemia) 
and after a median of 74 minutes (interquartile range 61–93 minutes; post-ischaemia), during 
which time the heart was arrested with cold blood cardioplegia for myocardial protection 
(summarised in Table 3-1). Because the heart muscle is without oxygen for this time, these 
samples were deemed to be a good model for mild cardiac ischaemia. Tissue samples were 
immediately placed in RNAlater (Ambion, Life Technologies) at +4°C for 48 hours and then 
frozen at -80°C until RNA extraction.  





Age (years) 71 (64–81)* 
Male gender 51 (60)† 
Caucasian Descent 84 (99)† 
Body mass index (kg/m2) 30 (26–34)* 
Diabetes 37 (44)† 
Coronary artery disease 40 (47)† 
Aortic cross-clamp (minutes) 74 (61–93)* 
Left ventricle ejection fraction (%) 60 (55–65)* 
Patients: n=85 *Median (inter-quartile range) †Number of patients (percent of patients).  
Table modified from Saddic et al [175] 
3.2.1.2 Preparation of Harvard heart tissue samples for RNA-Seq 
The following steps were performed at the Harvard Medical School, and the RNA-Seq raw 
reads sent to our laboratory for analysis. Total RNA was isolated with Trizol, and RNA 
quality was assessed using the Agilent Bioanalyzer 2100 (Agilent, Santa Clara, CA). 
Ribosomal RNA was removed by performing 1 to 2 washings of RNA annealed to poly-T 
oligo beads (Invitrogen, Life Technologies, Grand Island, NY). RNA was fragmented and 
reverse transcribed using random hexamers (Invitrogen). Double stranded cDNA synthesis 
was performed using Pol I and RNAse H. Short fragments were purified with QiaQuick PCR 
extraction kit (Qiagen, Hilden, Germany) and resolved with elution buffer for end reparation 
and poly(A) addition followed by ligation with sequencing adaptors for cluster generation and 
sequenced on the Illumina HiSeq 2000 (Illumina, San Diego, CA). Read length was 100 base 
pairs.  
3.2.2 Nanopore Validation using RNA from Cleveland Clinic Kaufman Centre 
Tissue bank Donor Heart Tissue 
To validate putative novel transcripts identified from the Harvard heart tissue samples I used 
RNA that had been extracted from donor human heart by my Primary Supervisor, Dr Anna 




Heart tissue from the left ventricular free wall of organ donors (n = 108) was collected by the 
Human Tissue Core Facility at the Kaufman Centre for Heart Failure, Cleveland Clinic, 
between August 1993 - May 2005. The Human Tissue Core Facility holds explanted human 
hearts from heart transplant recipients and healthy heart tissue from unmatched organ donors 
(Cleveland Clinic IRB ethics approval: IRB 2378). Left ventricle tissue (< 0.5 g) was 
provided to the Christchurch Heart Institute (CHI) for gene expression and genotyping studies 
in collaboration with Professor Christine Moravec, Professor Wilson Tang and Ms Wendy 
Sweet (New Zealand Health and Disability Ethics Committee approval 
CTR/03/11/199/AM03). 
From these 108 samples, I performed approximate matching on age and gender against the 
Harvard Heart samples by choosing Cleveland samples within the age range of the Harvard 
patients (37-90 years) and randomly selecting the same percentage of males/females. From 
these, I tested the RNA integrity of 44 samples selected at random on an Agilent TapeStation 
and chose those samples with an RNA Integrity Number (RIN) of ≥8, which yielded 8 
samples. The RNA from these 8 samples was then pooled for use in Nanopore library 
preparation (Section 2.4). 
Table 3-1 Samples chosen for Nanopore sequencing. 
sample ID Age Gender Ethnicity Cause of 
death donor 
RIN 
41 55 M Caucasian CVA 8.5 
50 58 M Caucasian CVA 8 
118 53 F Caucasian CVA 8.3 
126 47 F Caucasian CVA 8.4 
131 41 F Caucasian GSW HEAD 8 




165 56 F Caucasian CVA 8.1 
167 57 M Caucasian CVA 8 
 
3.2.3 Human Plasma Samples 
3.2.3.1 Healthy Volunteer and Coronary Heart Disease Cohorts 
To identify mRNAs, lncRNAs, novel lncRNAs and circRNAs associated with ischaemic heart 
disease and progression to HF, RNA was extracted from plasma from two cohorts– a healthy 
volunteer cohort (HVOLs) and the Coronary Disease Cohort Study (CDCS).  The CDCS 
cohort was split into two - those patients who did not develop HF (CDCS HF-) and those that 
did develop HF (CDCS HF+). The HVOLs and CDCS cohorts are described in the next 
Sections and a summary of cohort clinical characteristics is presented in Table 3-3. The 
results of this analysis are presented in Chapters 6 and 7. 
 
Table 3-2 The HVOL and CDCS cohorts clinical characteristics 
 HVOL (n=31) CDCS HF – (n=31) CDCS HF + (n=30) 
Age, years* 70(61-76) 69(64-76) 72(61-77) 
Male Gender† 22(71) 23(74) 19(63) 
European† 25(81) 26(84) 21(70) 
Diabetes† 2(6) 12(39) 12(40) 
Smoker† 0 0 1(3) 






Hypertensive† 9(29) 23(74) 23(77) 
BMI, kg/m2* 29(25-33) 29(26-33) 28(25-33) 
eGFR at baseline* 68(63-74) 64(52-75) 64(52-75) 
LVEF %* 67(64-70) 52(47-66) 52(39-60) 
Systolic BP at baseline* 140(130-147) 135(113-147) 130(117-140) 











Atrial Fibrillation†  6(19) 6(19) 
Cholesterol mmol/L* 5.6(4.9-6.0) 4.6(4.4-4.7) 4.1(3.7-4.7) 
NT proBNP at baseline* 14(11-40) 7.6(6.4-9.8) 8.7(7.1-10.0) 
hsTnI at baseline* 2.7(1.6-4.9) 2.8(2.4-3.7) 3.2(2.5-4.8) 
BB1 at baseline 3(10) 30(97) 26(87) 
ACE_or_ARB 
inhibitors† 
6(19) 30(97) 28(93) 
Statins at baseline† 9(29) 28(90) 28(93) 
Diuretics at baseline† 3(10) 8(26) 9(30) 
*Median (inter-quartile range) †Number of patients (percent of patients). BMI, Body Mass Index, 
eGFR, estimated Glomerular Filtration Rate, LVEF, Left Ventricular Ejection Volume, BP, Blood 
Pressure, NT-BNP, N-Terminal Brain Natriuretic Peptide, hsTni, High sensitivity Troponin I, BB1, 
Beta Blocker 1, ACE, angiotensin converting enzyme, ARB, angiotensin-receptor blockers 
3.2.3.1.1 Christchurch Healthy Volunteers for Heart Disease Research Cohort (HVOLs) 
Volunteers randomly selected from the Canterbury electoral rolls and age- and sex-matched to 
existing Christchurch Heart Institute (CHI) acute coronary syndromes, MI and HF patient 
cohorts were recruited into the Canterbury Healthy Volunteers study between 2003-2013 
(HVOLs, n=3,358) Participants were aged 18 to 100 years and were screened before 
recruitment using hospital Patient Management Systems databases to confirm they had no 
documented personal history of overt cardiovascular disease, including IHD and MI. 
Participants attended a research clinic where they completed a study questionnaire on their 
medical history, smoking status, alcohol consumption, and self-reported physical activity. 
Height, weight, waist, and hip measurements were documented, blood pressure was recorded 
(seated, with duplicate readings at least 10 mins apart), and a blood sample was taken for 
neurohormone and genetic analyses. Subsequent cardiovascular events during follow-up were 
identified through the hospital Patient Management Systems and New Zealand Health 
Information Services (NZHIS) databases, with a median follow-up of 9 years. The study was 
approved by the Upper South A Ethics Committee (Reference No. CTY/01/05/062), and each 
participant provided written, informed consent. 




From July 2002, patients (n=2140) admitted to either Christchurch Hospital or Auckland City 
Hospital, New Zealand, were recruited into the Coronary Disease Cohort Study (CDCS). 
Inclusion criteria were ischaemic discomfort plus one or more of the following: ECG changes 
(ST-segment depression or elevation of at least 0.5 mm, T-wave inversion of at least 3 mm in 
at least 3 leads, or left bundle branch block), elevated levels of cardiac markers, a history of 
coronary disease, or 64 years of age in patients with diabetes mellitus or vascular disease. 
Patients were excluded from the study if they had a severe comorbidity that limited their life 
expectancy to 3 years. Within the CDCS cohort, unstable angina accounted for 26.1% of all 
diagnoses at discharge, non-ST-segment elevation MI (NSTEMI) for 51.2%, and ST-segment 
elevation MI (STEMI) for 22.7%. Anthropometric and clinical characteristics were recorded 
at planned follow-up clinic visits at baseline, 4 months, and 12 months after admission. 
Clinical events were recorded from questionnaires, patient notes, and NZHIS and hospital 
PMS databases. Median follow-up was 3.7 years (range, 0.1–7.9 years). The study conformed 
to the principles outlined in the Declaration of Helsinki and Title 45, US Code of Federal 
Regulations, Part 46, was approved by the New Zealand Multi-region Ethics Committee 
(Reference No. CTY/ 02/02/018) and registered with the Australian New Zealand Clinical 
Trials Registry (ACTRN12605000431628). Each participating patient provided written, 
informed consent. 
3.2.3.2 Plasma collection 
All plasma samples required for this study were collected, processed and bio banked at -80 C 
by CHI study coordinators. Bloods were taken from an indwelling intravenous cannula placed 
30 min prior to sampling, with the patient remaining semi recumbent. Whole peripheral blood 
samples were drawn into 9mL EDTA tubes.  Centrifugation occurred within 30 minutes of 
collection at 4C, 300rpm for 10 minutes. The separated plasma was carefully pipetted off with 
care taken not to disturb the red blood cells pelleted at the bottom of the collection tube. 




3.2.4 Plasma sample selection 
Plasma samples, collected ~4 months post-index coronary event once the patients were stable 
and early left ventricular remodelling was underway, were selected from CDCS patients and 
healthy control samples from the HVOLs (see Figure 3-1 for a schematic of the procedure). 
The CDCS group was split into two groups – those that went on to develop heart failure 
within 3 years (HF+) and those that did not (HF-). Patients who developed HF after admission 
were filtered to exclude patients that had HF prior to baseline, had a diagnosis of HF beyond 3 
years of sampling and lastly, those samples that had less than 5mL of plasma in storage. This 
left 30 samples in the HF+ group. The CDCS patient samples that had no HF prior to, or after 
baseline (HF-), and the HVOL control samples were to exclude samples that had less than 
5mL of plasma in storage.   
 
Figure 3-1 The selection procedure for plasma samples from the HVOLs and CDCS cohort. 
After filtering the CDCS HF positive group had 30 samples available. The CDCS HF negative and 
HVOLs samples were then chosen to match the 30 CDCS HF positive samples as closely as possible 
using the R package MatchIt. All categories were matched between CDCS HF positive and CDCS HF 





The CDCS HF negative and HVOLs samples were then exactly matched to the CDCS HF 
positive samples for age, gender and ethnicity and nearest matched for previous medical 
history and severity of disease where possible, using the MatchIt package in R software 
(https://github.com/kosukeimai/MatchIt).  The following variables (collected at the baseline 
clinic) were selected to be nearest matched:  Body mass index, history of smoking, activity, 
heart rate, history of MI, history of valve disease, history of cerebrovascular accident, LVEF, 
E/e’ (an echocardiogram index of diastolic dysfunction), creatinine, history of coronary artery 
bypass grafting, history of percutaneous coronary intervention, history of hypertension, 
history of diabetes, history of pulmonary disorder, history of peripheral vascular disease, 
levels of NT-proBNP, levels of High‐Sensitivity Troponin I, and medications - Beta Blocker 
I,  angiotensin converting enzyme inhibitors (ACE) and angiotensin-receptor blockers 
(ARBs), statins and diuretics. A total of 31 CDCS HF - samples and 31 HVOL samples were 
selected to achieve a total sample pool of 95 samples (including CDCS HF + and positive 
controls) for the Nova-Seq sequencing run, enabling each sample to be sequenced to a depth 
of ~100M reads. Confirmation that there were no statistically significant differences between 
the groups for any of the variables that had been selected using chi square and anova tests was 
carried out (data shown in Appendix A). 
3.3 Laboratory Methods 
As several of the laboratory methods were commercial protocols, for clarity of the chapter, 
where possible these have been abbreviated. The next section has been abbreviated and the 
full-length versions are shown in Appendix B-1.  
3.3.1 RNA extraction from tissue 
For the validation experiment using Nanopore sequencing (Section 3.4), RNA from the 
Cleveland donor heart samples was used (previously extracted by Dr Anna Pilbrow). 
Left ventricular tissue from donor hearts was broken into small blocks (100-150 mg) in liquid 




grinding was performed for 10 minutes in 800 µL pre-chilled TRIzol® (Invitrogen, Carlsbad, 
CA). Samples were mixed with 160 µL chloroform for 15 seconds, incubated at room 
temperature for 2-3 minutes and then centrifuged at 12,000g for 15 minutes. The supernatant 
was transferred to a fresh 1.5mL Eppendorf tube.  
RNA clean-up was performed with the Norgen Biotek CleanAll Kit according to 
manufacturer’s instructions.  Briefly, RNase-free 70% ethanol was added to the supernatant 
and vortexed. This was applied to a spin column with collection tube and centrifuged. Flow-
through was discarded and the column reassembled. This was repeated. Wash solution was 
added and centrifuged. This was repeated twice. The column was transferred to a fresh elution 
tube, elution buffer was added and centrifuged. RNA was quantified using the Nanodrop 8000 
(ThermoFisher Scientific Inc, Waltham, USA). 
3.3.2 RNA extraction from plasma 
Following selection of plasma samples from CDCS and HVOLs cohorts (HVOL n=31, CDCS 
HF – n=31, CDCS HF + n=30), I performed RNA extraction and clean-up from plasma using 
Norgen Plasma/Serum RNA Purification kits (cat #56200, Norgen Biotek Corporation, 
Thorold, Canada). This kit purifies RNA from up to 5 mL of fresh or frozen serum/plasma 
and concentrates high purity, cell-free circulating and exosomal RNA using a two-column 
method. The first column processes the large volume of serum/plasma fluid which is followed 
by a concentration of the RNA on a second mini column. Frozen plasma was thawed on ice 
and centrifuged at 400 g for 2 minutes to remove cell debris. Up to 5 mL of plasma was 
transferred to a 50 mL tube (if the sample volume was less than 5 mL it was topped up to 
5mL using nuclease free water). Lysis Buffer A (15 mL) along with 150 µl of β-
mercaptoethanol was added to each plasma sample and vortexed for 10 seconds. Isopropanol 
(10 mL) was added and vortexed for 10 seconds. Then 15mL of this solution was transferred 
to a Maxi Spin column with collection tube (lids were left loose) and centrifuged for 3 




reassembled. This was repeated until all of the mixture had been added to the column. Wash 
Solution A (5 mL) was added and centrifuged for 3 minutes at 1,000 g. The flow-through was 
discarded, and column and tube reassembled, and this wash was repeated a second time. The 
column was spun empty at 2000 g for 3 minutes to dry the column. The Maxi Spin column 
was transferred to a fresh 50 mL tube, 800 µl of Elution Buffer F was added to the column, 
incubated at room temperature for 2 minutes and then centrifuged for 2 minutes at 500 g.  To 
maximise RNA recovery the eluted RNA was reloaded onto the same Maxi Spin column, 
incubated at room temperature for 2 minutes and then centrifuged for 2 minutes at 500 g. To 
concentrate the RNA, 600 µl of Lysis Buffer A was added to the eluate and vortexed for 10 
seconds. This was followed by adding 800 µl of 96-100% Ethanol and vortexing for 10 
seconds, and then 750 µl of the ethanol-RNA eluate mix was transferred to a Mini Spin 
column and centrifuged for 2 minutes at 3,300 g. The flow-through was discarded and this 
step was repeated until all of the mixture had been transferred.  For every sample, a mix of 15 
µL of DNase I and 100 µL of Enzyme Incubation Buffer was prepared using Norgen’s 
RNase-Free DNase I Kit (Product # 25710). Prior to DNase I treatment, 400 µl of Wash 
Solution A was added to the column, centrifuged for 3 minutes at 3,300 g and the flow-
through discarded. After adding 100 µl of the prepared RNase-free DNase I solution to the 
column and centrifuging at 8,000 g for 1 minute, the flow-through was pipetted back to the 
column and incubated at 25-30°C for 15 minutes, to ensure maximal degradation of DNA.  To 
wash the RNA bound to the column, 400 µl of Wash Solution A was added to the column, 
centrifuged for 3 minutes at 3,300 g and the flow-through discarded.  This step was repeated a 
second time to ensure removal of digested DNA.  The column was spun empty for 2 minutes 
at 13,000 g to dry it completely before transferring it to a fresh 1.7 mL Elution tube and 
adding 50 µL of Elution Solution A to the column, incubating at room temperature for 2 
minutes and centrifuging for 1 minute at 400 g followed by 2 minutes at 5,800 g. To 




temperature for a further 2 minutes and centrifuged for 1 minute at 400g followed by 2 
minutes at 5,800 g. RNA was quantified using the Qubit™ adapted protocol (Section 
3.3.3.1.3). This final 50 µl elution containing the RNA was stored at -80 C prior to 
sequencing.   
3.3.3 Assessing RNA Quantity and Integrity 
3.3.3.1 RNA Quantification 
3.3.3.1.1 Nanodrop Spectrophotometry 
The amount of RNA extracted from each Cleveland human heart tissue sample was estimated 
by ultraviolet spectrophotometry using NanoDrop. RNA (and DNA) absorb light with a 
characteristic peak at 260 nm. Elution buffer was used as a blank and 1.5 µl of sample was 
loaded onto the cleaned Nanodrop pedestal to obtain an approximate estimate of the sample 
concentration prior to quantitation on the Qubit Fluorometer and assessment of RNA integrity 
on the TapeStation 2200 system. 
3.3.3.1.2 Fluorometry (Qubit™) Standard protocol for RNA quantification of heart tissue 
RNA extracted from human heart tissue was quantified on the fluorescence-based Qubit 2.0 
Fluorometer using the Qubit™ RNA HS Assay Kit (ThermoFisher Scientific Inc., Waltham, 
USA). The Qubit™ working solution was prepared at room temperature by mixing Qubit 
RNA HS Reagent to Qubit RNA HS Buffer in a ratio of 1:200 (~200 µL of working solution 
per sample/standard). Qubit™ working solution (190 µL) was added to 10 µL of the Qubit™ 
standards (Standard #1 served as a blank, Standard #2 contained RNA at 500 ng/µL) and 
vortexed for 3 seconds. 199 µL of Qubit™ working solution was added to 1 µL of each 
sample and vortexed for 3 seconds. All tubes were incubated at room temperature for 2 
minutes. The two kit standards were used to create a standard curve that the Qubit™ uses to 
generate a curve fitting algorithm that is uses to calculate concentration. Each sample 
measurement was performed three times, averaged and multiplied by 200 (the dilution factor) 




3.3.3.1.3 Fluorometry (Qubit™) Adapted protocol of RNA quantification for plasma 
Because the concentration of RNA extracted from human plasma was below the detection 
limit of the Qubit™ high sensitivity RNA kit described above, a modified protocol that could 
detect RNA concentrations between 250 pg/µL and 55.6 pg/µL [369] was used. 
The Qubit™ working solution and standards were prepared as described above. A 2.5 ng/µL 
RNA ‘spike in’ master mix was prepared by diluting the Qubit™ RNA Standard #2 4 -fold 
with RNase free water. The ‘spike in’ master mix (182 µL) was mixed with 18µL of RNAse 
free water (‘spike in’ alone tube) or 17 µL of RNAse free water and 1µL of sample. All tubes 
were vortexed for 3 seconds, centrifuged for ~ 5 seconds (to collect the solution at the bottom 
of the tube) and incubated at room temperature for 2 minutes. After calibrating the Qubit™ 
fluorometer with both standards (described above) the RNA ‘spike in’ alone tube was 
measured (Read 1) followed by the RNA sample tubes (Read 2). RNA sample concentration 
was calculated as: 
Concentration (pg/uL = (Read2 – Read1) (pg/μL) × 200 (μL) ÷ volume of sample added (μL) 
3.3.3.2 Agilent TapeStation RNA ScreenTape System for assessing RNA 
integrity 
RNA from the Cleveland Heart tissue was quantified and assessed for integrity using the 
Agilent TapeStation 2200 System (Agilent, Santa Clara, CA).  This is an automated 
electrophoresis system which uses 1-2 µl of RNA sample to determine the RNA Integrity 
Number (RIN) based on the relative intensity of 28S:18S rRNA bands. Ratios >2.0 indicate 
intact, high-quality RNA and equate to RIN values which can be between 10 (intact) to 1 
(totally degraded). [370]. 
RNA was thawed on ice and all reagents were allowed to equilibrate to room temperature for 
30 minutes. 1 µl of RNA ladder or sample was added to 5µl RNA sample buffer and vortexed 
briefly to mix. Tubes were heated to 72 °C for 3 minutes, placed on ice for 2 minutes and 




were loaded onto the instrument and automated electrophoresis performed according to 
manufacturer’s instructions.  
3.3.4 Sequins – synthetic internal controls. 
The Garvan Institute (Sydney, Australia) have developed RNA standards for use in RNA-Seq 
experiments called ‘sequins’ (synthetic spike-ins to act as internal controls) [371]. Sequins are 
provided with a range of isoforms and at varying concentrations, covering 78 artificial genes 
ranging from single exons to large, multi-exonic transcripts (up to 36 exons) and including 
164 alternative isoforms ranging in length. The sequins are derived from an artificial 11 Mb 
chromosome designed to reflect the GC composition and repeat density of the human 
genome. Any sequence similarity of the artificial chromosome to the human genome was 
avoided by sequence inversion and shuffling. By spiking in these synthetic RNAs of known 
amounts it is possible to check that the library preparation and sequencing has worked 
successfully. It is also possible to detect the limit of detection (e.g. what is the lowest 
abundant sequin transcript we can detect) and extrapolate that to the transcripts we are 
analysing. Sequins were spiked (1%) into Cleveland Heart tissue RNA when I validated novel 
heart tissue transcripts from the Harvard data. Also, sequins were tested to see if they could be 
successfully added to the plasma samples. 
3.4 Methods for Nanopore long read sequencing 
3.4.1 Reverse transcription and strand-switching 
The integrity of RNA previously extracted from Cleveland Heart Donor Patients (section 
3.2.2) was assessed on the TapeStation 2200 as described in Section 3.3.3.2. Of 44 RNA 
samples tested, 8 samples had RIN scores ≥8 indicating good quality RNA and were selected 
for analysis by Nanopore long read sequencing. These were pooled for the validation 
experiment, which aimed to confirm the presence of putative novel lncRNAs identified in the 




The Nanopore cDNA-PCR Sequencing protocol (SQK-PCS109) uses a ‘strand switching’ 
method which gives higher yields of cDNA and enriches for full length cDNAs.  When the 
first strand synthesis reaches the end of the fragment, the reverse transcriptase adds several 
non-templated Cs to the end of the cDNA. A strand switching primer in the reaction binds to 
these Cs and the reverse transcriptase switches template from the RNA to the strand switching 
primer. The second strand cDNA is then synthesised (Figure 3-2). 
Briefly, the strand switching method produces full length cDNAs from total RNA (or polyA 
RNA). These were then amplified by PCR which at the same time adds ‘rapid attachment’ 
primers, sequencing primers were then attached, and the library was loaded onto the flow cell. 
 
Figure 3-2 A schematic of Nanopore ‘strand switching’ cDNA library preparation protocol. 
An oligo dT primer is annealed to the polyA tail of the RNA and reverse transcription takes 
place.  Several non-templated Cs are then added and a strand switching primer anneals. A 
second cDNA strand is then generated producing a full-length cDNA. Amplification happens 
by PCR and sequencing primers are attached. Figure adapted from Nanopore website  
(https://nanoporetech.com/sites/default/files/s3/literature/Nanopore-cDNA-Guide.pdf) 
Total RNA (50 ng) was combined with 1% RNA sequins (0.5ng) [372], 1 µL of polyT-VN 




the final volume was adjusted to 9 µL with RNase-free water. Samples were mixed by 
tapping, briefly spun by microfuge, incubated at 65°C for 5 minutes and immediately snap 
cooled on a pre-chilled freezer block. Next, 4 µL of 5x RT Buffer (ThermoFisher, EP0751), 1 
µL of RNaseOUT (40 U/µL Life Technologies, 10777019), 1 µL of nuclease free water and 2 
µL Strand-Switching Primer (SSP, ONT SQK-PCS109) were added to the samples, which 
were mixed by tapping, briefly spun, and incubated at 42 °C for 2 minutes. Finally, 1µL of 
Maxima H Minus Reverse Transcriptase (ThermoFisher, EP0751) was added to each of the 
19 μL reaction mixes. Samples were mixed by tapping, briefly spun by microfuge and 
incubated in a thermocycler (Eppendorf® Mastercycler®, Hamburg, Germany) under the 
following conditions: 42 °C for 90 minutes (RT reaction and strand-switching), 85°C for 5 
minutes (heat inactivation); and then held indefinitely at 4 °C.  
3.4.2 Selecting for full-length transcripts by PCR 
The reverse-transcribed sample (20µL) was split into four 5µl aliquots and mixed with 25 µL 
LongAmp Taq 2x Master Mix (NEB M0287), 1.5µL cDNA Primer (cPRM, ONT SQK-
PCS109) and 18.5µL of Nuclease-free water.  Reactions were incubated in a thermocycler 
under the following conditions: 95 °C for 30 seconds (initial denaturation) followed by 14 
cycles of 95 °C for 15 seconds (denaturation), 62 °C for 15 seconds (annealing), 65 °C for 50 
seconds per kilobase (extension), and a final extension of 65 °C for 6 minutes. After thermal 
cycling, samples were held at 4 °C. Exonuclease (NEB, M0293) (1µL) was added to each 
tube and each reaction was incubated at 37 °C for 15 minutes followed by 80 °C for 15 
minutes. The four sample aliquots were pooled, and the combined cDNA sample was purified 
by a 5-minute rotating mixer incubation with 160μL (1.8X) resuspended Agencourt AMPure 
XP magnetic beads (A63880, Beckman Coulter) at room temperature. While bound to the 
magnet, two 200 μL washes with 70% ethanol were performed, with the ethanol then 
discarded.  Tubes were air dried for 30 seconds and eluted in 12 μL Elution Buffer (EB, ONT 




(next section) On average, the samples had a fragment length of 1500 bp and a concentration 
of 40 ng/µL. Elution Buffer (7 µL) was added to 5µL of sample to make up between 100-200 
fmol of amplified cDNA.  
3.4.3 Agilent Genomic DNA ScreenTape System 
As part of the Nanopore library preparation, sizing analysis of the generated cDNA fragment 
was assessed with the Agilent Genomic DNA ScreenTape was used for this (used for 
fragments between 200bp to > 60,000bp).  
All reagents were allowed to equilibrate to room temperature for 30 minutes.  Genomic DNA 
ladder (1 µl) or sample (1 µl) was added to 10 µl Genomic DNA sample buffer, vortexed at 
2000 rpm for 1 minute then spun to collect the liquid at the bottom of the tube. ScreenTape, 
tips and tubes were loaded onto the instrument and automated electrophoresis performed 
according to manufacturer’s instructions. The instrument outputs a gel image (alongside the 
ladder) and an electropherogram from which the length of the fragment was assessed.  
3.4.4 Adapter addition 
To ligate sequencing adaptors to each transcript, 1 µL of Rapid Adapter (RAP, ONT SQK-
PCS109) was added to each cDNA sample, the tube was mixed by tapping and briefly spun 
by microfuge, then incubated for 5 minutes at room temperature. The sample was loaded onto 
the gridION according to the ONT SQK-PCS109 kit instructions.  
3.4.5 Bioinformatic analysis for Nanopore sequencing 
Oxford Nanopore Technologies (ONT) reads were base called using the on-sequencer Guppy 
base calling software (v3.03 High accuracy) without the trimming option as this removes 
primers needed for the Pychopper software to work. Full length transcripts were identified 
using Pychopper (https://github.com/nanoporetech/pychopper) which is a software tool 
developed by Oxford Nanopore Technologies (ONT) to identify full length Nanopore cDNA 




(hg38) and the sequins in silico chromosome (chrIS) using Minimap2 (v2.17-r941) [373] 
which is a general purpose alignment program to map long reads (parameters: –ax splice –
secondary = no.)[373]. Reads were then  processed using the Pinfish suite 
(https://github.com/nanoporetech/pinfish), a pipeline generated by ONT to generate 
annotations from long read cDNA (parameters: -p 1.0 -c 3 -d 10 -e 30). These full-length 
transcripts were then run through part of the bioinformatics pipeline to generate a list of 
putative novel transcripts identified by Nanopore sequencing. These transcripts were then 
compared to the putative novel transcripts identified from the Harvard data (which used 
Illumina short read sequencing). 
3.5 Methods for Illumina short read sequencing of plasma RNA  
RNA that had been extracted from plasma was sent to the Otago Genomics facility (Dunedin, 
New Zealand), so that sequencing libraries could be made and then sent to the Ramaciotti 
Centre for Genomics, Sydney, Australia for sequencing on the NovaSeq6000. The following 
sections (2.5.1-2.5.6) were carried out by Dr Aaron Jeffs at the Otago Genomics facility. 
For Illumina total RNA library preparation, the SMARTer® Stranded Total RNA-Seq Kit v2 
- Pico Input Mammalian (Takara Bio, USA) was used. A control total RNA sample was used 
(human brain, diluted to 0.25ng/µl), which was supplied with the kit. Briefly, the protocol 
involves first strand cDNA synthesis, addition of Illumina adapters and barcodes (for 
multiplexing), library purification and AMPure beads, a final PCR amplification and a second 
purification with AMPure beads. The following section has been abbreviated and the full 
protocol is in Appendix B-2 
3.5.1 First strand synthesis 
Option 2 (starting with degraded RNA) without fragmentation was used.  RNA sample (8 µl) 
was mixed with 1 µl of SMART Pico Oligos Mix v2 on ice and incubated at 72 °C for 3 
minutes, then chilled rack for 2 minutes.  The First-Strand Master Mix was prepared with 4 µl 




SMARTScribe Reverse Transcriptase, added to each reaction tube and vortexed and 
incubated at 42 °C for 90 minutes, 70 °C for 10 minutes and then held at 4 °C 
3.5.2 Addition of Illumina adapters and indexes 
A PCR master mix with 2 µL nuclease-free water, 25 µl SeqAmp CB PCR Buffer (2X), 1 µl 
SeqAmp DNA Polymerase was added to each sample. PCR Primer HT was added (1 µl), and 
PCR was performed: 94 °C for 1 minute, 5 cycles of 98 °C for 15 seconds, 55 °C for 15 
seconds, 68 °C for 30 seconds, 68 °C for 2 minutes. 
3.5.3 Purification of the RNA-Seq Library Using AMPure Beads 
AMPure beads (40 µL/sample), were added to each sample tube and incubated for 8 minutes. 
Tubes were placed onto a magnetic separation device for 5 minutes, the supernatant was 
removed and discarded and 200 µl of freshly made 80% ethanol was added then removed and 
discarded, and the wash step was repeated.  Pellets were air dried, 52 µl of nuclease-free 
water added, incubated for 5 minutes at room temperature, and placed back onto the magnetic 
separation device for 1 minute. Supernatant (50 µl) was transferred to a new tube, mixed with 
40µL of AMPure beads and incubated for 8 minutes. 
3.5.4 Depletion of Ribosomal cDNA with ZapR v2 and R-Probes v2 
Tubes were placed on the magnetic separation device for 5 minutes, supernatant removed and 
discarded, and 200 µl of freshly made 80% ethanol added to each sample. Supernatant was 
removed and discarded, and the wash step was repeated. Tubes were aired dried on the 
magnetic separation device. A ZapR master mix was prepared:  16.8 µl Nuclease-Free Water, 
2.2 µl 10X ZapR Buffer, 1.5 µl ZapR v2 and lastly 1.5 µl ‘activated’ R-Probes v2 (that bind 
rRNA and mitochondrial rRNA which had been preheated hot-lid thermal cycler at 72°C for 2 
minutes and held at 4°C for at least 2 minutes). The dried beads were resuspended in 22 µl of 
the ZapR master mix, incubated at room temperature for 5 minutes and placed on the 




PCR tube. Tubes were incubated in a preheated hot-lid thermal cycler at 37 °C for 60 minutes 
followed by 72 °C for 10 minutes then held at 4°C. 
3.5.5 Final RNA-Seq Library Amplification 
Library fragments were further enriched in a second round of PCR. A PCR master mix was 
prepared: 26 µl Nuclease-Free Water, 50 µl SeqAmp CB PCR Buffer, 2 µl PCR2 Primers v2 
and 2 µl SeqAmp DNA Polymerase. 80 µl of master mix was added to each sample tube.  
Tubes were incubated for 94 °C for 1 minute, 16 cycles of 98 °C for 15 seconds, 55 °C for 15 
seconds, 68 °C for 30 seconds, and held at 4 °C. 
3.5.6 Purification of Final RNA-Seq Library Using AMPure Beads 
A second purification step with AMPure beads. Essentially the process was the same as 
Section 3.5.3 but instead of 40 µl/sample of AMPure beads, 100 µl AMPure beads were 
added to each sample. Also, the final elution was into 12 µl of Tris buffer. The samples were 
then sent to the Ramaciotti Centre for Genomics, Sydney, Australia for sequencing on the 
NovaSeq6000. 
3.6 WGCNA: Weighted Correlation Network Analysis 
For the Harvard data RNA-Seq analysis, to identify clusters of highly correlated genes that 
share a similar pattern of expression across patients and may be co-regulated, a weighted gene 
co-expression network analysis was performed using the WGCNA package [374] in R.  
WGCNA is a network approach to construct gene networks (modules) and identify modules 
that are correlated with a particular trait. Genes within a module that are highly interconnected 
are recognised as ‘hub’ genes – those genes which are thought to play a central role in the 
particular module. An unsigned weighted correlation network (negative as well as positive 
correlations were considered) was constructed for all genes across all samples (pre- and post-
ischaemia), with the aim of identifying gene modules associated with ischaemia. WGCNA 




represented by a weighted average of the expression level of all genes within the module, 
referred to as the module eigengene (kME). Individual genes and modules were then tested 
for association with ischaemia by correlating module eigengenes with ischaemia. In this way, 
modules with the strongest association to ischaemia were identified, and the genes with the 
strongest association to each module indicated highly interconnected hub genes that may be 
driving ischaemia.   
3.7 Ingenuity Pathway Analysis (IPA) 
To identify the molecular pathways, networks and related biofunctions, differentially 
expressed genes within those modules identified by WGCNA as significantly associated with 
ischaemia were assessed with the Core Analysis Workflow with Ingenuity Pathway Analysis 
(IPA) software (http://www.ingenuity.com, Qiagen, Redwood City, CA, USA). Along with p-
values, IPA gives a z-score which represents a statistical measure of the match between the 
expected vs observed direction of gene expression. The magnitude of the z-score is a measure 
of the proportion of genes with expression patterns consistent with activation of the pathway. 
Any z-score > 2 (indicating pathway activation) or < -2 (indicating pathway repression) was 
considered to be potentially biologically meaningful. 
3.8 RNAscope 
To identify the cellular localisation of mRNAs or lncRNAs associated with ischaemia, 
RNAscope (Advanced Cll Diagnostics, ACD, Newark, CA, USA) was used. RNAscope is a 
novel in situ hybridisation assay developed by for detection of target RNA within cells and 
tissue whilst preserving the structural integrity of both. Briefly, a specific double ‘Z’ shaped 
probe hybridises to the target RNA sequence (about 18-25 bases).  The probe is then bound 




3.8.1 RNAscope probes 
Custom RNAscope probes for two annotated lncRNAs (PCAT 19 and VASH1-AS) and one 
novel lncRNA (MSTRG. 10265.1) that were associated with ischaemia by WGCNA analysis 
were ordered from ACD, along with NEAT1  – a lncRNA that has been demonstrated to be 
expressed predominantly in the nucleus of cells and which acted as a positive control and a 
negative control dapB probe. The RNAscope 2.5 HD fast red detection kit was used (CAT 
NO: 322360).  
3.8.2 Tissue section preparation 
Formalin-Fixed Paraffin-Embedded (FFPE) left ventricle tissue glass slides were kindly 
provided in collaboration with Professor Christine Moravec and Ms Wendy Sweet (Cleveland 
Clinic Foundation, Cleveland Ohio). Slides were baked for 1 hour at 65C°. They were then 
incubated for 5 mins at room temperature in xylene, followed by a second xylene incubation 
for 5 minutes, and then 1 minute in 100% ethanol (ETOH) twice. The slides were air dried at 
room temperature, before 5-8 drops of hydrogen peroxide (provided in the kit) were added to 
the slides and left for 10 minutes at room temperature. The slides were rinsed twice in 
distilled water. Slides were then placed in boiling(100-104°C) pre-treatment 2 solution 
(provided in the kit) for 30 minutes then rinsed in distilled water twice and once in 100% 
ETOH then left to air dry. A hydrophobic barrier was then drawn around the tissue section 
using an ImmEdge™ pen (Vector Laboratories Inc. Burlingame, CA, USA) to contain further 
treatments.   
3.8.3 Hybridisation with RNA probes. 
Hybridisation was conducted following the manufacturer’s instructions in FFPE Detection kit 
(Red) Part 2. Protease plus solution was added to the slides (5 drops) and incubated at 40°C in 
the HybEZ™ Oven (ACD, Newark, CA, USA) for 30 minutes. The two lncRNA probes 
(PCAT 19 and VASH1-AS), a negative control (no antibody) and a positive control (NEAT1) 




drops). All slides were then placed onto the HybEZ™ Humidity Control Tray, the lid placed 
on and placed in the HybEZ™ Oven and incubated at 40 ˚C for 2 hours. Slides were then 
rinsed with two changes of Wash Buffer for 2 minutes at room temperature.   
Next, a series of incubation steps with pre-amplifier and several amplifier probes was carried 
out. AMP1-AMP4 (kit provided) were serially incubated at 40°C, AMP1 for 30 minutes, 
AMP2 for 15 minutes, AMP3 for 30 minutes, AMP4 for 15 minutes. AMP 5 was then added 
at room temperature for 60 minutes and lastly, AMP6, added at room temperature, for 15 
minutes. Between each incubation step slides were washed twice in wash buffer, consisting of 
two-minute incubations at room temperature. 
3.8.4 Signal detection 
To detect the hybridisation probes, 120µl of a 1:60 ratio mix of Fast RED-B to Fast RED-A 
was pipetted onto each slide and incubated at room temperature in the HybEZ™ Humidity 
Control Tray for 10 minutes. Slides were rinsed twice in fresh distilled water. 
3.8.5 Counterstaining 
Slides were placed into a dish containing 50% Gills Haematoxylin II (Leica Biosystems, 
Richmond, IL, USA) for two minutes at room temperature after which the slides appeared 
purple, then washed in distilled water until the slides were clear whilst tissue sections were 
still purple. Slides were then rinsed in 0.02% Ammonia water, followed by tap water. Slides 
were dried in a 60°C oven for at least 15 minutes after which they were briefly dipped into 
fresh xylene. A cover mount was applied using 1-2 drops of SurgiPath DPX mounting 
medium. Slides were analysed and Tagged Image Format (.TIF) images captured using a 
Zeiss Apotome Microscope and associated software (AxioVersion 4.5. Apotome software, 




3.9  Bioinformatic analysis of novel lncRNAs 
3.9.1 Quality control to identify tissue origin of transcriptome 
As a quality control step for the Harvard data RNA-Seq analysis the R package TissueEnrich 
was used [375]. TissueEnrich calculates the enrichment of tissue specific genes in a set of 
input genes and in this way identify the tissue most expected for that set of genes. 
3.9.2 Conservation of novel lncRNAs 
Evolutionary conservation of novel lncRNAs was assessed using precomputed nucleotide 
level calculations of evolutionary selection from phastCons score. PhastCons identifies 
evolutionary conserved elements in multiple-aligned sequences and assigns a score between 0 
and 1; the closer the score is to 1, the more evolutionarily conserved the base [376]. A bigwig 
file containing phastCons base-by-base conservation scores across 20 mammalian species was 
downloaded from the UCSC site 
(http://hgdownload.soe.ucsc.edu/goldenPath/hg38/phastCons20way/hg38.phastCons20way.b
w) and converted to bed format using the bigWigToBedGraph tool 
(http://hgdownload.soe.ucsc.edu/admin/exe/). Novel lncRNAs, annotated lncRNAs and 
coding mRNAs were aligned to the phastCons bed file and a mean phastCons score was 
extracted for each exon using bedtools map (bedtools map -a genes.bed -b 
phastCons.bedgraph -c 4 -o mean). To compare the conservation profile of exon sequences 
between novel lncRNAs, annotated lncRNAs and mRNAs, the frequency of scores were 
plotted for each group separately in R. 
3.9.3 Novel lncRNAs overlapping Regulatory Features: SNPs, enhancers, 
promoters 
Potential interactions between novel lncRNAs with regulatory elements were explored using 
Bedtools v2.27.1 [377]. Overlap of novel lncRNAs with disease-associated single nucleotide 
polymorphisms (SNPs) (https://www.ebi.ac.uk/gwas/downloads) curated for cardiovascular 




transcription factor binding regions that flank promoters (Ensembl biomaRt 
https://www.ensembl.org/biomart/)) were interrogated along with nearest neighbouring genes, 
by comparing against annotated SNPs, regulatory elements and gene coordinates in 
GENCODE v29.   
3.9.4 Novel lncRNAs overlapping expression quantitative trait locus (eQTLs) 
Expression quantitative trait locus (eQTLs) analysis investigates associations between single 
nucleotide polymorphisms (SNPs) and gene expression levels. The novel lncRNAs were 
analysed to see if any overlapped eQTL SNPs, thereby potentially implicating the lncRNA in 
the mechanism underlying the eQTL association. Overlap of both novel and annotated 
lncRNA exon coordinates with cis-eQTL SNPs from GTEX v.8 left ventricle 
(https://gtexportal.org/home/datasets) was assessed using Bedtools Intersect 
(https://bedtools.readthedocs.io/en/latest/content/tools/intersect.html). LncRNAs found to be 
associated with an eQTL SNP were analysed to see whether the lncRNA and eQTL gene were 
members of the same WGCNA module (and therefore suggested to be co-regulated), to 




     Chapter 4 
The bioinformatic pipeline 
4.1 The Bioinformatic pipeline explained 
The raw data files from the sequencing instrument are essentially the starting point for the 
Illumina short-read sequencing bioinformatic pipeline developed in this thesis. The first part 
of this chapter describes the development of the pipeline, the software involved and 
justification for choosing the software.  The second part of the chapter describes validation of 
the pipeline using publicly available data. For an overall schematic of the pipeline, which 
begins with raw RNA Sequencing reads in a fastq file see Figure 4-1. 
4.1.1 The start of the pipeline QC - Trimming of adapters and low-quality reads 
The primary limitation of short read sequencing is that, as the name suggests, only short 
fragments of RNA or DNA (up to 300 bp) can be sequenced. The length of the read is limited 
by the availability of reagents (one base is sequenced per cycle on the sequencing instrument) 
and so the number of cycles equals the number of bases that can be sequenced per fragment. 
For applications such as transcriptome sequencing, as in this thesis, 2 x 150bp is commonly 
used, representing a compromise between cost and maximising sequence length and accuracy. 
Mapping accuracy is increased with paired-end sequencing, as it has the advantage of 
producing twice the number of reads for the same fragment, which means that when the reads 
are aligned back to the reference genome we have additional information on how far apart the 
paired reads should be, helping with more accurate read alignment. 
Preparation of RNA-Seq libraries involves RNA fragmentation followed by size selection and 
ligation of adapters. Adapters are necessary for forward and reverse priming during the 





Figure 4-1 An overview of the bioinformatics pipeline developed in this thesis 
Blue boxes indicate the software used, green boxes represent the input or output files. Each section of the pipeline and the justification as to the choice of software is 




Size selection is used to purify sequences that are the appropriate length for the sequencing 
chemistry, to maximise the information gained without redundancy (overlapped read pair 
sequences). For example, for 2 x 150 bp sequencing we would choose fragments at least 300 
bases long so that 150 bases can be sequenced from each end of the fragment without 
overlapping bases in the middle (Figure 4-2). However, size selection (usually with solid 
phase reversible immobilisation beads) is an imperfect process and most RNA libraries 
include a range of fragment sizes. Inclusion of shorter fragments means that the number of 
cycles will exceed the fragment length and we will sequence into the adapter at the 3’ end. 
This is especially true for low quality, fragmented RNA, and applied to RNA from plasma 
samples as in this thesis.   
Read ‘quality’ is usually measured as a Phred quality score by the sequencing instrument. 
This score indicates the probability of the base being called correctly. It is calculated by the 
equation [378]as:  
Q= -10 log10 E, where E is the base-calling error probability. 
The higher the score, the greater the probability that the base is correct. For example, a Phred 
score of 30 equates to a 1 in 1000 chance of the base being incorrect. Base errors can occur 
due to polymerase errors during library preparation or sequencing errors such as cluster 
density (where the imaging software cannot distinguish between two closely positioned 
clusters on the flowcell) and, for Illumina sequencing which uses the sequence by synthesis 
technique, phasing errors (whereby one fragment of the cluster can either be one cycle behind 
or in front when imaging takes place). Phasing tends to accumulate over time and so the 3 
prime end of the read is more prone to quality loss.  
Several software tools have been developed to minimise the number of ‘unaligned reads’ by 
ensuring that only high quality, non-adapter containing sequences are selected for alignment 




(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), bbduck from the BBMap 
suite (https://sourceforge.net/projects/bbmap/) and cutadapt (although this only trims adapter 
sequences https://opensource.scilifelab.se/projects/cutadapt/).  For the pipeline described in 
this thesis, I used the Trimmomatic software [379] to trim the raw fastq files as it compares 
favourably to other trimming software, allows input of paired-end reads. A Q score of 20 was 
chosen as it appears to be the optimum score to maximise the percentage of mapped reads 
[380] and a default minimum length of 36 bases was chosen as this appears to be the length at 
which we can minimise mapping to multiple locations [381].   
 
Figure 4-2 Why size selection during library preparation eliminates redundancy 
The size selection step of RNA/cDNA during library preparation ensures enrichment of fragments of 




overlap resulting in redundant (duplicated) part of the read B) When the fragment is >300 bases then 
there is no overlap. Created in Biorender.com 
Trimmomatic has the additional feature of using a ‘sliding window’ where removal of the 3’ 
end of a read occurs when the average quality of a group of bases drops below a user-defined 
quality threshold, thus preventing a single low quality base causing the removal of adjacent 







Figure 4-3 QC plots showing reads before and after trimming 
FastQC plots of a representative sample pre (A) and post (B) trimming with Trimmomatic. A & B 
Upper panel): Boxplots indicating quality scores for bases at each position across all fragments: the 
x-axis shows the position in the read, the y-axis the Phred quality scores. For each boxplot, the central 
red line is the median value, the yellow box represents the inter-quartile range (25-75%), the upper 
and lower whiskers represent the 10% and 90% points, and the blue line represents the mean quality. 
The background of the graph divides the y axis into very good quality calls (green), calls of 
reasonable quality (orange), and calls of poor quality (red). Bases that fall below a Phred quality 
score of 30 are trimmed. A & B Middle panel): Line graphs showing the cumulative percentage of 
transcripts within the library which contain adapter sequences at each position. The software contains 
the sequences of the commonly used adapter sequences, in our case the Illumina universal adapter. 
Post trimming, all adapter sequences have been removed. A & B Lower panel) Line graphs showing 
the sequence length distribution : 
4.1.2 Alignment of spliced reads 
After selecting short, 100-300 bp, high quality reads, the next task was to align them to the 
reference genome (GENCODE v29.gtf used in this thesis). The alignment step for RNA-Seq 
is less straightforward than that for DNA as the reads may not be mapped continuously. In 
other words, the reference contains the linear genome, including both introns and exons, 
whereas mature RNA transcripts have the introns spliced out and exons joined. Therefore, an 
individual RNA transcript may include sequences from more than one exon. For this reason, I 
chose the ‘splice aware’ alignment software, STAR (which stands for Spliced Transcripts 
Alignment to a Reference) [268]. 
When considering STAR against other aligners, STAR performed extremely well on several 
parameters including the percentage of reads aligned, accuracy of gene detection and the 
number of genes falsely quantified when compared against 8 and 13 other splice-aware 
aligners respectively [382, 383]. In addition to superior performance, STAR allows the 
identification of two alternative alignment strategies that were appropriate for the 
identification of both circRNAs and lncRNAs in this thesis. First, STAR allows the detection 
of ‘chimeric’ reads, which allows us to identify circRNAs. The reads are not ‘chimeric’ in the 




two different genes) but are ‘back-spliced’ (as discussed previously in section 1.3.3). These 
transcripts would normally be discarded due to a downstream 5’ splice site joining to an 
upstream 3’ slice site (rather than the usual linear splicing involving an upstream 5’ splice site 
joining to a downstream 3’ splice site).  The choice of aligner dictates somewhat which 
software can be used to detect circRNAs. 
Second, when aligning the linear reads, STAR allows two-pass mapping, which is important 
for detecting novel splice sites and enabling identification of putative novel transcripts.  
Briefly, transcripts were mapped using annotated splice junctions from the reference genome 
(first pass mapping). From this, highly confident novel splice junctions (e.g., the splice site 
had canonical splice sites, mapping scores were of high quality and it was seen in a minimum 
number of samples) were collected and added to the annotated junctions before re-running the 
alignment (second pass mapping), allowing STAR to map the reads to novel splice sites 
where appropriate. 
The output from alignment of linear reads is a SAM file (Sequence Alignment Map) or its 
compressed binary version – a BAM file. The SAM/BAM file contains all of the information 
regarding alignment for each read in the sample such as read name, read sequence, read 
quality, where the read mapped in the genome (with genome co-ordinates), whether the read 
mapped uniquely or if it mapped multiple times in the genome or if it did not map at all, 
whether it mapped as a pair or if only the first or second read of the pair mapped 
(http://samtools.github.io/hts-specs/SAMv1.pdf). Using this information, the SAM/BAM file 
could be filtered, for example only taking the uniquely mapping reads (i.e. the reads only 
align to one place in the genome) and removing ambiguous multi-mapping reads, before any 
downstream analysis. At this point I also performed several very useful quality control checks 
to check that the library preparation had gone as planned using the RSeQC tool [384]. An 
overview of the quality control checks and plots are shown in Figure 4-4. First, I used the 




contamination. The ‘Infer experiment’ module predicts the percentage of reads aligned to 
each strand by analysing a subset of reads from the BAM file. For uncontaminated stranded 
RNA libraries, the majority of reads will map to either the sense or the antisense strand 
(depending in which kit was used), whereas in an unstranded or contaminated library I would 
expect to see a 50%-50% distribution. The ‘Read distribution’ module determines the 
percentage of reads mapping to coding exons, 5′-untranslated region (UTR), 3′-UTR, introns, 
and intergenic regions. For RNA analyses we would expect to see the majority of reads 
mapping to the coding, 5’ and 3’-UTR regions; a more uniform distribution across all regions 
is indicative of DNA contamination. The RSeQC tool also plots the fragment length 
distribution of the libraries (discussed in Section 4.1.1). Along with the mapping statistics 
from the STAR aligner, RSeQC analysis can be nicely visualised with MultiQC software 
(Figure 4-4). 
4.1.3 CircRNA read identification 
CircExplorer2 was chosen to identify circRNA back spliced reads it is compatible with the 
STAR2 aligner and compares favourably on sensitivity and specificity when compared with 
other software [385]. Briefly, STAR outputs ‘chimeric’ or split reads which can then be 
filtered to be on the same chromosomes and within a certain distance. These are then input to 
CircExplorer2 which outputs a table of annotated circRNAs with raw counts which is then 
input with the linear reads into DESeq2 (section 4.1.6). Normalising for library size for 
circRNAs is challenging, as quantification of circRNAs is based only on back-spliced 
junction reads and therefore represents only a tiny fraction of the entire library size. 
Normalising using back-spliced junction reads alone would potentially ‘normalise away’ any 
difference in total circRNA production. Consequently, back spliced junction reads were 
normalised using the normalising factors generated from the linear reads (i.e., annotated 




4.1.4 Transcript assembly – StringTie 
After splice aware read alignment, the next bioinformatic challenge was to assemble these 
reads accurately into transcripts and genes for abundance estimation. This is a computational 
challenge: the software needs to correctly piece together the millions of short reads (~200-300 





Figure 4-4 An overview of the quality control pipeline showing representative RNA samples 
To plot the percentage of reads mapping uniquely, multiple times or not mapping, data is extracted from alignment log files and plotted with MultiQC 
software. For the remaining plots ‘read distribution’- the percentage of reads mapping to each feature of the genome, ‘infer experiment’ – the 
percentage of reads mapping to each strand, and ‘fragment length distribution’ data from the BAM files are input to RSeQC and visualised with 











Issues included correctly assigning reads to regions of the genome that are very similar to 
other regions, for example pseudogenes (which are sequences that have high homology to 
functional genes but are not coding into proteins) [386] or multicopy gene families (groups of 
similar genes that have originated from a common ancestral gene) where reads cannot be 
placed unambiguously. Additionally, different isoforms may share the same exons. Reference 
guided assembly clusters reads in the same location together, rather than using overlapping 
sequences. StringTie, which was chosen for transcript assembly in the pipeline, compares 
favourably when tested against other popular reference guided assemblers [387].   StringTie 
uses annotation as a guide but finds novel transcripts when the data dictates.  StringTie 
clusters the reads and builds a splice graph model to represent all possible isoforms of a gene.  
Where StringTie differs is that it also estimates the ‘heaviest path’ of transcript abundance 
(i.e., identifies the most abundant isoform among all splice variants for each gene). StringTie 
then removes these reads from the splice graph and repeats the process until all reads have 
been assigned to a splice variant. In contrast, Cufflinks, one of the most popular assemblers, 
uses a different algorithm to calculate the minimum number of transcripts that explains all of 
the reads without taking abundance into account. After initial assembly, the assembled 
transcripts are merged together by a special StringTie module, which creates a uniform set of 
transcripts for all samples [388]  
Of note, sequencing assembly will become less ambiguous as sequencing reads become 
longer with the evolution of third generation sequencers. As already mentioned, with longer 
read lengths, transcript assembly becomes more accurate as there are fewer ambiguous 
options for the assembler software to consider. Indeed, if the read is long enough it will cover 
the entire transcript and a more accurate representation of the different isoforms for each gene 




4.1.5 Detection of novel transcripts 
Once the transcripts were identified and mapped with genomic co-ordinates, I then used the 
GFF compare software (https://ccb.jhu.edu/software/StringTie/gffcompare.shtml) to compare 
these transcripts against all of the known transcripts in the reference genome (GENCODE 
annotation). GFF compare outputs a ‘class code’ for each transcript as to where it is in the 
genome with regards to annotated genes. For example, if it is a complete match to a reference 
transcript, that is all exons and introns match, then it is given a ‘=’ class code (Figure 4-5A). 
Once each transcript was given a class code, potential novel lncRNAs were selected by 
filtering transcripts with the following class codes: ‘u’ which denotes an intergenic transcript 
(in between two transcripts/genes), ‘i’ which is an intronic transcript, ‘x’ which overlaps an 
exon of a known transcript/gene but the transcript is on the opposite strand of the reference 
and ‘y’ where the novel transcript straddles a known transcript/gene (Figure 4-5B).
 
Figure 4-5 A schematic of the differing transcript class codes output by GFF compare. 
A) A complete match is given a ‘=’ class code, B) Class codes for putative novel transcripts. The 
black boxes denote the reference exons on the genome (blue box), the red boxes denote the transcript 
in the test data set. The exons connecting intron(s) are denoted by the triangular lines.  This is not an 





To identify putative novel lncRNAs, I also selected for transcripts longer than 200 bases (the 
length which differentiates long from short non-coding RNAs). These transcripts were then 
assessed for their lack of coding potential using the Coding-Potential Assessment Tool 
(CPAT)[389]. CPAT uses four features to predict coding potential: open reading frame 
(ORF) length, ORF coverage, Fickett Score and Hexamer usage bias. ORF length is used, as 
a long ORF indicates coding potential (although to complicate matters, it is now known that 
short ORFs can be translated from lncRNAs in what are termed micro peptides [102, 390]). 
Independent but complementary to this is the ORF coverage, which is defined as the ratio of 
ORF length to transcript length. Non-coding transcripts may contain ORFs by chance, but 
they usually have a shorter length relative to the overall length of the transcript. The Fickett 
score assesses the nucleotide composition of codons and considers the degree to which each 
base is favoured in a codon position and the percentage composition of each base.  The score 
represents the probability that the nucleotide composition of that codon would be predicted to 
be coding or non-coding. Lastly, the Hexamer score considers certain dependencies of 
adjacent hexamers (6 bases or 2 codons) in protein-coding sequences. The software was 
developed using all four features on training data to optimise an algorithm for different 
species.  A threshold of 0.364 gave the highest sensitivity and specificity (0.966 for both) for 
human data [389] This default threshold for human was used for the pipeline.  
4.1.6 Gene and transcript quantification. 
The final step of the pipeline for linear transcripts and genes was quantitation and differential 
expression analysis. Again, this was not straightforward, due to well-known biases in RNA-
Seq data that need to be accounted for, mainly due to what is known as ‘positional bias’ 
(which stems from a preferential generation of fragments from either the start or end of the 
transcript during the fragmentation process)  and under representation of transcripts with a 




Positional bias stems from a preferential generation of fragments from either the start or end 
of the transcript during the fragmentation process of library preparation. There may also be 
positional bias due to degradation of the RNA itself.  GC biases are thought to arise from the 
PCR amplification step (GC rich regions can form secondary loop structures that may impede 
the PCR reaction) during library preparation and results in fragments with high GC content 
being underrepresented. Either bias makes transcript estimation problematic as exons from 
different isoforms may not be represented accurately. Consequently, Salmon software was 
chosen over StringTie for gene and transcript abundance estimations in the pipeline [395] as 
it has a transcriptome-wide estimation method which can simultaneously estimate and correct 
for these biases and compares favourably to other transcript quantification software [396]. 
Similarly, the developer of StringTie also used Salmon for abundance estimation in a large-
scale RNA-Seq experiment [397]. The tximport package [398] (developed by the authors of 
two of the best-known RNA-Seq statistical packages, EdgeR and DESeq2) was used to 
summarise the output of Salmon (as well as other transcript level quantifiers) to give 
estimated transcript levels counts and transcript lengths which were input to EdgeR or 
DESeq2 for gene level analysis [399]. 
Finally, once the number of each transcript in a sample had been counted (termed raw 
counts), DESeq2 [400] was used for differential expression analysis. DESeq2 is a popular 
statistical package for RNA-Seq and performs well when compared to other packages [401]. 
RNA-Seq experiments usually suffer from non-normality of data and the presence of outliers 
making inferential statistics difficult. DESeq2 performs a normalisation where it takes the 
geometric mean for each gene across all samples (the geometric is less affected by very small 
or vary large values in skewed data). Each gene’s count in the sample is then divided by this 




library size and composition bias (e.g., to account for a small number of genes being very 
highly expressed in one sample but not the other) [400]  
When looking at differential gene expression between two groups the most common 
approach is to test the null hypothesis that the logarithmic fold change (LFC) between the 
two groups is zero [400]. This produces a list of genes passing multiple-test adjustment. This 
is difficult for noisy data such as RNA-Seq data which is likely with small biological 
replicates and lowly expressed genes (where small differences are exacerbated) as within 
group variance is likely to be high. DESeq2 tackles this problem by sharing information 
across genes - assuming that genes with similar expression levels have similar variance levels 
(or dispersion levels). DESeq2 builds a model of dispersion by plotting each genes dispersion 
and then fitting a smooth curve to capture the expected dispersion for genes at a given 
strength.  It then shrinks noisy gene-wise dispersion towards this curve. The strength of the 
shrinkage depends on the number of samples: as the sample size increases, the shrinkage 
decreases in strength and also how close the dispersion is to the fit (curve).  
DESeq2, the final step in the pipeline, generated a list of differentially expressed genes and 
transcripts, for subsequent analyses.  
4.1.7 Summary 
The bioinformatics pipeline was developed to analyse RNA-Seq data for differentially 
expressed annotated messenger (m)RNAs and long noncoding (lnc) RNAs, novel lncRNAs 
and circular (circ)RNAs combined trimming, quality control, alignment, mapping and 
quantification steps into a seamless analysis. Each step offered multiple different software 
options, were thoroughly assessed at the time of pipeline development and the best 




needed to be compatible with the next piece of software. Added to this was the challenge of 
amalgamating pipelines for mRNA, lncRNA and circRNA analysis.  
The main advantages of this pipeline is that it is unique in that it is interrogating three 
different classes of RNAs simulataneously – annotated mRNAs and lncRNAs, novel 
lncRNAs and circRNAs. 
The next section – the first results section, reviews the validation of this pipeline using 
publicly available data. Once each part of the pipeline was validated, the pipeline was 
combined into SnakeMake (https://snakemake.readthedocs.io/en/stable/) which is a Python 
language workflow management tool developed to create reproducible data analysis. 
4.2 Pipeline Validation 
4.2.1 Introduction 
The pipeline was validated with three publicly available datasets – one dataset for annotated 
coding genes [95], one dataset for annotated and novel lncRNAs [402] and one dataset for 
circRNAs [403]. Differences between my pipeline and that of Yang et al [95], Mirsafian et al 
[402]and Memczak et al [403] are listed in Table 4-1 and discussed in the text.  
For clarity I have combined the methods for all three branches of the pipeline into the 
following section. I then present the results of each data set sequentially and discuss the 
pipeline development and validation in the final section. 
4.2.2 Methods: 
The following methods are summarised in Figure 4-1 For all datasets the raw reads in 
FASTQ format were trimmed to remove adapter sequences and low-quality bases using 
Trimmomatic v0.38 [379]. A sliding window was used to trim bases with a Phred quality 




to the human reference genome sequence (GRCh38.p12) using STAR2 v2.6.0 [268] using 
ENCODE parameters (options for long RNA-Seq detection, see STAR v2.6.0 manual 
https://docplayer.net/91085649-Star-manual-2-6-0a-alexander-dobin-april-23-2018.html) 
providing GENCODE v29 [404] as a reference annotation.  
Table 4-1 Differences between the bioinformatic analysis for the publicly available datasets versus 
the pipeline. 
Annotated mRNA 
 Yang et. al. 2014 Pipeline 




Hg19 (University of California 





Reference Annotation: RefSeq (version unknown), 
Ensembl (version unknown) 
NONCODE 3.0 (January 2012) 
GENCODE v29 (December 
2017) 
Aligner: TopHat (version unknown) STAR2 v2.6.0 
Annotated and novel lncRNAs 
 Mirsafian et. al. 2016  
Trimming: Adapter and quality > Q20 
Trimmomatic (version 
unknown) 
Adapter and quality > Q20 
(Trimmomatic v0.38) 
Human Reference: GRCh38.79 GRCh38.p12 (Genome 
Reference Consortium 
December 2017) 
Reference Annotation: GENCODE v22 GENCODE v29 (December 
2017) 
Aligner: HISAT v0.1.4 STAR2 v2.6.0 
Transcript Assembler: Stringtie v1.3.3 Stringtie v1.3.3 
Coding Potential Software: Coding Potential Assessment 
Tool (CPAT) v??? Cut-off 0.375 
Coding Potential Assessment 







CuffQuant, Cuffnorm Salmon v0.10, Tximport 
v1.9.12, DESeq2 v1.21.23 
CircularRNAs 
 Memczak et. al. 2015 Pipeline 
Trimming:  -  Adapter and quality > Q20 
(Trimmomatic v0.38) 
Human Reference: Hg19 (Feb 2009, GRCh37) GRCh38.p12 (Genome 
Reference Consortium 
December 2017) 
Aligner: Bowtie2 v2.1.0 STAR2 v2.6.0 
Annotation: ENSEMBL release 75 Stringtie GTF (including 
GENCODE v29 and novel 
transcripts), hg38 RefSeq, hg38 
KnownGenes 
Circular detection Reads not mapping 
continuously to the genome 
and head-to-tail splicing 
CIRCexplorer v2.3.2 
The STAR2 chimeric read alignment option was turned on for circRNA detection. The 
aligned reads were then assembled into transcripts using Stringtie v1.3.3 [388] to produce 
Gene transfer format (GTF) files for each sample. Transcripts with a minimum Fragments Per 
Kilobase of transcripts per Million mapped reads (FPKM) of 0.1 (as stipulated from the 
Mirsafian et al study I replicated) from individual sample GTF files were merged to form a 
single set of non-redundant transcripts using the “Stringtie merge” command.  This merged 
Stringtie GTF was then compared against the reference genome using gffcompare v0.10 to 
classify annotated and novel transcripts. For novel lncRNA detection, transcripts that were 
non-homologous to any known coding or non-coding transcripts were filtered to only include 
transcripts (1) longer than 200 nucleotides; (2) with a low coding potential <0.364 (calculated 
using the Coding Potential Assessment Tool (CPAT) v1.2.3 [389]; (3) expressed at ≥0.1 




are multi- exonic (as stipulated by Mirsafian et. al., this filter is for validation purposes only) 
and (5) are intergenic to any GENCODE transcript (as stipulated by Mirsafian et. al., for 
validation purposes only). 
For comparison with the published data FPKM values were assessed using the Bioconductor 
package Ballgown v2.13.1.  Abundance estimation for differential expression analysis (not 
presented here) was generated using Salmon v0.10 [395].  Salmon requires an index built 
from the transcript sequences to quasi-map RNA-Seq reads in the quantification step. 
GFFREAD (http://ccb.jhu.edu/software/stringtie/gff.shtml) was used to build an index from 
the transcript sequences to quasi-map RNA-Seq reads in the quantification step.  The raw 
sequencing reads were then used to generate abundance estimates for each sample. There was 
a more stringent filter for the annotated genes (mRNAs and lncRNAs) compared to the novel 
lncRNAs and circRNAs as the analysis for these was more exploratory. 
For circRNA detection the chimeric reads that were output from the STAR2 alignment were 
input to CIRCexplorer2 v2.3.2 [242]. For annotation of the chimeric reads, the reads were 
compared against the Stringtie GTF. I chose CIRCexplorer2 as it was an established software 
is the analysis of circRNAs. When compared against all other circRNA detection software it 
was rated in the top 3 [385] and of the 3 software was the only one compatible with output 
from STAR. 
4.2.3 Results 
4.2.3.1 Annotated mRNAs 
As no single dataset was available to validate all aspects of the pipeline the mRNAs, 
lncRNAs and circRNAs had to be validated separately with three different datasets. The 
following section describes the validation against the first dataset which tested the mRNAs, I 
could not test for lncRNAs also as the authors provided the annotations of these from 




the transcriptome in failing human heart before and after mechanical support with a left 
ventricular assist device (LVAD).  The transcriptome of 8 patients with ischemic heart failure 
before mechanical support with a left ventricular assist device (LVAD) was compared with 
that of 8 heart donors with no previously diagnosed heart disease.   
There was a total of 233,838,517 input reads from Yang et al analysis compared to 
216,298,854 from my analysis after trimming (Table 4-2) with 89% uniquely mapped to the 
human genome (hg19) (Yang et al) compared to 94% uniquely mapping to GRCh38 (my 
data).  
Table 4-2 A comparison of total reads after trimming, read alignment and mRNA detection 
between Yang et al and the my bioinformatics pipeline developed here 
 Yang et al  Thesis pipeline 
 Total reads after trimming 233,838,517 216,298,854 
Total reads uniquely mapping  208,203,328 (89%) 202,997,711 (94%) 
mRNAs detected (≥3 FPKM in ≥2 samples) 8831 6896 
After converting the hg19 co-ordinates to hg38 via UCSC Batch Coordinate Conversion 
(lifOver) tool https://genome.ucsc.edu/util.html and using the same criterion as Yang et al 
that mRNAs had to be detected at ≥3 FPKM in at least 2 different samples, there were 8,831 
mRNAs detected by Yang et.al. compared to 6,896 for my pipeline. A total of 6077 of these 
were detected by both analyses (69%). There were 819 mRNAs that were detected in my 
analysis that were not detected in Yang et.al. analysis with 2,754 mRNAs detected by Yang 





Figure 4-6 Comparison of the number of protein coding genes detected between the thesis pipeline 
and Yang et.al. 
There was a strong correlation between the geometric mean FPKM values of each gene for 
the two analyses (Spearman correlation of 0.81 after removing genes with geometric means = 
0, Figure 4-7). 
 
Figure 4-7 Scatter plot showing the geometric mean across all samples for protein coding genes 
that were identified in both analyses. 
Low abundance genes were filtered out leaving only genes that had geometric means > 0 for both 




4.2.3.2 Annotated lncRNAs 
Annotated lncRNA genes were validated using the dataset from Mirsafian et. al. Mirsafian et. 
al  performed RNA-Seq in blood cells from four individuals and combined their data with 
eleven other publicly available datasets to characterise lncRNAs in human primary 
monocytes (as publicly available dataset for heart tissue could not be found). As the thesis 
pipeline was designed for paired-end analysis the single-ended Hrdlickova et. al. sample was 
not included in the analysis. 
After applying the filter threshold of 0.1 FPKM in at least 1 sample (to replicate analysis 
from the paper), there were 2,214 (49%) genes that overlapped between the analysis (Figure 
4-8). There were 1,392 lncRNA genes that were identified in my pipeline and not Mirsafian 
et. al. with 2,329 lncRNAs being detected by Mirsafian et. al. but not by my pipeline. If I did 
not apply any filter and looked at read counts normalised for sequencing depth only (and not 
convert to FPKM, which normalises for both sequencing depth and length) 4,473 (98%) 
genes overlapped which suggests a greater proportion of low abundance genes were being 
filtered out with the 0.1 FPKM filter when using my pipeline.  
 
Figure 4-8 A comparison of the number of annotated lncRNA genes detected between the thesis 
pipeline and Misafian et.al. 




Again, genes that were robustly expressed (with geometric means > 0) and identified in both 
analyses were strongly correlated (Spearman correlation of 0.75, Figure 4-9). 
4.2.3.3 Novel lncRNAs 
As the Mirsafian et.al. dataset also identified novel lncRNA transcripts, I was able to use this 
dataset for the validation of the novel lncRNA part of the pipeline. After removing transcripts 
that mapped to annotated  mRNAs and lncRNAs, passed an expression threshold of 0.1 
FPKM, had a Coding-Potential Assessment Tool (CPAT) score of less than 0.375 and were 
intergenic Mirsafian et.al. were left with 1032 transcripts. For the same data set with the same 
filters (except the CPAT filter for which I used the human default threshold of 0.364) my 
pipeline identified 504 putative novel lncRNAs.    
 
Figure 4-9 A plot showing the geometric mean for each lncRNA that was identified in both 
analyses. 
Low abundance genes were filtered out leaving only genes that had geometric means > 0 for both 




Comparing the sequences (using the BLAST software) of the putative novel lncRNAs from 
each analysis I extracted any transcripts that had an overlap of 70% of their length. For some 
transcripts this resulted in several shorter transcripts aligning to a longer one e.g. three 
transcripts identified by Mirsafian et al aligned to one of the transcripts identified by my 
pipeline. This meant that 404 (81%) of all putative novel lncRNAs identified by my pipeline 
overlapped 707 (69%) of putative novel lncRNAs identified by Mirsafian et al (Figure 4-10). 
For this reason the abundance of the overlapping novel transcripts could not be compared 
between the two analyses. 
 
Figure 4-10 A comparison of the number of novel lncRNA transcripts detected between the thesis 
pipeline and Misafian et.al 
707 (69%) of lncRNAs identified by Mirsafian et. al. overlapped 404 (81%) identified by my pipeline. 
4.2.3.4 CircRNAs 
The circRNA part of the thesis pipeline was validated with data from Memczak et al [403]. 
Memczak et al aimed to identify circulating circRNAs by sequencing RNA in human 
peripheral whole blood from five individuals, including one in duplicate.   
Again, as the thesis pipeline trimmed for adapter and quality there were slightly fewer total 




detection was considerably lower in the thesis pipeline, the number of circRNAs identified 
was markedly higher in all samples. A summary of the mapping statistics can be seen in 
Table 4-3. 
Table 4-3 A comparison of read numbers for circular RNA detection between Memczak et.al. and 
my pipeline. 
 Memczak et. al. My pipeline 






















H1 57.85 9.45 4,550 56.63 242,287 13,066 
H1_rep 169.86 28.27 9,996 164.93 701,386 23,746 
H2 48.04 7.88 4,105 47.02 246,609 12,211 
H3 164.93 24.44 11,113 160.63 888,659 25,942 
H4 171.76 13.91 5,739 166.24 376,774 15,740 
H5 170.20 29.02 10,002 165.67 618,166 23,977 
There was an overlap of 77% circRNAs in both analyses. A total of 38,557 circRNAs were 
detected by the thesis pipeline that were not detected by Memczak et. al. (of which 575 had 
read counts for all samples), whereas only 4,249 circRNAs were detected by Memczak et. al. 
but not detected in my pipeline (of which 171 had read counts for all samples, Memczak et. 





Figure 4-11 A comparison of the number of circRNAs detected between my analysis and Memczak 
et.al.  
A Spearman correlation of 0.91was seen for the geometric mean of read counts for the 1709 
circRNAs that were robustly expressed and detected by both analyses (Figure 4-12). 
 
Figure 4-12 A plot showing the geometric mean for each circRNA that was identified in both 
analyses. 
Low abundance genes were filtered out leaving only genes that had geomatric means > 0 for both 





4.2.4.1 Overview of the validation principle 
For each part of the pipeline (mRNA, lncRNA, novel lncRNA and circRNA), I searched for 
publically available data that was i) as close to my project dataset as possible (namely the use 
of paired-end RNA-Seq data in human heart tissue and, if possible, in human ischaemic 
and/or failing heart tissue) and ii) in a form conducive to reproducibility.  Only the dataset 
from Yang et al. [95] originated from heart tissue with the other two datasets [402, 403] 
coming from whole blood highlighting the rarity of RNA-Seq data in human heart.  
Each part of the pipeline was assesed using the raw fastq files from Yang et al., Mirsafian 
et.al and Memczak et. al [95, 402] [403] These were run through the thesis pipeline which 
differed from the original analyses in several ways, including use of a more recent version of 
the reference genome (summarised in Table 4-1). In bioinformatics, software, reference 
sequences and annotations are constantly being updated. Because of these slight differences I 
was not expecting to achieve 100% reproducibility, but wanted to see significant overlap with 
the original analysis of the three datasets. 
4.2.4.2 Performance of the pipeline for mRNAs 
Yang et. al. carried out RNA-Seq on five groups of patients to look at the myocardial 
transcriptome in a non-failing heart group along with failing ischemic and non-ischemic 
human heart before and after mechanical support with a left ventricular device. To validate 
the thesis pipeline two groups that were most similar to my the CDCS HF + and HF -patients 
were selected, namely RNA from non-failing heart and ischemic heart pre-implantation of a 
left ventricular device. 
After trimming for quality and adapters the number of input reads were slightly lower for my 
pipeline ~216 million compared to Yang et. al ~233 million. This was perhaps to be expected 




every fragment of DNA during library preparation and can be incorporated into the read 
sequence. It is important to remove these adapter sequences with trimming software to 
minimise the number of reads that do not align uniquely to the genome –the adapter sequence 
is synthetic and does not appear in any genomic sequence. The choice of trimming for both 
adapter and quality is to maximise the number of reads that unambigously and uniquely align 
to the genome. From the validation against the Yang et al. data,  a higher percentage of 
uniquely mapping reads after trimming was achieved for the pipeline 94% compared to 89% 
for Yang et. al. As mentioned in section 1.4.2.1, the sequencer outputs a quality score for 
each base that it incorporates into the read. This score is represented as a PHRED (Q) score 
which is a probability that is logarithmically linked to the corresponding base being incorrect 
[378].  
The choice of parameters for quality trimming is a trade off between maintaining the 
accuracy of the bases in the read (in order to maximise mappability) and preserving the 
number and length of reads for downstream analysis.  Indeed, accurate gene expression 
estimates depend on getting this balance right with large estimation differences and biases 
being introduced if the balance is less than optimum. [380, 381].  
For the alignment step STAR2 was chosen for the thesis pipeline compared with TopHat in 
pipeline used by Yang et al. STAR2 can discover both non-canonical splice sites and 
chimeric reads both of which the pipeline uses for the discovery of novel lncRNAs and 
circRNAs respectively. There is a ‘two pass’ mapping strategy in which the second alignment 
is supplied with junctions discovered from the first. STAR2 uses this splice junction database 
as a guide to more accurately align any non canonical (novel) junctions. However, if too 
many junctions are provided then the number of multi mappers – reads that can align in two 




affects the read counts. A filter was implemented that was strict enough to ensure that splice 
junctions did not occur by chance yet permissive enough to encourage detection of novel 
splice junctions and thus novel transcripts. Different filters were tested and showed that as the 
number of splice junctions passed to the second mapping increased (with a permissive filter) 
the number of splice sites increased but with fewer uniquely mapped reads which resulted in 
lower read counts per transcript. A strict filter, which resulted in fewer splice junctions being 
passed to the second mapping, increased the number of uniquely mapped reads at the expense 
of splice sites being seen which adversely effected novel transcript detection.  A pragmatic 
filter was chosen: splice junctions had to be present in at least 3 samples with at least 3 
uniqely mapped reads spanning the splice junction, in other words, a filter that was 
permissive enough to allow for novel transcript detection but would filter out junctions that 
could occur by chance. 
After running the pipeline and applying the same filters for abundance as Yang et. al., there 
was a detection overlap of 69%. However, the Yang et. al study included 827 annotated genes 
that were not present in GENCODE v29 (the pipeline’s annotation) due to either name 
changes (e.g. C14orf2 is a synonym for ATP5MPL in GENCODE v29), or an update as to the 
classification of the gene (e.g. GPX1 listed as an mRNA in Yang et. al. is classified as a 
polymorphic pseudogene in GENCODE v29), this issue could be avoided somewhat by the 
use of Ensembl identifiers which were not provided by the authors . An overlap of 91% was 
seen if the analysis was run with no filter of abundance suggesting that the same genes were 
being detected by the thesis pipeline, albeit at a lower level. Additionally, if I did the analysis 
providing GENCODE gtf instead of the stringtie gtf there was a Spearman correlation of 
0.94. For future analysis I will run the annoatated branch of the pipeline with the GENCODE 




Frustratingly, this dataset could not be used to validate the annotated lncRNA part of the 
pipeline.  Unlike the annotated mRNA results, Yang et. al. created a lncRNA database, which 
instead of containing the lncRNA ‘global’ transcript name such as Non-Coding RNA 
Activated By DNA Damage (NORAD),  used hg19 co-ordinates and transcript names from 
the NONCODE and Human Body Map lincRNA catalog database (e.g. n407887) along with 
the software ids of the 113 novels that they identified. After converting the hg19 coordinates 
to hg38 coordinates there was still no overlap between the lncRNAs identified by the thesis 
pipeline and Yang et. al. Worryingly, it was discovered that even for well known, highly 
expressed lncRNAs such as NORAD, the co-ordinates between GENCODE and NONCODE 
were different (e.g. in GENCODE there is only one isoform of NORAD – a single exon 
transcript ENST00000565493.1 with hg38 start position on chromosome 20 of 36045622 and 
stop position of 36050960; for NONCODE the same transcript has a hg38 start position of on 
chromosome 20 of 36045643 and a stop position of 36051016).  Thus without a matching 
gene/transcript name or matching co-ordinates a reliable comparison could not be made. 
Also, Yang et. al. presented the annotated lncRNAs as transcripts and not as genes (there 
were 81 transcripts with duplicated start and stop co-ordinates – no exon information was 
given).  These findings suggest that providing transcript co-ordinates is not always enough to 
ensure reproducible research. 
As the dataset that was used for validation of novel lncRNAs used the current version of the 
genome (hg38), this dataset was also used to validate the annotated lncRNAs. The Yang et. 
al. dataset could not be used for novel lncRNAs pipeline validation as the published data 
contained truncated transcript co-ordinates, although, as demonstrated above, this is not 




4.2.4.3 Performance of the pipeline for lncRNAs  
A key difference between lncRNA analysis pipelines was the genome annotation.  Mirsafian 
et. al. used GENCODE v22 which contained a total of 15,900 human lncRNAs genes, 
whereas the thesis pipeline used the latest (at the time of analysis) GENCODE v29 annotation 
which contained 16,066 lncRNAs. Mirsafian et. al. identified 6,382 lncRNAs, but on further 
inspection 460 genes were duplicated in the results table. This left 5,922 genes, of which, 
4,543 were present in GENCODEv29. Once the same filter of FPKM >0.1 in at least 1 
sample was applied, 4,543 lncRNAs remained for comparison, of which 2,214 (49%) 
overlapped with the lncRNAs identified by the thesis pipeline. However, normalising the 
thesis pipeline analysis for sequencing depth alone (rather than sequencing depth and length)  
gave 4,473 (98%) genes overlapping, suggesting the same lncRNAs were being detected in 
both analyses but at a lower abundance in the thesis pipeline. 
One explanation for lower number of read counts from the thesis pipeline is that it uses 
relatively strict quality filters, such as filtering the BAM files (the files that contain the 
mapping information from the sequencing reads) for unique mapping reads only. Multi-
mapping reads are ambigous and documentation for most software packages that quantify 
abundance provide insufficient detail on how these multi-mapping reads are dealt with; Are 
they assigned to only one position based on other quality metrics? Are they counted twice? 
Or are they not counted at all? By using this filter the thesis pipeline may be discarding reads 
but at least the remaining reads are of high quality and unambigous. 
Another parameter affecting read count is the splice junction filter between the first and 
second pass alignment as discussed earlier. The pipeline wais designed to identify novel 
transcripts and this is reflected in the choice of splice junction filter. This, may be at the cost 
of introducing slightly more multi mapping reads, resulting in fewer reads passing the quality 




this lower read count appeared to affect the lncRNA detection rate more than the mRNA rate 
(although as already mentioned mRNA expression levels were also affected). Again, if I did 
the analysis providing GENCODE gtf instead of the stringtie gtf there was a much higher 
Spearman correlation. For future analysis I will run the annotated lncRNA branch of the 
pipeline with the GENCODE gtf and the novel branch with the stringtie gtf. 
Normalising for length is only necessary when the expression of genes with different lengths 
are compared (because longer genes will have a greater number of reads by chance).  Because 
the proposed analyses will only compare the expression of genes between groups (and not 
with other genes), the thesis pipeline does not need to normalise genes for length. 
Normalising for sequence depth alone is the approach recommended by DESeq2 [395], 
considered to be one of the best performers in RNA differential analysis [402]. 
For novel lncRNA identification, the thesis pipeline used CPAT as it compared favourably 
against other software [389, 406]. Mirsafian et. al. provided their novel lncRNA transcripts in 
FASTA format, which is convenient as it removes the introns and only gives the exonic, 
sequence therefore any differences between intron lengths are redundant. After applying the 
same filters as Mirsafian et al (retaining only multi-exonic, intergenic transcripts that were 
expressed at 0.1 FPKM in at least 1 sample), the thesis pipeline identified 504 putative novel 
lncRNAs compared to 1,032 for by Mirsafian et. al. A total of 707 (69% of the novel 
lncRNAs identified by Mirsafian et. al.) and 404 (81% of the novel lncRNAs identified by 
the pipeline) had over 70% alignment and were considered to match. The reason why the 
number is not the same for both is that some transcripts matched multiple transcripts from the 
other analysis. Overall, the putative novel transcripts identified by the thesis pipeline were 
longer than novel lncRNAs identified by Mirsafian et. al., which would suggest that more 




Interestingly, Mirsafian et. al. neither used or justified not using the default coding 
probability cut-off used by CPAT (as used by the pipeline), which gives highest sensitivity 
and specificity for human data [389]. This default setting was tested against mock data (using 
known coding and non-coding sequences) and displayed the best true positive versus true 
negative count.  
4.2.4.4 Performance of the pipeline against circRNA validation 
For the circRNA detection CIRCexplorer2 was chosen as it performs well against other 
circRNA detection software [238, 385]. Memczak et. al. did not use specialist software to 
detect circRNAs but rather developed an in house pipeline that filtered reads that did not 
align continously to the genome.  From these reads, the 20 nucleotide terminal sequences 
were re-aligned to the genome and any reads that were in reverse orientation were further 
filtered for mismatches, breakpoint detection, alignment scores, reads counts and distance. 
Additionally, they also filtered for only GT/AG flanking splice site signals (the canonical 
splice site motif), whereas the thesis pipeline does not filter out non-canoncial splice site 
motifs.  Consquently, the two analsyses are quite different in the way they identify circRNAs 
- Memczak et al. built psuedo reference sequences containing back splice junctions and 
aligned the unmapped reads to these, whereas the pipeline used STAR and circExplorer2 uses 
split read alignment of chimeric reads. This perhaps explains why the mapping statistics are 
also very different. It is not clear whether the number of reads used for circRNA detection for 
the Memczak analysis includes all reads that do not uniquely align (i.e. multi mapping reads, 
reads that are too short or chimeric reads). This may be the case as although the Memczak 
analysis stated much higher read numbers used for circRNA detection, their analysis had 
lower numbers of circRNA candidates for each sample compared to the pipeline. Another 
difference was Memczak et. al. used the older hg19 version of the reference genome and so 




differences there was an encouraging 77% overlap in circRNAs, which suggests that 
circRNAs are robustly detected by both methods.  There were a large number of circRNAs 
detected in the pipeline that weren’t detetced in the Memczak analysis although a large 
proportion of these were not detetced across all samples suggesting they may be of low 
abundance. 
4.2.5 Conclusions 
The development of the pipeline was an interesting exercise in demonstrating how 
reproducible bioinformatic research is. There are constant updates in hardware, software, 
reference files and methods of analysis (as highlighted with the circRNA analysis). The main 
challenge of genetic research is unambiguous annotation of coding and non-coding genes 
especially in the field of lncRNAs and circRNAs, where studies are discovering novel genes 
at what seems like an overwhelming rate.  The challenge of pipeline development was to 
amalgamate three separate branches into one coherent and systematic method of analysis and 
to validate this using three separate datasets. It was encouraging that there was such a high 
degree of reproducibility for the datasets, giving confidence in the bioinformatic analysis in 




     Chapter 5 
RNAs Associated with Ischaemia in Human Heart 
5.1 Introduction 
This chapter aimed to use the bioinformatics pipeline developed and validated (Chapter 4) to 
identify annotated mRNAs and lncRNAs and novel lncRNAs associated with myocardial 
ischaemia. Illumina RNA- Seq data from 85 paired samples collected from the left ventricle 
before and after a period of ischemia during cardiopulmonary bypass for aortic valve 
replacement was provided by Drs Muehlschlegel and Body at the Harvard Medical School 
[175]. My hypothesis was that lncRNAs help coordinate the post ischemic stress response 
and that some if these lncRNAs may not have been annotated previously. The idee was to 
both identify candidate genes and then to generate a set of genes altered in ischaemic cardiac 
tissue that could be used to look for overlap of genes altered by ischaemia in plasma. 
5.2 Overview of research design 
A summary of patient characteristics was provided in Section 3.2.1.1 and Table 3-1 gives a 
summary of patient demographics.  Briefly, punch biopsies were taken from the left ventricle 
apex immediately after the start of cardiopulmonary bypass at the time of routine placement 
of a surgical vent (pre-ischaemia) and after a median of 74 minutes (interquartile range 61–93 
minutes; post-ischaemia), during which time the heart was arrested with cold blood 
cardioplegia for myocardial protection. The purpose of the experimental design comparing 
paired pre- and post-ischaemic tissue from the same patient, was to reduce the confounding 
of underlying factors such as sex, or presence of CAD in some patients.  Saddic et al checked 
post operation Creatine kinase-MB levels (an enzyme found in heart muscle test for MI) and 




Illumina RNA-Seq data files were run through my pipeline (described in Section 4.1) and 
lists of mRNAs, lncRNAs and novel lncRNAs, including those that were differentially 
expressed between pre- and post-ischaemia, were produced (circRNAs were not able to be 
studied owing to the library preparation method used). Quality control checks were carried 
out by plotting a Principal Component Analysis (PCA) for gene expression for the 85 paired 
samples and the R package TissueEnrich [375] was used to confirm tissue specificity. A 
conservative selection criterion was used to identify a ‘high-confidence’ set of differentially 
expressed genes/transcripts for downstream analysis: (i) p-value adjusted (padj) <0.001 after 
adjustment for multiple comparisons (Benjamini-Hochberg), (ii) absolute fold-change >1.2 
(post-ischemic/pre-ischemic) and iii) for annotated genes, at least 90% of each ‘pre’ and 
‘post’ group had to have an expression level of at least 0.5 transcripts per million (TPM). 
Putative novel lncRNAs detected from Illumina sequencing were validated with long read 
Nanopore sequencing. Nanopore sequencing sequences the full-length transcript so we can be 
more confident it is not a partial transcript. Additionally, by using Nanopore sequencing we 
could validate all putative novels rather than selecting a handful to validate with RT-PCR.  
Nanopore sequencing was performed on RNA extracted from 8 donor heart tissues (left 
ventricle, provided by Cleveland Clinic, Section 3.2.2) with 1% RNA Sequins [371] spiked in 
as internal controls (Section 3.3.4). Bioinformatic analysis of Nanopore sequencing was 
performed (Section 3.4.5) to identify a list of putative novel lncRNAs. These were compared 
to the novel lncRNAs identified with Illumina sequencing (Figure 5-1) using gffcompare 
software.  Differentially expressed mRNAs, lncRNAs and novel lncRNAs were analysed 
with a weighted gene correlation networks analysis (WGCNA [374], Section 3.6) and 
pathway analysis (Ingenuity Pathway Analysis, IPA Section 3.7) to identify gene modules, 




In situ hybridisation with RNA Scope was performed on two annotated lncRNAs, one from 
each module that WGCNA identified as significantly associated with ischaemia to examine 
their subcellular location. Lastly, one of the differentially expressed novel transcripts that was 
identified by the pipeline, validated with Nanopore sequencing and identified in one of the 
modules associated with ischaemia was also analysed with RNAscope to further validate its 
expression and identify its subcellular location. RNAscope was performed on Formalin-fixed  






Figure 5-1 A schematic of the pipeline for novel lncRNA discovery and validation. 
Illumina reads were aligned with STAR v2.6 and transcripts assembled with Stringtie v1.3.3; Nanopore long reads were aligned with minimap2 v2.11 and 
transcripts assembled with Pinfish. Transcripts were then assigned class codes with gffcompare v.0.10.1 using GENCODE v.29 as annotation. Transcripts 
were then filtered for class codes of either ‘u’ – intergenic; ‘i’ – intronic; ‘x’ – transcripts had an exon overlapping an annotated transcript but was on the 
opposite strand or ‘y’ – contained an annotated transcript within its intron. Transcripts were also filtered for length > 200 bases and passed the default filter 
for non-coding human transcript with CPAT v1.2.3 software. Transcripts that passed filters from both read technologies were then compared with each other 




Positive controls using the lncRNA Nuclear enriched abundant transcript 1 (NEAT1) was 
used as examples of a nuclear enriched lncRNAs respectively [407] .  
5.3 Results 
5.3.1 Quality Control 
Principal Component Analysis (PCA) for the 85 paired samples identified five outlying 
samples: 47V (-pre and -post), 56V (-post), 73V (-pre) and 107V (-post) (Figure 5-2).  The 
fragment length distribution quality control plot showed that the cDNA libraries for patient 
47V (-pre and -post ischaemia samples) had a much longer fragment lengths than the libraries 
for the rest of the samples (150-350 bases versus the majority <150 bases, Figure 5-3).  
  
Figure 5-2 Principal Component Analysis (PCA) on the transcriptome of 85 paired pre- and post- 
ischaemia left ventricular samples. 
A) The plot indicates four samples that are outliers B) Data re-plotted with the four outliers removed 
Red indicate pre ischemic samples, blue indicates post ischemic samples. 
While fragment lengths of up to 350 bases are not too long for sequencing, it was concerning 
that this sample displayed a very different profile compared with the rest of the cohort when 
all fragments should be uniform, and the sample was discarded.  For the remaining three 







originated solely from heart or skeletal muscle was much lower (Figure 5-4). This suggests 
that there may have been other tissue taken when the biopsy was performed. These samples 
were also discarded, which left 81 pairs of samples for analysis. 
 
 
Figure 5-3 Fragment length distribution plots. 
Sample 47V shows much larger fragment lengths compared to the rest of the sample, indicating a 























Figure 5-4 Plots from TissueEnrich for the three remaining outlying samples 
A) 56V -post, B) 73V -pre and C) 107V -post (and their paired sample for comparison, shown in the 
upper panel). For the non-outlier sample for each patient the most probable tissue of origin for the 
expressed genes are heart or skeletal muscle (-log10 p-adjusted = ~50). In contrast, for the outlier 
sample, the heart and skeletal muscle p-adjusted value is much lower (-log10 p-adjusted = 0.4-4) and 





5.3.2 Protein-Coding, Annotated and Novel lncRNAs Associated with 
Ischemia identified with Illumina Short Read Sequencing 
Illumina RNA-Seq generated an average of 33.7 ± 12.6 million uniquely mapped reads per 
sample (approximately 85% of the total reads per sample). Unique reads mapped to 12,656 
mRNAs and 1,488 annotated lncRNA genes and 10,567 putative novel lncRNAs in human 
left ventricle, including reported lncRNAs that are strongly expressed in cardiac tissue (but 
also expressed elsewhere), MALAT1, NEAT1, H19, TUG1 [177, 408-410]. The overall 
expression levels of lncRNAs were lower than mRNAs (Table 5-1).  
Table 5-1 Expression levels (median and IQR) of mRNAs and lncRNAs detected by my pipeline. 
Gene type Median TPM (IQR) 
mRNAs 7.7 (3.4-17.8) 
lncRNAs  1.9(1.3-3.3) 
N.B. Putative novel lncRNAs could not be compared as no abundance filter was applied and 
novel lncRNAs were detected at the transcript level, rather than the gene level. 
Expression of 2,446 mRNAs, 270 annotated lncRNAs and 1149 novel lncRNAs differed in 
response to ischemia (padj <0.001, absolute fold change >1.2, Figure 5-5). The 40 genes most 
differentially expressed genes from each class of RNA (ranked on fold-change) are shown in 
Appendix C. Of the differentially expressed mRNAs, 11 of the 20 most abundant genes were 
mitochondrial (MT-CO1, MT-ND4, MT-ATP6, MT-ND1, MT-CYB, MT-ND4L, MT-CO2, MT-
CO3, MT-ND2, MT-ND3, MT-ATP8). Analysis of the RNA spike in controls (Sequins) 
showed a strong correlation (Spearman correlation = 0.82) between their measured 
abundance and their input concentration (Figure 5-6), confirming that library preparation and 





Figure 5-5 Volcano plots showing differential expression in 81 paired human left ventricle 
samples, comparing pre- versus post-ischemia 
A) mRNA genes, B) annotated lncRNA genes, and C) 39 putative novel lncRNA transcripts identified 
by both Illumina and Nanopore technologies. They are annotated with arbitrary MSTRG identifiers 
by the Stringtie package in the Bioinformatics pipeline. Green indicates differentially expressed 
genes/transcripts with an adjusted p value (padj) <0.001 and an absolute fold change >1.2. 
5.3.3 Confirmation of Novel lncRNAs in Human Left Ventricle with Nanopore 
long read technology 
Nanopore RNA-Seq yielded a total of 10,638,219 base-called reads of which 65.1% passed 
the QC filter of a minimum quality score of 7 (the nanopore base caller sets a minimum 
quality score of 7.0. These are not phred scores but the algorithms to calculate this score are 




score of 10 Of these, 2,710,486 full-length transcripts were identified, which had an 
alignment rate of 96.33% (75.6% to hg38 and 20.7% to chrIS). From these transcripts 153 
potential multi-exonic, novel lncRNAs were identified. 
 
 
Figure 5-6 Detection of Sequin Controls. 
Alignment and quantification of the internal sequin controls was carried out alongside heart tissue 
RNA. A strong correlation was seen between measured abundance (transcripts per million TPM) and 
input concentration (R2 = 0.82). 
Comparison of the putative novel lncRNA transcripts identified by Illumina RNA-Seq and 
Nanopore RNA-Seq identified 39 transcripts from 35 unique genes (four transcripts 
represented different isoforms) that shared complete intron chains (gffcompare class code 




were intronic (‘i’), five were novel antisense (‘x’) and one contained a reference gene within 
its intron (‘y’, class codes illustrated in Figure 5-1).  
As the pipeline used the GENCODE v.29 annotation, confirmation as to whether the 39 
putative novel lncRNAs were indeed novel was sought by searching the updated version of 
GENCODE (v.32), and the lncRNA databases, FANTOM CAT  
http://fantom.gsc.riken.jp/cat/?fd=source_data and NONCODE v.5. Of the 39 potentially 
novel lncRNAs, 12 transcripts (from 10 unique lncRNA genes) had subsequently been 
reported in GENCODE v.32, 21 transcripts (from 19 unique lncRNA genes) were reported in 
FANTOM CAT and 15 transcripts (from 12 unique lncRNA genes) were reported in 
NONCODE v.5 (28 unique lncRNAs in total).  
The finding that 28 lncRNAs were now annotated in public databases confirmed the validity 
of our discovery pipeline, However, this left 10 remaining novel lncRNAs that were not 
previously described in any dataset (Figure 5-5C, Appendix C). Moreover, 1 of these was 
differentially expressed between pre- and post-ischaemia time points (padj. = 7.27 x 10-13, 
fold change = 1.35, Figure 5-7). 
 
Figure 5-7 A screenshot from IGV showing RNA sequencing reads of the novel transcript 




5.3.4 Evolutionary Conservation of lncRNAs 
Previous reports have observed that annotated lncRNAs have lower primary sequence 
conservation compared to mRNAs [65, 106, 107]. To test whether the novel lncRNAs 
showed similar profiles of conservation to annotated lncRNAs rather than protein coding 
transcripts, averaged, pre-computed, per-base evolutionary conservation scores for each exon 
were compared. The novel lncRNAs showed lower primary conservation and had a similar 
profile to annotated lncRNAs compared with protein coding genes suggesting they are likely 
to be non-coding transcripts (Figure 5-8). 
 
Figure 5-8 Geometric density plots showing the frequency of phastCons conservation scores for 20 
mammalian species averaged base-wise for each exon. 
Exons from protein-coding transcripts (expressed in this study) are shown in blue, the exons from 
annotated lncRNAs (expressed in this study) are shown in green and identified novel lncRNAs are 
shown in red. The phastCons score estimates the probability that a nucleotide is conserved; the closer 




5.3.5 Overlap of Putative Novel lncRNAs with Regulatory Elements in the 
Genome  
To explore whether the novel lncRNAs had potential to regulate gene expression through 
known mechanisms, novel lncRNAs overlapping known regulatory elements and genome 
wide association study (GWAS) SNPs associated with cardiovascular traits were 
investigated.  Promoters and enhancers were downloaded from Ensembl biomart with ‘left 
ventricle’ selected as the tissue filter.  Of the 11 novel lncRNAs, 8 overlapped enhancers, 2 
overlapped promoters with a further 7 overlapping promoter flanks. One novel 
(MSTRG.72507.1 which was later identified as AC100756.4 when comparing to a later 
version of GENCODE overlapped the SNP rs937741 which was associated with Blood 
pressure (smoking interaction) from the GWAS catalogue (Appendix C). 
5.3.6 Overlap of novel lncRNAs with cis-eQTLs  
eQTL SNPs are associated with changes in the expression level of a gene and are mostly 
located in non-coding regions [411].  Because an eQTL effect may be mediated by a 
lncRNA, the overlap between each of the novel lncRNAs and known eQTL SNPs in left 
ventricle was analysed.  Of the 11 novel lncRNAs, the two exons of MSTRG.8333.38 
overlapped five cis-eQTL eSNPs (rs259352, rs259354, rs3820345, 
rs10783001 and rs35070110) associated with expression of the gene RWD Domain-
Containing Sumoylation Enhancer (RWDD3) (GTEx SNP-gene associations p < 1 x 10-06. 
This lncRNA is situated immediately downstream of RWDD3 and expression of 
MSTRG.8333.38 - RWDD3 was weakly correlated (Figure 5-9 Spearman -0.2 and p-value 





Figure 5-9 Spearman correlation of novel lncRNA-mRNA pair MSTRG.8333.38 - RWDD3. 
MSTRG.8333.38 also overlapped cis-eQTLs associated with RWDD. 
The first exon of the two-exon novel MSTRG.10265.1 also overlapped an eQTL 
(chr1_117128873_A_G_b38) which is associated with V-Set Domain Containing T Cell 
Activation Inhibitor 1 (VTCN1) in left ventricle tissue. However, VTCN1 was not robustly 
expressed in this data set and was filtered out. 
5.3.7 Identifying gene networks associated with ischemia 
WGCNA interrogated all genes from the dataset and identified 18 modules of highly 
correlated genes with similar expression profiles across patients. Of these, two were strongly 






Figure 5-10 Module-trait relationships predicted by WGCNA. 
Each cell shows the correlation and p-value between the module eigengene (row, with each module 
arbitrarily assigned a colour) and the trait (column).  The table is color-coded by correlation 
according to the colour legend. ME: module eigengene. 
Expression of genes in Module 1 (Turquoise Module) decreased from pre- to post-ischemia 
(Pearson correlation coefficient (PCC) =-0.69, p=1 x 10-23).  IPA analysis showed that the 
genes in this module (n = 2038) were enriched for pathways associated with cell death, 
apoptosis, and necrosis (Table 5-2).  Module 1 also included one novel lncRNA which was 
moderately associated with ischemia (MSTRG.10265.1, PCC=-0.37, p= 2.46E-06)). Also, in 
Module 1, 39 annotated lncRNAs were moderately associated with ischemia (PCC > |0.4|, all 
padj<0.001).  Three of these lncRNAs had module membership correlation values > 0.7, 
suggesting they may act as network hubs (genes with potential to co-regulate multiple genes 




CTBP1-DT. Module 1 mRNAs with the highest module membership and potential to serve as 
network hubs were Oxoglutarate Dehydrogenase (OGDH), Kinesin-like protein (KIF1C), 
Mitofusion 2 (MFN2),  and MRPS27 (module memberships of =0.95, 0.93, 0.93 and 0.92 
respectively). 
In contrast to Module 1, on average, the expression of genes in Module 2 (Green Yellow 
Module) increased from pre- to post-ischemia (Pearson Correlation coefficient (PCC) module 
eigengene with ischemia=0.67, p=2 x 10-17). Genes in Module 2 (n=250) were predicted to 
activate pathways involved in angiogenesis and vascular development in the cardiovascular 
system and proliferation of white blood cells and immune cells in response to ischemia 
(Table 5-2). 
Potential network hubs (transcripts with the highest module membership with correlation 
values >0.7) included mRNA transcripts overwhelmingly associated with vasculogenesis and 
angiogenesis, consistent with pathway analysis. These include TEK Receptor Tyrosine 
Kinase (TEK, a member of the tyrosine kinase Tie2 family), ETS Transcription Factor 





Table 5-2 The top five disease or functions predicted by IPA (sorted by z-score) associated with the two modules most associated with ischemia (WGCNA). 






Organismal Survival 1 Morbidity or mortality 9.2E-08 Increased 12.7 
Organismal Survival 1 Organismal death 5.58E-08 Increased 12.7 
Organismal Injury and Abnormalities 1 Organ Degeneration 4.3E-06 Increased 4.3 
Cell Death and Survival 1 Apoptosis 9.03E-08 Increased 4.1 
Cell Death and Survival 1 Necrosis 6.47E-09 Increased 3.4 
Cardiovascular System Development and Function 2 Development of vasculature 1.02E-13 Increased 4.4 
Cardiovascular System Development and Function, 
Organismal Development 
2 Angiogenesis 6.31E-13 Increased 4.4 
Cardiovascular System Development and Function, 
Organismal Development 
2 Vasculogenesis 1.23E-12 Increased 4.3 
Hematological System Development and Function, 
Lymphoid Tissue Structure and Development, Tissue 
Morphology 
2 Quantity of lymphocytes 1.42E-06 Increased 3.7 
Cellular Development, Cellular Growth and 
Proliferation,Hematological System Development and 
Function,Hematopoiesis,Lymphoid Tissue Structure 
and Development, Tissue Development 
2 Hematopoiesis of 
mononuclear leukocytes 





Among the annotated lncRNAs in Module 2, five lncRNAs were moderately associated with 
ischemia (PCC > 0.4). Of these, Prostate Cancer Associated Transcript 19 (PCAT19) and 
AC093278.2 had module membership correlation values > 0.7, suggesting they may also 
serve as network hubs.  There were no novel lncRNAs present in Module 2. 
5.3.8 Overlap of annotated lncRNAs with cis-eQTLs  
Investigation of lncRNAs overlapping cis-eQTLs was carried out to identify possible 
functional mechanisms. A total of 47 annotated lncRNAs overlapped 52 cis-eQTL snps 
(GTEx SNP-gene associations p-value < 10E-07). 
For Module 1, 12 annotated lncRNAs overlapped significant cis-eQTL SNPs, of which 3 
were differentially expressed in response to ischemia.  These cis-eQTL eGene associations 
were: AC005523.2- Fem-1 homolog A (FEM1A), AC011476.3 - retinol dehydrogenase 13 
(RDH13) and AC012313.1 - Zinc finger protein 84 (ZNF584).   Expression of AC005523.2- 
FEM1A and AC011476.3 - RDH13 was highly correlated (Spearman correlation 0.87, 0.81 
and p-value 6.13 e-52, 2.63 e-38 respectively, Figure 5-11).  However, the correlation of 
AC012313.1 - ZNF584 was not significant.  None of the annotated lncRNAs in Module 2 
overlapped any eQTL eSNPs. 
5.3.9 Subcellular localisation of ischaemia associated lncRNAs with RNA 
Scope 
RNAscope – an in-situ hybridisation technique for RNA - was used to identify the subcellular 
localisation of two annotated lncRNAs as well as a novel lncRNA (VASH1-AS1, PCAT19 
and MSTRG. 10265.1 Figure 5-12). These specific lncRNAs were chosen as they were 
significantly associated with the significant ischaemia-associated modules from WGCNA. 
They were either one of the highest differentially expressed (VASH1-AS1, turquoise module) 









Figure 5-11 Spearman correlation of lncRNA-mRNA pairsAC005523.2- FEM1A (top panel) and 
AC011476.3 - RDH13 (bottom panel) where the lncRNA also overlapped cis-eQTLs associated with 

















Figure 5-12 RNA Scope showing VASH1-AS1, PCAT19 and the novel MSTRG.10265.1 expression 
in cardiomyocytes.  
The dark blue haematoxylin staining indicates the cell nucleus. Red circles indicate the location of the 
red RNA-Scope probes.  A) VASH1-AS1 probe nuclear localisation at x63 magnification, B) VASH1-
AS1 probes cytoplasmic localisation at 63x magnification C & D) Shows PCAT19 probe nuclear and 
cytoplasmic localisation at x63 magnification E & F) Shows novel (MSTRG.10265.1) probe nuclear 
and cytoplasmic localisation at x63 magnification G) NEAT1 lncRNA positive control with an 
exclusively nuclear location  H) Negative control   Scale bar = 50µm  
5.4 Discussion 
Before the Saddic paper [175], there were no studies that had examined the profile of 
lncRNAs of acute ischemia in the human heart. Saddic et al described the first lncRNA 
profile of acute ischemia in the human heart. This study builds on the Saddic analysis with 
addition of novel lncRNAs and whole genome correlation network analysis to examine the 
association of lncRNAs with the ischaemia heart and their potentially regulatory roles. 
A total of 11 novel lncRNAs in human left ventricle were identified using a strategy of both 
short- and long-read sequencing. Of these, the expression of two novel lncRNAs, along with 
270 annotated lncRNAs and 2,446 mRNAs, were altered in response to ischemia. Co-
expression analysis of these lncRNAs and mRNAs identified two networks of genes that may 
promote angiogenesis, neovascularisation and cardiomyocyte cell death and form part of the 





Accumulation of atherosclerotic plaque in the coronary arteries can lead to a prolonged 
reduction in blood flow and oxygen to the heart. At the cellular level, this can cause 
metabolism to switch from aerobic oxidative phosphorylation to anaerobic glycolysis, leading 
to increasing intracellular acidosis and radical oxygen species levels. High levels of 
intracellular calcium activate proteases that degrade the cytoskeleton. Cell death by necrosis, 
apoptosis, and autophagic mechanisms are the end result [412]. With cell death, cytokines are 
released to initiate an inflammatory response. Neutrophils, macrophages, and leukocytes 
infiltrate the area and cell adhesion molecules are secreted on the surface of endothelial cells 
and leukocytes to facilitate infarct healing, and subsequent ventricular remodelling.  Data 
from the current study suggests that lncRNAs may help coordinate these immediate 
metabolic, inflammatory, and microscopic myocardial remodelling responses to ischemic 
injury, and may involve previously unannotated lncRNAs. 
As Saddic et al had previously published analysis of mRNAs and annotated lncRNAs as 
markers for ischaemia, this analysis focussed more on novel lncRNAs as potential ischaemic 
markers. However, the WGCNA analysis also adds to the annotated genes with a novel 
approach to looking at gene network co-expression. The two novel lncRNAs identified here 
could serve as potential markers for myocardial ischemia if they are found to be exported into 
the circulation. Established biomarkers such as the troponins and creatine kinase are used for 
diagnosis and risk stratification of patients with chest pain and suspected acute coronary 
syndrome (ACS). However, they are unable to detect myocardial ischemia in the absence of 
necrosis and there remains a need for markers of subclinical atherosclerosis and ischemia 
[413]. My data suggest that lncRNAs along with mRNAs respond to ischemic changes in the 
left ventricle suggesting they may represent novel therapeutic targets or candidate biomarkers 
for early myocardial dysfunction.  
WGCNA [374] collapses co-expressed groups or networks of genes into modules in an 




whole transcriptome analysis. It can be used for finding clusters (modules) of highly 
correlated genes, relating modules to phenotypic traits and for calculating module 
membership and gene significance to identify important hub genes which may be strong 
drivers of that module.  One of the novel lncRNAs (MSTRG.10265.1) belonged to a gene 
module (Module 1) of highly correlated, and potentially co-regulated, genes that included 39 
annotated lncRNAs that were also correlated with ischemia. This module was associated with 
activation of cell death potentially through pathways involved in energy metabolism. Among 
the 39 annotated lncRNAs, three had high module membership which is indicative of highly 
interconnected ‘hubs’ (AC005523.2, AF111167.2, CTBP1-DT). While the mechanisms by 
which these lncRNAs might influence gene expression are unknown, it was observed that 
AC005523.2 lies antisense to FEM1A, which was in the same Module and also overlaps a cis-
eQTL SNP associated with FEM1A suggesting AC005523.2 may be acting as a cis-regulator 
of FEM1A. FEM1A is localised within mitochondria of cardiac muscle and is increased in 
mouse hearts after myocardial infarction, [414] and may regulate apoptosis [415].  The other 
two lncRNAs may also regulate nearby genes:  AAF111167.2 is antisense to, and overlaps the 
active promoter of, JDP2, a transcription factor associated with maladaptive cardiac 
remodelling [416], and CTBP1-DT is antisense to CTBP1 which is involved in cell 
proliferation [417].  As well as AC005523.2-FEM1A, two other differentially expressed 
lncRNAs had significant cis-eQTL eGene associations, these were: AC011476.3 - retinol 
dehydrogenase 13 (RDH13) and AC012313.1 - Zinc finger protein 84 (ZNF584). RDH13 is 
localized in the mitochondria and may function to protect the mitochondria against oxidative 
stress [418]. ZNF584 has the highest level of expression in the left ventricle [419] and is one 
of the KRAB-ZNF transcriptional regulatory family of proteins which are transcriptional 
repressors. Despite their abundance in the genome little is known about their gene targets and 
biological functions. There is however, emerging evidence that they are involved in apoptosis, 




In Module 1, mRNAs with the highest module membership were i) OGDH, which forms part 
of the 2-oxoglutarate dehydrogenase complex to catalyse conversion of 2-oxoglutarate (alpha-
ketoglutarate) to succinyl-CoA and CO2 during the Krebs cycle and is an important 
mitochondrial redox sensor [421], ii) KIF1C, which regulates actin-rich adhesion structures 
(podosomes) that remodel the extracellular matrix of cells including macrophages and 
synthetic vascular smooth muscle cells [422], iii) MFN2, which encodes a mitochondrial 
membrane protein that contributes to the maintenance and operation of the mitochondrial 
network, regulation of vascular smooth muscle cell proliferation and is pivotal during 
recovery from ischemia/reperfusion injury [423] and iv) MRPS27, which is required for the 
translation of mitochondrially encoded proteins and mitochondrial protein synthesis [424].  
The second gene module strongly associated with ischemia was associated with angiogenesis 
and inflammation which have been demonstrated to be linked with atherosclerosis and 
ischaemia [425-427].  Potential hub genes (genes with the highest module membership) were 
overwhelmingly associated with vasculogenesis and angiogenesis. TEK mediates embryonic 
vascular development [428, 429] whereas ELK3 regulates angiogenesis through the control of 
vascular endothelial growth factor (VEGF)[430], CDH5, is involved in vascular permeability 
and leukocyte transmigration and angiogenic sprouting [431] and Eprhin B2, present in 
arteries, and is involved in the angiogenesis process [432]. 
Among the annotated lncRNAs, 5 (PCAT19, AC093278.2, CARMN, AC005550.2, 
AC007743.1) were associated with ischaemia and were strongly correlated with other genes 
within the module suggesting they may play a significant role in the immediate response to 
ischaemia in the left ventricle. PCAT19 has been shown to negatively regulate p53 in lung 
cancer [433] whist p53 has been shown to negatively regulate ischemia-induced angiogenesis 
[434].  While the function of AC093278.2 has not been described, it lies 2.7Mb upstream 
from an enhancer that is active in the left ventricle and overlaps the 3’UTR of ZNF366.  




and has been shown to control cardiac specification and differentiation [435], AC005550.2 is 
antisense and overlapping to Homeobox protein MOX-2 MEOX2 (also in Module 1) which 
regulates cardiac energy metabolism via fatty acid uptake in heart capillary endothelium 
[436], and AC007743.1 overlaps an active CCCTC-Binding factor (CTCF site thought to 
regulate the 3D structure of chromatin) and is antisense to Conserved Protein Domain Family 
85A (CCDC85A also in Module 2). 
In addition to the two lncRNAs associated with ischemia, 9 novel lncRNAs that were not 
associated with ischemia but were robustly detectable in left ventricle samples were also 
identified. These included MSTRG.8333.38, which overlapped cis-eQTLs associated with 
RWDD3.  RWDD3 is an enhancer of Small Ubiquitin-like Modifier (SUMO) conjugation 
which modifies post translation modification of proteins and is involved in heart specific 
development, metabolism, contractility, and protein quality control [437].  Both RWDD3 and 
MSTRG.8333.38 were present in the same WGCNA module.  
LncRNAs exert their functions via several mechanisms (reviewed in Section 2.2.4). This 
study identified several lncRNAs that overlapped cis-eQTLs in human left ventricle. One 
possibility is that this SNP(s) is affecting the secondary structure of the lncRNA and therefore 
its binding capacity either to chromatin, a transcription factor, a promoter, or the mRNA. 
However, currently this is speculative. It could be tested with analysis of the lncRNA with 
either allele (three genotypes). 
By identifying the subcellular localisation of the lncRNA (nucleus versus cytoplasm), a 
biological mechanism can be hypothesised. There were initial technical issues when using 
RNAscope with heart tissue. Firstly, the kit provided positive control Peptidylprolyl 
Isomerase B (PPIB) did not appear to work with cardiomyocyte cells and, as the 
cardiomyocytes appeared to have a brown background stain inherent in the tissue, we had to 




12) the two annotated lncRNAs (VASH1-AS1 and PCAT19) as well as the novel 
MSTRG.10265.1 appear to be located in both the nucleus and the cytoplasm. As the lncRNAs 
had high module membership which indicates those genes that have high connectivity with 
other genes in the module, it is possible that the lncRNAs assert their functions both inside the 
nucleus and in the cytoplasm by having more than one biological mechanism as has been seen 
with other lncRNAs [438]. Alternatively, it is possible is that the lncRNAs act in the 
cytoplasm and the probes identified in the nucleus are in the process of being transported to 
the cytoplasm and lastly it could be possible that the signal seen in the nucleus are in fact 
originating from cytoplasm on top of the nucleus. Further interrogation using z-stacks could 
confirm this. The handful of studies available for PCAT19 propose it may function through 
interactions with microRNAs, however this still does not rule out either location as miRNAs 
and Argonaute are also found in both [433, 439, 440]. There are currently no studies on 
VASH1-AS1. The successful demonstration of RNA Scope for the novel MSTRG.10265.1 is 
further validation that this lncRNA is a genuine transcript. MSTRG.10265.1 also overlaps an 
eQTL (chr1_117128873_A_G_b38) which is associated with VTCN1 in the left ventricle, 
although this gene did not appear to be robustly expressed in the data and correlations of 
MSTRG.10265.1 and VTCN1 expression could not be tested.  As VTCN1 is has been 
implicated in post-ischaemic cardiac remodelling [441], it could be that this gene is not turned 
on until a later, post ischaemic response.  Additional work would be needed to gain insight 
into the functional role of these lncRNAs. Such experimental techniques may include RNA-
binding protein immunoprecipitation (RIP) assays (which interrogate lncRNA and miRNA 
binding to Argonaute proteins within the cytoplasm) to test lncRNA/miRNA interaction, 
Chromatin Isolation by RNA Purification (ChIRP) where high throughput sequencing is used 
to find regions of the genome that are bound by a specific RNA, or RNA Antisense 





The study has several limitations.  First, as the median ischaemic time was only 74 minutes, 
the gene expression changes seen here reflect the immediate response to a relatively short, 
mild ischaemia and lncRNA changes associated with prolonged ischaemia or a more severe 
response (e.g., after myocardial infarction) may have been missed. Second, although it is a 
good model for human myocardial ischaemia, it is possible some of the changes in gene 
expression may also be due to a cardioplegic cold response, rather than ischaemia per se. 
Finally, this data is largely descriptive and further work would be needed to confirm the role 
of these genes, particularly for potential hub genes, in the early response to myocardial 
ischaemia.  Also, whether any of the transcripts can be detected in circulation and may have 
potential as biomarkers is unknown. 
5.5 Conclusion. 
Expression of 2,446 mRNAs, 270 annotated lncRNAs and 2 novel lncRNAs were associated 
with the early response to myocardial ischemia in human left ventricle (padj <0.001, absolute 
fold change >1.2). An additional 9 novel lncRNAs were identified in human left ventricle that 
were not altered by ischaemia. In addition to mRNAs, several lncRNAs appear to act as hub 
genes, potentially coordinating the expression of several genes within the same module. These 
findings suggest that both mRNAs and lncRNAs are altered in association with an early 
ischaemic stress response and may therefore have potential as therapeutic targets or 




     Chapter 6 
Establishing an RNA-Seq protocol to investigate cell-
free RNA in plasma from heart patients and healthy 
volunteers 
6.1 Introduction 
Human biofluids contain a collection of cell-free nucleic acids.  Historically, studies in 
biofluids have focussed either on circulating DNA of the foetus, to determine foetal sex, 
aneuploidies, micro-deletions and the detection of paternally inherited monogenic disorders 
[443], or on circulating tumour DNA, to characterise mutations and assess response to 
treatment [444]. More recently, there has been a growing body of evidence linking RNAs in 
biofluids with various diseases, including lncRNAs, circRNAs and miRNAs, making them 
excellent candidates for biomarkers [199, 445, 446] 
Advances in RNA-Seq now allow us to study the transcriptome in ‘liquid biopsies’ such as 
plasma and other bodily fluids, to identify new diagnostic and prognostic markers for various 
diseases in a non-invasive manner [447-449]  Circulating RNAs found in plasma include 
mRNAs, lncRNAs, circRNAs, miRNAs as well as other RNA species such as tRNAs, 
snoRNAs and piRNAs [450, 451]. They can be present in membrane-bound extracellular 
vesicles, such as exosomes, micro-vesicles and apoptotic bodies, they may be bound to 
ribonucleoprotein (RNP) complexes or high-density lipoproteins [HDLs], or circulating freely 
[452, 453]. Extracellular vesicles are highly abundant in biological fluids and are secreted by 
most cell types to transfer proteins, lipids and RNA between cells for the purpose of 
intercellular communication and signalling [454].   
However, RNA-Seq of biofluids is technically demanding. The low input amounts of RNA, 
partial degradation of transcripts due to ribonucleases in blood that are not protected by 




in challenging technical hurdles. These reasons may explain why most RNA-Seq studies in 
biofluids have sequenced small-RNA or microarrays or used targeted strategies such as RT-
qPCR. To date, only a handful of studies have carried out total RNA-Seq in bodily fluids 
[451-453, 455]. Despite the challenges, there are benefits to total RNA-Seq over microarrays 
and targeted strategies.  These include an unbiased, genome-wide approach without a priori 
hypotheses, allowing capture of novel transcripts and isoforms. With the falling costs of RNA 
Sequencing, allowing samples to be sequenced to a much greater ‘depth’ (i.e. many more 
reads), and the development of specialist RNA library kits, enabling sequencing with smaller 
amounts of input RNA, we are in an exciting position to achieve a complete account of the 
circulating, cell-free transcriptome.  
This chapter aimed to establish a method for detecting mRNAs, lncRNAs and circRNAs in 
archived plasma from heart patients and healthy controls. The bioinformatics analysis pipeline 
previously developed for identifying lncRNAs with altered expression in ischaemic cardiac 
tissue could be applied to RNA-Seq data acquired from plasma. Sequencing of plasma was 
carried out from 31 Healthy volunteers (HVOLs), 31 patients with unstable angina or 
myocardial infarction who remained free of heart failure for at least three years (‘CDCS heart 
failure negative’) and 30 patients with either unstable angina or myocardial infarction who 
were diagnosed with heart failure within three years (‘CDCS heart failure positive’). 
Specific Objectives were to: 
1. Determine the quality and quantity of RNA able to be extracted from human plasma 
(pilot 1) 
2. Remove DNA contamination from RNA extracted from human plasma (pilot 2) 
3. To ascertain if any mRNA/lncRNAs and heart-related mRNAs/lncRNAs could be 
detected when sequencing at a greater depth using the Illumina HiSeq (pilot 2a) 




5. Assess the background level of RNA contamination present in the kit reagents by 
performing an RNA extraction on a no-template control (pilot 3) 
6. Test plasma samples from a heart patient and a healthy control that have been stored 
for >10 years (pilot 4) 
7. Test inclusion of artificial spike-in controls (Sequins, pilot 4). 
6.2 Overview of research design 
 
The protocols for recruitment of patient and healthy volunteer samples and the methods for 
RNA extraction, addition of artificial spike-in controls (Sequins) and library preparation are 
described in Chapter 2.  Additions to, and deviations from, these protocols are summarised for 
each of the four pilot studies in Table 6-1. For the laboratory volunteer plasma consented 
blood was obtained in accordance with CHL, Endolab policy manual dated Sept 2020, section 
12.3.13.  RNA extraction from frozen plasma samples was carried out using the Norgen 
Plasma/Serum RNA purification Maxi kit (Thorold, Canada). Each pilot included a positive 
control RNA sample from human brain, which was provided with the Takara Bio SMARTer 
Stranded Total RNA-Seq Kit v2 (Pico Input Mammalian, Shiga, Japan).  All sequencing was 
performed on an Illumina MiSeq sequencer using the Micro Kit v2, San Diego, California, 
U.S. except pilot 2a which used the Illumina HiSeq to sequence the same library from pilot2 
but at a greater depth. 
6.2.1 Bioinformatic Analysis 
All bioinformatics analyses were carried out using the in-house pipeline as described in 
Section 4.1 At the time of running the plasma experiment, the GENCODE version had been 
updated to v33 so this newer version was used. Briefly, the raw FastQ files were trimmed 
using Trimmomatic software [379] and FastQC (Bioinformatics, Babraham Institute, 




STAR2 splice aware software [268].  Transcripts were assembled with Stringtie [388] and 
quantified with Salmon [395].   
Table 6-1 Overview of the samples used and the differences from the final protocol for the four pilot 
studies. 






(Takara Bio SMARTer 
Stranded Total RNA-Seq Kit 
v2 (Pico Input Mammalian, 
Shiga, Japan).   
Pilot 1 • CDCS patient plasma1 (5 mL) 
• HVOL plasma 1 (5 mL) 




loss of RNA 
- Positive control spiked into 
library pool at 10% v/v 
Pilot 2 • HVOL plasma 2 (4.5 mL) 
• Positive control RNA 
- - Positive control spiked into 
library pool at 15% v/v 
Pilot 2a • HVOL plasma 2 deep 
sequencing on HiSeq 
  Same library as pilot 2 
Pilot 3 • Lab volunteer 1 (4 mL) 
• Lab volunteer 1 (3 mL) 
• Lab volunteer 1 (2 mL) 
• No template control (Nuclease 
free water) 
• Positive control RNA 
- - Samples and positive control 
added to library pool at 
equimolar concentrations 
Pilot 4 • CDCS patient plasma 2 (4 mL) 
• HVOL plasma 3 (5 mL) 
• Positive control RNA 
- 1% Sequins 






Samples and positive control 
added to library pool at 
equimolar concentrations 
 
Sequencing metrics and mapping statistics from the BAM file were assessed with RSeQC 
[384], and visualised with MultiQC [456].  
For pilot 4, which included artificial RNA spike-ins (Sequins), the Sequins reference 
sequence was added to the human reference prior to read alignment. The percentage of reads 
aligning to the Sequin reference was calculated by aligning the FastQ reads to the Human 
genome and Sequins reference sequences combined, as well as the Sequins reference alone. 






6.3.1 Pilot 1 Determining the quality and quantity of RNA able to be extracted 
from human plasma 
To test if enough RNA of sufficient quality could be extracted from archived patient and 
healthy volunteer plasma, pilot 1 included a sample from each of the CDCS and HVOL 
cohorts (Table 6-2).   
Table 6-2 Sample information for pilot 1 
Sample ID Sample information 
CDCS 
plasma 1 
CDCS cohort (heart failure negative) 5ml plasma starting volume 
HVOL 
plasma 1 
Healthy volunteer 5ml plasma starting volume 
Positive 
control 
Brain tissue RNA from the library preparation kit added at the sequencing 
facility (spiked into library pool at 10% v/v) 
 
The STAR Alignment Scores showed the majority of reads uniquely mapped to the reference 
genome (~85% for all samples).  The positive control was added at 10% v/v compared to the 
patient and healthy volunteers’ plasma and this is reflected in the reduced number of reads 
aligning (Figure 6-1A). The percentage of reads mapping to coding regions, 5’UTR and 
3’UTR for the CDCS and HVOL samples was much lower (3.7% and 3.6% respectively) than 
for the positive control (75%) (Figure 6-1B). In contrast, in the ‘infer experiment’ plots, 
which showed the ‘strandedness’ of the library, the positive control RNA sample had ~85% of 
reads aligning to the antisense strand, and the CDCS and HVOL samples had a near 50%-
50% distribution of reads on sense/antisense strands (48% and 47%, respectively, Figure 6-
1C). 
These findings suggested the presence of DNA contamination in the CDCS and HVOL RNA 
samples. In the read distribution plot (Figure 6-1B), the reads mapped mostly to intronic and 
intergenic regions whereas an RNA sample would be expected to map predominantly to 
coding regions (CDS), the 5’UTR and the 3’UTR (as seen for the positive control). 




strand and half the reads mapped to the antisense strand (Figure 6-1C). As this library was 
stranded, the majority of reads from an RNA sample would be expected to come from the 
antisense strand (as in the positive control).  The presence of DNA was likely explained by 
the deliberate omission of the DNase step from the RNA extraction (in an attempt to 








Figure 6-1 Pilot 1: Determining the quality and quantity of RNA able to be extracted from human 
plasma 
A) Alignment scores from STAR for pilot 1 showing the majority of reads were uniquely mapping to 
the genome. Each read is categorised as either ‘uniquely mapping’, ‘mapping to multiple loci’, 
‘mapping to too many loci’ (by default STAR only outputs reads that map to <=10 loci, others are 
considered "mapped to too many loci") - unmapped as the proportion of the reads mapping is ‘too 
short’ or ‘unmapped other’ B) The distribution of reads over genomic features. In contrast to the 
positive control, the plasma samples show very few reads aligning to coding regions (Some reads are 
assigned to more than one category e.g. “TSS/TES_up_1kb” reads were also assigned to 
“TSS/TES_up/down_5kb” and “TSS/TES_up/down_10kb” Reads spliced once will be counted as 2 
tags, reads spliced twice will be counted as 3 tags, etc. Therefore, “Total Tags” >= “Total Reads”. 
CDS:coding sequence, UTR: untranslated region, TSS: transcription start site, TES: transcription end 
site) C) The percentage of reads aligning to the sense or antisense strand. For the plasma samples 
there is an approximate 50%/50% distribution to both strands whereas the majority of reads in the 
positive control map to the antisense strand. Note the fragment length distribution plots from RSeQC 
are not presented here or in the other RSeQC plots as they showed expected distributions. 
In summary, pilot 1 failed to show whether RNA could be extracted from archived patient and  
Healthy volunteer plasma. The next pilot was designed to test including the DNAse step in the 
RNA extraction protocol. 
6.3.2 Pilot 2 Removing DNA contamination from RNA extracted from human 
plasma 
To test whether addition of a DNAse step could remove DNA contamination from the RNA 
samples while retaining sufficient RNA, pilot 2 tested a single HVOL sample alongside the 




Table 6-3 Sample information for pilot 2 
Sample ID Sample information 
HVOL plasma sample 2 Healthy volunteer 4.5ml starting volume 
Dunedin Positive Control Brain tissue RNA from the library 
preparation kit added at the sequencing 
facility spiked into library pool at 15% v/v 
 
MiSeq sequencing generated a total of 1 million reads for the HVOL sample and 200,000 
reads for the positive control (reflecting the lower 15% v/v percentage that the positive 







Figure 6-2 Pilot 2: Assessing DNA removal 
A) Alignment scores for pilot 2. A large percentage of reads were classified as ‘Unmapped: too short’ 
for the plasma samples B) The read distribution plot showing reads aligning mostly to coding regions 
which is indicative of RNA not DNA C) Consistent with this, the majority reads aligned to the 
antisense strand rather than a random alignment to both strands (as was seen in pilot 1). 
Only 33% of reads for the HVOL sample uniquely mapped to the human reference genome, 
with a large percentage (62%) being classified as ‘Unmapped: too short’ (Figure 6-2A). In 
contrast, the positive control had 75% reads mapping uniquely with only 11% being 
‘Unmapped: too short’. The DNAse step appeared to have been successful as the read 
distribution and ‘infer experiment’ plots gave the expected pattern for an RNA sample, 
namely the majority of reads aligning to coding regions and the majority of reads aligning to 
one strand (Figures 6-2B and 6-2C). In contrast to the HVOL sample in pilot 1, the pilot 2 
HVOL sample closely resembled the positive control, with reads mostly aligning to coding 
regions rather than across the genome (Figure 6-3). To elucidate why a large percentage 
(~62%) of reads were classified as ‘Unmapped: too short’, the developer of the mapper 
STAR, Dr Alex Dobin (Cold Spring Harbor Laboratory), was contacted. He suggested three 
potential reasons: 
• There was an issue with over trimming 
• One of the pairs of the reads (either the forward or reverse read) may have mapping 
incorrectly. 




Over trimming was ruled out as the trimming software included a minimum length filter 
(confirmed by the QC plots). The second suggestion (incorrect mapping) was tested by 
mapping forward and reverse reads separately and again ruled out as the issue remained. 
Contamination with non-human transcripts was tested by mapping the unmapped reads from 
STAR (containing all but uniquely mapping reads) using Kraken2 software which assigns 
taxonomic labels to reads 
(https://genomebiology.biomedcentral.com/articles/10.1186/s13059-019-1891-0) and 
visualises the data using Krona 
(https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-12-385). To 
reduce memory and storage requirements prebuilt bacterial, archaeal, and viral genomes, 
which contain 5% of sequences from the original databases, were used. For the HVOL 
sample, the majority of reads that were originally classified as ‘Unmapped too short’, mapped 
to bacterial genomes (63%), although there was still 13% mapping to the human reference 
(Figure 6-4). When several of the reads aligning to the human reference (selected at random) 
were searched in the human genome using BLAST, they appeared to be from regions that 
share high sequence similarity and are problematic to map, such as the human leukocyte 
antigen (HLA) complex (a group of highly related proteins). Among the remaining reads, 
21% had ‘no hits’ and 3% were classified as ‘other,’ which may reflect that the database used 
contained only 5% of the original bacterial, archaeal, and viral genome database. For 
comparison, in the positive control, 96% of unmapped reads were classified as human with 






Figure 6-3 Bar plots comparing the read distributions across genomic features 
Pilot 1 HVOL sample and brain tissue control (top panel) and pilot 2 HVOL sample and brain tissue 






Figure 6-4 Visualisation of the taxonomic classification of the unmapped reads from STAR for pilot 
2 using Kraken2 software. 
A) HVOL sample: 63% of the unmapped reads aligned to bacterial genomes (yellow), 13% 
were classified as Homo sapiens (orange), 21% did not align to any genomes (‘no hits’, blue), 
and 3% aligned to archaeal or fungal genomes (‘other’ grey) compared to B) positive control 





Unmapped reads STAR for the HVOL sample
No Hits Homo Sapiens Other Bacteria
95%
3%
Unmapped reads STAR for the positive control 
sample




0.9 ‘no hits’ (blue), an 0.2% other (grey) . For the full output from the Krona visualisation 
software, which has a breakdown of the bacterial classifications, see Appendix D-2. 
Thus, the issue of the high percent of ‘Unmapped: too short’ reads from the HVOL sample 
appears to be contamination or bacterial RNA inherent in the plasma sample. In summary, 
these data suggested addition of the DNAse step was successful, with the read distribution 
and ‘strandedness’ plots indicative of an RNA sample not DNA. However, there was also 
bacterial contamination or bacterial transcripts inherent in the plasma samples which resulted 
in a large percentage of reads not being mapped to the human reference. 
6.3.3 Pilot 2a Ascertaining whether heart related mRNAs/lncRNAs could be 
detected in plasma 
Table 6-4 Sample information for pilot 2a 
Sample ID Sample information 
HVOL plasma sample 2 Healthy volunteer 4.5ml starting volume 
 
As pilot 2 on the MiSeq pilot was successful in eliminating contamination with DNA, the 
same HVOL RNA library (Table 6-4) was run on the HiSeq to ascertain the level of mRNA 
and lncRNA detection and if any heart related mRNAs and lncRNAs could be detected when 
the sample was sequenced to a depth of 85 million reads. The QC metrics showed similar 
profiles to that of the MiSeq pilot 2 (Appendix D-3). The reads were imported into the R 
package DESeq2 [400] and transcript per million (TPM) values were determined for all 
annotated mRNA and lncRNA genes (comparing to GENCODE). A total of 5,161 annotated 
mRNAs and 553 annotated lncRNAs were detected at a minimum of 1 TPM.  
To assess whether cardiac mRNAs may be present in plasma, expression levels of the 100 
most abundant genes in heart left ventricle were downloaded from the GTEX portal 




ventricle mRNAs, 25%were detected in plasma, and showed a high correlation when 
expression levels were compared. (Spearman correlation coefficient = 0.75, Figure 6-5). 
 
 
Figure 6-5 The most abundant left ventricle mRNAs are detectable in plasma  
 
Similarly, to assess whether heart-related lncRNAs may be present in plasma, plasma 
lncRNAs were compared to ten human lncRNAs involved in heart disease [457]  Of these, 
eight were detected in plasma in the current study, although four were below 1 TPM (Table 6-
5). 
In summary, these data suggested that despite only ~30% of reads uniquely aligning to the 
human reference, heart-related mRNAs and lncRNAs could be detected in plasma, when 




Table 6-5 Eight out of ten human heart disease related lncRNAs were detected in plasma 
gene Ensembl ID HVOL TPM 
MALAT1 ENSG00000251562.8 319.060002 
SENCR ENSG00000254703.2 12.667896 
FTX ENSG00000230590.9 2.442054 
H19 ENSG00000130600.18 1.866076 
MEG3 ENSG00000214548.16 0.15 
MIAT ENSG00000225783.7 0.14 
FENDRR ENSG00000268388.5 0.07 








6.3.4 Pilot 3 Determining the minimum volume of starting plasma and 
assessing the level of RNA contamination present in the kit reagents 
Table 6-6 Sample information for pilot 3 
Sample ID Sample information 
Lab volunteer  4ml starting volume 
Lab volunteer 3ml starting volume 
Lab volunteer 2ml starting volume 
Negative Control Nuclease free water 
Positive Control Brain tissue RNA from the library preparation kit added at the 
sequencing facility at equimolar concentrations 
 
As the volume of archived plasma was limited, with less than the advised starting volume of 
5mL available, pilot 3 set out to test the minimum volume of plasma required using starting 
volumes of 4 mL, 3 mL, and 2 mL. A negative control with fresh nuclease free water was also 
tested to explore the origin of the bacterial RNA contamination (Table 6-6).  Even though the 
samples were added to the library pool at equimolar concentrations, it was impossible to 
achieve this exactly, with the total number of aligned reads ranging from ~450 K to 1.1 
million reads, as can be seen in the read alignment plots (Figure 6-6). Table 6-7 gives a 





Table 6-7 A summary of the percentage of reads mapping to the human genome and bacterial 
genomes in pilot 3. 


























% Unmapped reads 
aligning to other 
genomes * 
Plasma 4 mL 22 68 89.3 75 63 • 7 Human 
• 2 ‘other’ 
• 23 ‘No hits’ 
Plasma 3 mL 16 73 88.5 78 68 • 9 Human 
• 1 ‘other’ 
• 23 ‘No hits’ 
Plasma 2 mL 1.4 98 59.7 70 75 • 0.7 Human 
• 3 ‘other’ 
• 21 ‘No hits’ 
Negative 
Control 
0.2 99.7 9.9 51 79 • 0.3 Human 
• 0.8 ‘other’ 
• 20 ‘No hits’ 
Positive Control 69 10 73.1 91 3 • 95 Human 
• 1 ‘other 








Figure 6-6 Pilot 3: Testing differing starting plasma volumes and a negative control 
A) Alignment scores. Starting volumes of 4 mL and 3 mL showed a similar percentage of 
uniquely mapping reads (22% and 16% respectively); The 2mL sample showed a very low 
percentage of uniquely mapping reads (1.4%). In contrast, a small percentage of reads were 
classified as ‘Unmapped: too short’ for the positive control B) Of the reads that did align, 
most aligned to coding regions which is indicative of RNA not DNA C) 4 mL and 3 mL 
samples showed similar profiles with respect to the ‘strandedness’ of the reads; the 2mL 
sample showed a lower percentage of ‘strandedness’.  
As in pilot 2a, Table 6-7 and Figure 6-6 show that RNA samples from plasma contain a high 
percentage of reads classified as ‘Unmapped: too short’ (subsequently shown to be of 
bacterial origin). The unmapped reads that were classified as human appeared to be reads 
from repetitive regions (after BLASTing these to the human genome) and may be from the 
‘mapped to multiple loci’ category. The 4 mL and 3 mL samples showed read distribution and 
‘strandedness’ plots indicative of RNA samples, whereas the 2mL sample showed a higher 
percentage of reads aligning to the sense strand, suggestive of DNA contamination.  
To confirm that the plasma RNA profile was consistent between the 4 mL, 3 mL and 2 mL 
starting volumes, a Spearman’s correlation was carried out for the 200 most abundant genes 
identified from each sample. In addition, to determine the degree of similarity in the RNA 
profile between individuals the RNA profile of the 4mL sample (lab volunteer) was compared 
with that of the 4.5ml HVOL sample from pilot 2. Strong correlations were found between the 




and 0.7 respectively, Figure 6-7A and 6-7B). I also saw a moderate correlation between the 
4mL sample from the lab volunteer versus the 4.5ml HVOL sample from pilot 2 (correlation 
coefficient = 0.4, Figure 5-7C). This suggested that the RNA profile was reproducible for 
starting volumes ranging from 2ml-4ml. However, the 2 mL sample performed less well in 
quality metrics (as seen in Figure 6-6A), with only 1.4% of reads uniquely mapping. 
Consequently, it was determined that the minimum volume of plasma to yield an acceptable 
percentage of uniquely mapping reads was 3 mL. Moreover, the moderate correlation between 
the lab volunteer and healthy volunteer sample from pilot 2 suggested that the genes identified 
were relatively reproducible between individuals, despite different plasma preparation 
conditions and the healthy volunteer sample having been in storage for over ten years.  
To explore if the bacterial reads were originating from the plasma (i.e. leakage from the gut 
microbiome) or there was exogenous contamination (i.e. from the RNA columns or other 
reagents), Spearman’s correlation was calculated for the 100 most abundant bacterial reads in 
each sample, including the no template control (NTC) which had been treated as if it was a 
plasma sample (i.e. spun through columns and had reagents added to it). When comparing the 
bacterial reads in the NTC with the 4mL, 3mL and 2mL samples, the Spearman’s correlation 
was 0.7, 0.7 and 0.4 respectively (Figure 6-8).  The high degree of correlation suggested that 
the bacterial reads in the plasma samples originated from the kits or the nuclease free water 
itself (added to the sample to top up the starting volume to 5 mL), rather than being 
endogenous to the plasma.  The bacterial reads from the positive control (brain tissue) were 
also moderately strongly correlated with the bacterial reads from the NTC (Spearman 







Figure 6-7 Spearman’s correlation plots of the 200 most abundant genes 
A) 4ml versus 3ml starting plasma volume, B) 4ml versus 2ml starting plasma volume C) 4ml 




However, the degree of contamination by bacterial reads in the brain sample was considerably 
less compared with the plasma samples: the most abundant bacterial transcript in the positive 
control that correlated with the NTC was only 0.4% of the total reads whereas this was 
between 12-20% of the total reads in the plasma samples (Figure 6-8A-D) 
In summary, there have been several previous reports of bacterial contamination originating 
from laboratory reagents and consumables, and this contamination is especially exacerbated 
in samples with low endogenous content (such as plasma samples) where the contaminating 
nucleic acids can outnumber the nucleic acids within the sample [458-462]. This was not seen 
in the brain tissue positive control in which RNA is much more abundant than in the plasma 
samples, with only 3% of total unmapped reads mapping to bacteria.  
 
Figure 6-8 Spearman correlation plots comparing the 100 most abundant bacterial species in each 
sample against the NTC. 
A) 4mL starting volume compared to the NTC B) 3mL starting volume compared to the NTC C) 2mL 




Because the Spearman correlation between the bacterial species in the positive control and the 
NTC was moderately strong (correlation coefficient = 0.5), it is likely that the relatively small 
number of bacterial species in the positive control originated from the kits or the nuclease free 
water itself. It seems that this bacterial contamination cannot be avoided for the plasma 
samples, in which the RNA is much less abundant. For future work these reads could be 
analysed to see if they align to bacterial ribosomal RNAs. If they do then oligonucleotide 
probes could be designed against the bacterial rRNAs to deplete them from the sample before 
sequencing [463].  The fact that 20-30% of the reads from plasma samples uniquely aligned to 
the human reference was encouraging and suggested that an accurate picture of the plasma 
transcriptome could still be achieved, even from starting volumes as little as 3 mL, provided 
the samples were sequenced deeply enough. 
6.3.5 Pilot 4: Testing plasma samples that have been stored for >10 years and  
inclusion of artificial spike-in controls 
Table 6-8 Sample information for pilot 4 
Sample ID Years in storage Sample information 
HVOL plasma 3 11 1% Sequins spiked in laboratory 
HVOL plasma 3 11 No Sequins spiked  
CDCS plasma 2 14 1% Sequins spiked in laboratory 
CDCS plasma 2 14 No Sequins spiked  
Positive Control - Brain tissue RNA from the library preparation 
kit added at the sequencing facility 
 
The aims for the final pilot were to confirm that the RNA from patient and healthy control 
plasma samples that had been in storage over ten years could be sequenced and to test 
whether Sequins - artificial RNA spike-ins [371] - could be used as internal controls in 
plasma samples (Table 6-8). Sequins were spiked into each sample at the recommended 1% of 
the total RNA concentration prior to reverse transcription, library preparation and sequencing 
(Appendix D-1). As they share no homology with the human reference genome, they could be 
aligned back to their in silico genome and in this way, they could be used as internal controls 




experiment, two plasma samples, with and without the addition of 1% v/v of Sequins, were 
compared.   
From the QC plots (Figure 6-9) the samples that had been in storage over ten years displayed 
similar QC metrics to the samples from previous pilots.  The read distribution and 
‘strandedness’ plots showed there was no DNA contamination and there were similar 
percentages of uniquely mapping reads and reads that were ‘Unmapped: too short’.  
Detection of sequins suggested that the library preparation and sequencing had worked 
successfully. Table 6-9 shows the number of reads aligned to the human reference and Sequin 
reference combined as well as the number of reads aligned to the Sequin reference alone, 
from which the percentage of reads originating from the Sequins was calculated. The 
percentage of reads aligning to the Sequins reference in the HVOL sample was 33% and in 
the CDCS sample was 55%, substantially different from the expected 1%. 
Table 6-9 Alignment statistics from the BAM file using Samtools flagstat. 
Total reads aligning to the Human and Sequin reference combined and the Sequin 
reference alone, and the percentage of total reads aligning to Sequins are presented. 
Sample ID Total Reads aligned to 
both Human and Sequin 
reference 
Total Reads 
aligned to Sequin 
reference 
Percentage of reads 
aligning to Sequins 
(column 2/column 
1)*100 
HVOL plasma 3 (1% Sequins 
added) 
280326 91654 33 
CDCS plasma 2 (1% Sequins 
added) 
500632 275424 55 
 
In summary, samples archived for more than 10 years can be reliably sequenced using this 
method.  However, the high percentage of sequin reads in the sample was unexpected.  
Sequins are usually added to RNA extracted from tissue and there is currently no information 
in the literature on adding Sequins to human plasma samples with such low RNA input 
amounts. Despite using the adapted protocol, [369] the high percentage of reads aligning to 




samples was a gross overestimate, potentially owing to the large amount of bacterial 





Figure 6-9 Testing whether synthetic spike ins can be added to the plasma sample. 
A) Alignment scores. This time reads were aligned to the human and in silico Sequin genomes 
combined, and hence the samples with no Sequins spiked in look to have fewer uniquely mapped reads 
aligning. B) Similarly, the samples with Sequins spiked in have a higher percentage of reads mapping 
to ‘other intergenic’ regions in the read distribution plot (as these are the reads aligning to the 




the same as the endogenous RNA with respect to reverse transcription, library preparation and 
sequencing 
Because the amount of human RNA could not be quantified, it was determined that the 
addition of Sequins to plasma samples would be omitted in the final project to avoid reducing 
the number of reads available for human RNA. 
6.4 Conclusions. 
RNA sequencing of plasma samples is technically challenging due to low RNA amounts, but 
the following conclusions can be drawn from the pilot studies. 
• The addition of the DNAse step to the extraction protocol is critical and outweighs any 
potential loss of RNA.  
• There was a large and unexpected proportion of reads that were bacterial, which 
appeared to originate from the kits. 
• Heart disease-associated mRNAs and lncRNAs can be detected in human plasma 
when sequenced at a depth of 85 million reads. 
• The minimum starting volume for RNA extraction was 3 mL plasma. 
• Samples with storage time > 10 years were still able to be sequenced reliably. 
While the addition of artificial RNA spike ins confirmed the sequencing run had performed as 
expected, they will be omitted in future experiments owing to the inability to reliably quantify 
the amount of human RNA in the sample and the potential for RNA sequins to take up a high 




     Chapter 7 
RNA-Sequencing of plasma from healthy volunteers and 
heart patients. 
7.1 Introduction 
Despite major advances in cardiovascular risk prediction over the last twenty years, we lack 
the ability to identify individuals at impending risk of MI or accurately identify all patients at 
risk of heart failure. To identify potential novel candidate RNA biomarkers, in this chapter I 
aimed to characterise the human plasma transcriptome and identify mRNAs, lncRNAs or 
circRNAs associated with the presence of Ischaemic Heart Disease (IHD) and progression to 
HF. Here, I describe a screening study to identify candidate diagnostic markers for follow up 
in larger cohorts.  
7.1.1 Overview of research design 
Building on the pilot studies in the previous chapter, this chapter presents the results from 
deep RNA-Seq of plasma from 31 Healthy volunteers (HVOLs), 31 patients with unstable 
angina or myocardial infarction who remained free of heart failure for at least three years 
(‘CDCS heart failure negative’) and 30 patients with either unstable angina or myocardial 
infarction who were diagnosed with heart failure within three years (‘CDCS heart failure 
positive’). Patient selection and a summary of patient characteristics is provided in Section 
3.2.3. Bloods were taken on average 4 months after the acute event when the patients were 
stable (i.e., gene expression changes associated with the acute injury had passed and 
expression changes would more likely to be associated with either cardiac re-modelling or 
compensatory mechanisms leading to heart failure). RNA extracted plasma from each of the 
three groups was sequenced to a depth of ~100M reads per sample and analysed with the 
bioinformatics pipeline to produce lists of mRNAs, lncRNAs, novel lncRNAs and circRNAs 




Prior to deep sequencing, all samples were barcoded, pooled at equimolar concentrations, and 
sequenced along with a positive (brain tissue) and negative control (RNase-free water), at a 
low read depth (~1 million reads) on an Illumina MiSeq to check that library preparation had 
worked satisfactorily. Quality control metrics showed similar distributions to the pilot 
experiments with only ~30% of reads uniquely mapping to the human genome (Appendix 
figure E-1A). The majority of reads aligned to coding regions and to the antisense strand 
indicating that the libraries consisted of RNA (Appendix Figure E-1B/C).  The combined 
sample library was then sequenced to a greater depth (10 billion reads) on the Illumina 
NovaSeq 6000.  
The raw reads were processed through the bioinformatics pipeline (presented in Section 4.1) 
to produce raw counts for annotated mRNA and lncRNA genes, novel lncRNA transcripts and 
back-spliced junction reads to identify circRNAs. The raw read counts were then analysed 
with DESeq2 to calculate differential expression (log2 fold change with Benjamin-Hochberg 
adjusted p-values) and transcript per million (TPM) values. For gene level analyses, a filter of 
at least 1 TPM for at least 90% of samples was applied.  
7.2 Results 
7.2.1 Quality assessment 
RNA-Seq on the NovaSeq 6000 resulted in a median of 108M reads per sample, ranging from 
5M-193M. However, upon closer inspection two libraries that had been prepared for a 
previous pilot and spiked into the final pool appeared to have much higher reads possibly due 
to being spiked in at a higher molarity. If we remove these two samples plus the outlying 
samples discussed in the next paragraph the range of reads was 84-138M. Analysis of 
variance (ANOVA) confirmed that read depth did not differ between the patient groups or 
controls, suggesting that read depth was not associated with disease phenotype or cohort and 
would be unlikely to confound differential expression analysis (p-value 0.58), see Tables 7-1 




(percentage) of uniquely aligned reads was 21M (19%) ranging from 1.5M-64M (2.2%-
73.9%) (Figure 7-1, Table 7-1) Quality control metrics for the NovaSeq 6000 sequencing of 
plasma samples and brain tissue positive control showed similar distributions to the 
preliminary HiSeq sequencing, confirming that the NovaSeq run was successful (also 
Appendix Figures D-1 and D-2).  
Table 7-1 Summary statistics for NovaSeq 6000 RNA-Seq for all samples 
 Total reads (million) % reads aligning Reads uniquely aligning 
(millions) 
Median 107.9 19.0 21.4 
Minimum 5.4 2.2 1.5 
Maximum 193.0 73.9 64.3 
 
Table 7-2 Summary statistics for the NovaSeq 6000 RNA-Seq per group 
 Median Total reads 
(millions) 
Median % reads 
aligning 
Median reads uniquely 
aligning (millions) 
HVOL 111.2 20.0 22.5 
CDCS HF - 100.1 19.1 21.9 
CDCS HF + 110.3 13.5 14.5 
 
Table 7-3 Summary statistics for the NovaSeq 6000 RNA-Seq outliers sequencing for all samples 
(outliers discarded) 
 Total reads 
(millions) 
% reads aligning Reads uniquely aligning 
(millions) 
Median 107.9 19.0 21.4 
Minimum 84.0 3.3 3.4 
Maximum 193.0 73.9 64.3 
 
Table 7-4 Summary statistics for the NovaSeq 6000 RNA-Seq per group (outliers discarded) 
 Median Total reads 
(millions) 
Median % reads 
aligning 
Median reads uniquely 
aligning (millions) 
HVOL 111.2 18.9 23.9 
CDCS HF - 102.0 19.0 22.4 






Figure 7-1 Plots of the three sample groups showing percentages of reads and millions of reads 
aligning for the three groups 
Healthy Volunteer cohort, CDCS NEG: Coronary Heart Disease (Heart Failure negative), CDCS 
POS: Coronary Heart Disease (Heart Failure positive) 
A Principal Component Analysis (PCA) identified three outlying samples, S25, S76 and S43 
(Figure 7-2), coincidentally one outlier from each experimental group. Samples S25 and S76 
had been flagged by the sequencing facility as failing the library preparation QC owing to a 
low yield of cDNA. The remaining sample, S43, had only 2.5 million reads (2.2%) aligning to 
the human genome and showed a 50/50 distribution on the infer experiment plot, indicative of 
a high degree of DNA contamination in the RNA library. All three samples were discarded, 
leaving 89 samples remaining for analysis (HVOL 30, CDCS HF negative 30, CDCS HF 
positive 29). The summary statistics were recalculated (Tables 7-3, 7-4) and this increased the 





Figure 7-2 Principal Component Analysis plotting the normalised gene counts for each sample. 
There are three outlying samples, S25, S76 (which were flagged by the sequencing facility as failing 
the minimum yield QC) as well as S43 which had the lowest number of reads aligning (second to S25). 
These three samples were discarded from the analysis. 
7.2.2 Differential expression analysis - annotated mRNA and lncRNAs 
RNA-Seq of the plasma transcriptome identified 60,317 annotated genes (GENCODE.v33), 
of which only 4,153 genes remained after applying the filter of at least 90% of samples having 
≥1 TPM. Of these, 3,986 were classified as mRNAs and 167 were classified as lncRNAs. 
Nearly a quarter of the genes (921, 22%) that were detected in the plasma were also detected 
in human left ventricle heart tissue (Harvard data, Section 5.3.2) with an abundance Spearman 
correlation of 0.33 Figure 7-3. To try to identify whether these were heart specific genes the 
genes detected in plasma were compared to a list of heart enriched genes generated through a 
median-based analysis of tissue-specific gene expression based on the GTEx data [464] 




higher than 5.0 in the heart versus all other tissues). From this analysis one gene was present 
in both datasets (FGF23). 
 
Figure 7-3 A scatter plot showing the correlation between normalised gene counts in plasma and 
left ventricle heart tissue 
22% of genes detected in plasma were also detected in heart tissue. 
In plasma, 13 out of the 20 most abundant protein-coding genes were mitochondrial (MT-
ND1, MT-ND2, MT-CO1, MT-ND4, MT-CO2, MT-ATP6, MT-ND5, MT-CYB, MT-CO3, MT-
ND6, MT-ATP8, MT- ND3, MT-ND4L) and 4 out of the 20 most abundant lncRNA genes had 
previously been shown to be expressed in the heart (MALAT1, SNHG6, RMRP and 
ZFAS1) [408, 465-468]. 
To identify candidate RNA biomarkers for the presence of IHD or progression from IHD to 
ischaemic HF, differential expression analysis was performed comparing gene expression i) 




Three patterns of differential expression were prioritised (Figure 7-4); namely that the CDCS 
heart failure positive group had significantly increased expression compared to the other two 
groups (indicating potential markers for progression from coronary heart disease to ischaemic 
heart failure, Scenarios 1 and 2, Figure 7-4) or that both CDCS groups had significantly 
increased expression compared to the HVOLs  (indicating potential markers for the presence 
of IHD, Scenario 3, Figure 7-4). 
Differential expression analysis (padj < 0.01 and absolute fold-change >1.2) between the 
CDCS HF positive versus CDCS HF negative showed no significantly differentially 
expressed genes (although there were four genes that were padj < 0.2 which suggest candidate 
markers for further investigation, Appendix Table E-1). This consequently ruled out scenarios 
1 and 2, leaving Scenario 3.  
 
Figure 7-4 A schematic of the scenarios of gene expression between the three groups for biomarker 
analysis of acute coronary syndromes or progression from coronary heart disease to ischaemic 
heart failure. 
Scenarios 1 -3 looked for upregulated genes for either or both of the CDCS groups compared to the 
HVOL group. Scenario 4 combined the two CDCS groups and looks for upregulated genes for the 





In contrast, significantly differentially expressed genes were identified when both CDCS HF 
positive and CDCS HF negative were compared to the HVOLs (separately). To improve 
statistical power, it was decided to combine the two CDCS groups and look at differential 
expression between CDCS vs HVOL (equivalent to scenario 4). enabling identification of 
possible biomarkers of IHD (HVOL n=30 versus CDCS n=59). 
This scenario distinguishes the CDCS cohort as a whole from the HVOL group, thereby 
DESeq2 analysis showed that 170 genes were differentially expressed between HVOLs and 
CDCS patients combined (padj < 0.01, absolute fold change > 1.2, with 96 genes up regulated 
in CDCS patients). Of these, 88 genes were mRNAs (Table 7-5), and 8 genes were lncRNAs 
(Table 7-6) which all appeared to directly overlap (n=7), or were very close to (7308 bases, 
n=1), CCCTC-binding transcription factor (CTCF)-binding sites (Appendix  . Of the 20 
mRNA genes with the highest fold change, 13 were mitochondrial genes (MT-ND6, MT-ND1, 
MT-ND5, MT-CYB, MT-ND3, MT-CO2, MT-ATP8, MT-CO1, MT-ND4, MT-CO3, MT-ATP6, 
MT-ND2, MT-ND4L, Table 7-5).  
Table 7-5 A list of the top 20 protein coding genes that were higher in the CDCS versus HVOL 
cohort  (padj < 0.01 CDCS versus HVOLs, sorted by fold change) 
Gene name Normalised Mean 
Read Counts 
log2 Fold Change padj 
MT-ND6 112460 2.2 1.64E-27 
MT-ND1 618841 2.2 1.65E-26 
MTRNR2L12 654 2.1 8.15E-20 
MT-ND5 218593 2.1 5.80E-28 
MT-CYB 139778 2.1 3.29E-27 
MT-ND3 48232 2.1 5.75E-29 
MT-CO2 299436 2.1 1.00E-27 
MT-ATP8 63002 2.1 3.25E-22 




MT-ND4 409106 2.0 9.42E-25 
MT-CO3 135217 2.0 1.82E-24 
CXCL14 145 2.0 1.40E-25 
MT-ND2 547684 2.0 6.49E-25 
MT-ND4L 16491 2.0 5.77E-26 
NEUROD2 2257 1.9 1.48E-31 
STAG2 2006 1.6 1.62E-36 
FGF23 3154 1.6 1.14E-16 
BTN3A2 1582 1.4 6.75E-24 
ZNF302 4814 1.3 9.00E-09 
 
 
Table 7-6 A list of lncRNAs that were higher in the CDCS versus HVOL cohort  (padj < 0.01 CDCS 
versus HVOLs, sorted by fold change) 
Gene name Mean Counts log2 Fold Change padj 
AL035078.1 673 1.8 6.48E-26 
CCDC26 6006 1.7 4.51E-25 
AC009404.1 230 1.6 1.50E-18 
LINC02245 227 1.3 1.26E-10 
RGPD4-AS1 193 1.3 1.01E-06 
AL360012.1 1675 1.0 0.000156 
MSC-AS1 148 0.8 0.000981 
AD000090.1 14545 0.7 0.000381 
 
7.2.3 Differential expression analysis - novel lncRNAs 
RNA sequencing of the plasma transcriptome detected 28,725 coding and non-coding 
transcripts (after the abundance filter was relaxed for lncRNA detection to at least half of the 
samples having a read count above zero). Of these, 4,544 were classified as putative novel 
transcripts. To minimise false-positive detection of novel transcripts, only multi-exonic 
transcripts on the main chromosomes (not scaffold chromosomes) were selected for 




at a much lower abundance than the annotated genes (median TPM of novel lncRNAs ranged 
from 0-50 compared to 2-33,374 for annotated lncRNAs) and only two putative novel 
lncRNAs were detectable in all 89 samples.  Comparing the 430 putative novel transcripts to 
the putative novel transcripts identified in the Harvard data using short- (Hi-Seq) and long-
read (Nanopore) sequencing with gffcompare (which can match transcripts with the same 
exons start and end co-ordinates) resulted in matches for two novel transcripts in the Harvard 
short-read data - MSTRG.74727.3 and MSTRG.202989.1, which overlapped a CTCF region 
(Table 7-7). While neither of these transcripts were differentially expressed, two other 
transcripts from the plasma dataset were significantly up regulated in CDCS patients 
compared with HVOLs (MSTRG.752033.2 log2 fold change 1.7, padj = 0.0017 and 
MSTRG.76602.1 log 2 fold change 2.4, padj = 0.003, Table 7-7). 
No statistically significant differentially expressed putative novel transcripts were identified 
when comparing CDCS HF negative and CDCS HF positive patient groups.  
7.2.4 CircRNA 
For circRNA detection two different software packages were used: CircExplorer2 [242] (part 
of the bioinformatics pipeline) and CircTools [262]. CircExplorer2 detected a total of 66,184 
circRNAs but after a filter of 90% of samples having reads above zero, 227 circRNAs 
remained. In contrast, CircTools detected 17,291 circRNAs (although this was with a filter of 
a minimum count of 5 reads in at least 6 samples - the default when running the software). 
After the same filter of 90% samples having reads above zero, 255 circRNAs remained. 
However, 50 genes appeared to be duplicated; in other words, there were 50 genes that had 
read counts for the same coordinates but on the opposite strand 
strand. The developer of CircTools, Dr Jakobi, was contacted regarding this issue who 
suggested that it is not uncommon to see circRNAs also on the other strand with the same 




While this was true for most genes, for some genes the dominant strand was the opposite 
strand to CircExplorer2 and was classified as ‘not annotated’ for CircTools (example shown 




Table 7-7 A list of interesting putative novel lncRNA  transcripts.   
The first two putative novel lncRNAs were expressed at higher levels in CDCS compared to HVOLs (padj < 0.01, sorted by fold change).  The last two putative novel 
lncRNAs were also detected in the Harvard Heart Tissue analysis. 
MSTRG ID Chromosome Start Stop Strand Number of 
exons 
Mean Counts log2 Fold 
Change 
padj 
MSTRG.76602.1 chr10 3408557 3409012 + 2 6.8 2.4 0.003361 
MSTRG.752033.2 chr7 113240035 113240441 - 2 7.6 1.7 0.001659 
MSTRG.74727.3 chr1 247363146 247363578 - 2 27.3 0.5 0.897159 
MSTRG.202989.1 chr13 20392432 20393540 - 2 9.8 0.5 0.753564 
 
 
Table 7-8 An example of circTools detecting circRNA reads on both strands 
Coordinates CircExp2 Strand CircExp2 Annotation CircExp2 Counts CircTools 
Strand 
CircTools Annotation CircTools Counts 
13:99238426- 99244624 + UBAC2 696 + UBAC2 157 






Consequently, the duplicates were discarded, leaving a total of 205 circRNAs detected by 
CircTools.  A key difference between the two software packages is that CircTools detects  
circRNAs from the mitochondria (CircTools includes an option to filter out mitochondrial 
reads, whereas CircExplorer2 filters out mitochondrial reads without giving the option to 
disable the filter). In R, an overlap between the two software packages was calculated by 
extracting circRNAs that had the exact same co-ordinates. This identified 180 circRNAs that  
were consistently detected by both packages.  
For CircExplorer2, no circRNAs were significantly differentially expressed between HVOLs 
and CDCS patients after normalisation (padj < 0.01, absolute fold change > 1.2), although 
three circRNAs had padj < 0.1 (UBAC2, padj 0.047; CLNS1A, padj 0.065 and ASH2L padj 
0.09, Table 7-9).  
Interestingly, CircTools, identified a potentially novel mitochondrial circRNA (detected in all 
89 patients), that was significantly downregulated in CDCS patients compared to HVOLs 
(padj< 1.65E-20, log 2-fold change -2.03, table 6-10). However, this circRNA was annotated 
as being antisense to mitochondrially encoded tRNA valine (MT-TV) and because CircTools 
had an issue with the ‘strandedness’ of circRNAs the reads could be originating from the gene 
itself and the strand of origin would need to be validated. Analysis of the remaining 
circRNAs, identified four circRNAs that were potentially differentially expressed between 
CDCS and HVOL groups at padj<0.1 (unannotated antisense to UBAC2, CLNS1A, 
unannotated antisense to FIP1L1, unannotated antisense to ZNF362). These findings 
demonstrated that circUBAC2 and circCLNS1A were differentially expressed in both software 
analysis. 
There were no statistically significant differentially-expressed circRNAs when comparing 




Table 7-9 A list of circRNAs identified from CircExplorer2   
CircRNAs were expressed at higher levels in the CDCS cohort compared to HVOLs (N.B. no circRNAs were padj < 0.01 so the following are padj < 
0.1, sorted by fold change). 









chr11 77619605 77625818 - CLNS1A 21 0.7 0.065036 6 83 
chr13 99238426 99244624 + UBAC2 696 0.4 0.047036 0 89 
chr8 38114191 38119363 + ASH2L 149 0.4 0.092905 0 89 
 
Table 7-10 A list of circRNAs identified from CircTools 
CircRNAs were expressed at higher levels in the CDCS cohort compared to HVOLs (Note no circRNAs were padj < 0.01 so the following are padj < 
0.1, sorted by fold change). 
chr start stop strand gene base Mean log2 Fold 
Change 




chr11 77619605 77625818 - CLNS1A 27 0.63 0.069782 3 86 
chr13 99238426 99244624 - not annotated 636 0.50 0.040348 0 89 
chr4 53414614 53428183 - not annotated 305 0.48 0.090983 0 89 
chr1 33294936 33295305 - not annotated 256 0.43 0.09515 1 88 






Despite a large percentage of reads not mapping to the human genome when sequencing from 
human plasma, a median of ~20M uniquely mapping reads per sample can be obtained, 
provided the sample is sequenced to a sufficient depth (~100M reads per sample). From the 
results I am able to present a genome-wide screen from human plasma that identified 
promising candidates for genes upregulated in the coronary disease cohort compared to the 
healthy cohort. This list of upregulated genes was dominated by mitochondrial RNAs and 
mitochondrial associated genes which is an exciting discovery and worth follow up studies. 
Also, among this list of differentially expressed plasma genes was fibroblast growth factor 23 
(FGF23) which is expressed in the heart, promotes hypertrophy and remodelling and has been 
identified as an independent marker for cardiovascular risk in various patient populations such 
as those with dilated cardiomyopathy, ischaemic heart disease, acute decompensated and 
chronic heart failure [469-473], along with STAG2 which is required both for proliferation 
and regulation of cardiac transcriptional programs [474]. 
A further gene which has one of the highest log fold changes between the coronary disease 
cohort compared to the healthy cohort, MTRNR2L12 - an isoform of Humanin, a 24 amino 
acid long molecule that is encoded by the mitochondrial 16S rRNA (MT-RNR2 gene) [475]. 
Humanin has been shown to protect against oxidative stress and apoptosis in the heart by 
reducing mitochondrial dysfunction [476-480]. 
Of downregulated genes, one lncRNA (which was the third most downregulated gene) was 
RNA Component Of Mitochondrial RNA Processing Endoribonuclease (RMRP) whose 
upregulation has been shown to aggravate myocardial I/R injury [465] and was demonstrated 
in mouse and human heart failure patients and displayed a nuclear intracellular localization 
[211]. Two out of the five most downregulated genes were also mitochondrial electron 




mitochondrial respiratory chain complex IV and absence of the protein leads to 
cardiomyopathy [481] and NADH:ubiquinone oxidoreductase complex assembly factor 2 
(NDUFAF2) whose protein is involved in the assembly of NADH dehydrogenase 
(ubiquinone) also known as complex I. Deficiency of this is a common cause of 
mitochondrial oxidative phosphorylation disease and is also associated with cardiomyopathy 
[482]. 
Of the differentially expressed circRNAs identified (UBAC2, CLNS1A, and ASH2L, Table 7-
9). These findings are consistent with a recent study that demonstrated that circUBAC2 was 
upregulated in peripheral blood of MI patients and, when combined with four other circRNAs, 
had good sensitivity and specificity for MI diagnosis (preprint 
https://www.researchsquare.com/article/rs-33371/v1). Furthermore, circASH2L promotes 
tumour invasion, proliferation and angiogenesis by regulating miR-34a in pancreatic ductal 
adenocarcinoma [483] and miR-34a itself having been shown to play a key role in cardiac 
repair and regeneration following myocardial infarction [484]. 
The analysis of DNA and RNA liquid biopsies is an exciting and relatively new field that has 
received considerable attention in the past decade. The ability to detect circulating DNA and 
RNA disease biomarkers in a minimally invasive and relatively cheap manner highlights their 
clinical potential.   
Initially, the focus of these studies was on circulating DNA but the potential of circulating 
cell-free RNA is slowly being realised. RNA-Seq tests have already been translated into 
clinical applications for cancer, for example, gene-fusion detection in blood [485, 486] and in 
prostate cancers [487].  
RNA-Seq in plasma is technically challenging due to the very low abundance of RNA. In the 
current study, three samples failed quality control testing (reassuringly two of these had 




for biomarker detection with small RNAs [488] microarrays and targeted analysis of lncRNAs 
with RT-qPCR [489, 490], very few studies have analysed total RNA in human plasma. 
However, the technical hurdles will diminish as RNA-Seq library preparations evolve. A 
recent study evaluated the performance in different biofluids of the strand-specific, total RNA 
library preparation kit used in this thesis (the SMARTer Stranded Total RNA-Seq Kit, Pico 
Input Mammalian). The kit was found to be highly accurate, allowing detection of several 
thousand transcripts from different classes, including mRNAs, lncRNAs and circRNAs [453].  
Interestingly, that study found similarly low percentages of unique read alignment (~25%) in 
human plasma as the current study (median 21%). In contrast, the percentage of reads ‘too 
short to map’ and ‘multi-mapping’ was quite different (~50% and 25% in Everaert et al [453], 
versus median 81% and 2% in the current study). Everaert et al suggested that RNA that is 
‘too short to map’ may represent degraded RNA, although they did not test these for 
alignment to bacterial genomes. The low percentage of uniquely mapping reads may be the 
reason why there are so few RNA-Seq studies in human plasma; if the sequencing was not 
deep enough, there would be too low a percentage of human reads aligning to be informative. 
Among the 20 coding genes most differentially expressed between the HVOL and CDCS 
cohorts, (ranked on fold-change), 13 originated from mitochondria.  In tissues with low 
energy demand such as the adrenal, thyroid and lung, mitochondria contribute ~5% of the 
total mRNA, whereas in the energy-demanding heart, mitochondrial transcripts make up 30% 
of total mRNA [491].  Mitochondria contain a circular genome of 16,569 bases which 
encodes 37 genes: 13 genes for four out of the five subunits of the respiratory complexes, 22 
tRNAs and 2rRNAs [491]. Under anaerobic conditions (e.g., cardiac ischaemia), the heart 
cannot maintain essential cellular processes and oxidative stress ensues. Mitochondria are 
thought to be particularly susceptible to damage from reactive oxygen species and, as they 
undergo apoptosis, they release damage-associated molecular patterns (DAMPs) and RNA 




increase in mitochondrial degradation due to oxidative stress in cardiomyocytes could result 
in an increase in circulating, cell-free mitochondrial RNA in patients with IHD. There was a 
good correlation between the circulating levels of mRNA in the plasma and in the human 
heart tissue data from Harvard (Figure 7-3) suggesting that gene expression in heart tissue 
may be reflected in the plasma, at least for some transcripts.  
The fact that the majority of mitochondrial mRNAs that were found to be upregulated in both 
cardiac tissue and in plasma are encoded by the mitochondrial genome (as opposed to the 
nuclear encoding mitochondrial genes), could be partly because of the abundance of 
mitochondrial genomes.  But it could also be telling us something about CDCS pathology. 
These 13 upregulated mitochondrial genes are genes that encode for four out of the five 
subunits of the respiratory complexes which are responsible for cellular metabolism, 
producing energy in the form of ATP in the presence of oxygen. Mitochondrial are major 
consumers of oxygen are severely affected by ischaemic conditions and sensitive to oxidative 
stress. Consistent fold change across all of the genes suggest they are being released in a co-
ordinated manner, being exported from the cytoplasm either passively as cell damage occurs 
or actively as danger signals in response to the ischemia. 
In support of these findings, intact, cell-free mitochondria have been found in human blood 
(proposed to be released by cells for signalling purposes) [493] and elevated levels of 
mitochondrial DNA have been shown in plasma post myocardial infarction and is a predictor 
of mortality in patients with acute coronary syndromes [494, 495]. An intriguing recent study 
found mitochondria to be translocated from cell-to-cell in both physiological and 
pathophysiological conditions [496].  Mitochondria from distressed cardiomyocytes acted as 
“danger-signal organelles”, which triggered anti-apoptotic and mitochondrial biogenesis in 
mesenchymal stem cells.  In this way, mesenchymal stem cells were able to ‘donate’ their 




suggest that mitochondria may be detectable in plasma and, as they become degraded, 
increase the levels of circulating cell-free mitochondrial RNA, as seen in the CDCS cohort. 
Circulating levels of eight lncRNAs were higher and two lncRNAs were lower (logfc >1.2, 
padj<0.01) in the CDCS cohort compared to HVOLs. Interestingly, lncRNAs with higher 
expression in patients directly overlapped (n=7), or were very close to (7308 bases, n=1), 
CCCTC-binding transcription factor (CTCF)-binding sites (www.ensembl.org). CTCF is a 
transcription factor that, along with the cohesion complex, creates large loop domains within 
nuclear DNA called topologically associated domains (TADs). Contacts of DNA within each 
TAD are strong (whereas they are weak between TADS) and in this way enhancers and 
promoters are brought into close contact for gene regulation [497]. A genome-wide analysis 
of CTCF proteins found that two sub-classes exists: those with an RNA-binding region (RBR) 
and those without that form RBR-independent and RBR-dependent loops [498]. A number of 
lncRNAs have been shown to regulate CTCF [499-502].  While the overlapping of CTCF-
binding sites raises the possibility that the lncRNAs identified in the current study may 
regulate CTCF binding, further analysis of these lncRNAs with techniques such as CLIP 
sequencing (where the RNA-protein complex is crosslinked and then immunoprecipitated, 
then the RNA is sequenced) are needed.  Of the two lncRNAs that were downregulated in the 
CDCS cohort, one lncRNA, RNA component of mitochondrial RNA processing 
endoribonuclease (RMRP), has previously been reported to be upregulated in myocardial 
ischaemia and heart failure and is thought to be involved in cardiac fibrosis and apoptosis 
[211, 467, 503]. 
Not surprisingly, the novel lncRNA transcripts were seen at a much lower abundance than the 
annotated lncRNAs. Only two novel lncRNAs were detected in all 89 samples, suggesting the 
majority of lncRNA transcripts are on the limit of detection for this dataset. Encouragingly, 
two transcripts identified in plasma had the exact same intron match as two transcripts from 




although these two were not seen in the Nanopore validation experiment. While identification 
of the same novel transcript in two tissue types (heart and plasma) is encouraging, these 
transcripts should be validated by a second method such as RT-qPCR because of their very 
low abundance.  Two novel transcripts from the plasma dataset were higher in CDCS patients 
compared with controls, suggesting they could have potential as novel markers for the 
presence of IHD. 
To increase the reliability of in silico circRNA prediction, two circRNA detection algorithms 
were combined. This approach balances the loss of true positives against the removal of false 
positives [504].  A similar number of circRNAs were detected with CircExplorer2 and 
CircTools software (227 versus 205); however, CircTools appeared to duplicate 50 loci. 
Either there is an issue with the software not annotating reads to the correct strand or there are 
genuinely sense and antisense circRNAs being expressed at the same loci.  
While this might be resolved by manually analysing the read sequences and alignments, for 
the purposes of this project, it was decided to focus on the circRNAs detected by both 
algorithms 
Despite this issue, there was extremely good overlap between the two algorithms, with 180 
circRNAs in common, suggesting they would be the prime candidates to validate as 
circulating RNA biomarkers. In addition, CircTools software identified a circRNA derived 
from the mitochondrial genome that was not detected by CircExplorer2 - likely due to the 
mitochondrial genome being filtered out by default for CircExplorer2.  This circRNA was 
detected in all 89 samples and was the only significantly differentially expressed circRNA 
between the groups, (log2 fold change of -2.03 in CDCS patients compared with healthy 
controls, padj < 1.65E-20). Interestingly, a study which compared the performance of 11 
different circRNA detection software packages did not consider any circRNA candidates 




that arose from mitochondria were considered as false positives, a recent paper identified 
circRNAs encoded by the mitochondrial genome in both human and mouse and validated 
these with RT-qPCR, Northern blots and FISH. They proposed a model where these 
circRNAs facilitate the entry of nuclear encoded proteins into the mitochondria [505]. A 
second study has identified four upregulated mitochondrial encoded circRNAs in plasma of 
Chronic Lymphocytic Leukaemia patients using microarray [506]. The mitochondrial 
circRNA detected in this study lies antisense to the mitochondrial tRNAVal gene, MT-TV 
(although this would need to be validated).  Mutations in MT-TV have been associated with 
cardiomyopathies and severe heart failure [507]. 
The circRNA that was most significantly higher in the CDCS cohort compared to the HVOL 
cohort from both software analyses (padj < 0.05, log2 fold change 0.4 (circExplorer2) log2 
fold change 0.5 (circTools)) was circUBAC2 (although again, for CircTools this was 
annotated to be on the antisense strand). This is consistent with a previous report showing 
circUBAC2 was higher in blood of MI patients compared to healthy controls [508], 
suggesting circUBAC2 has potential as a circulating marker for the presence of stable IHD. 
This study has identified several ischaemia-related circRNA candidates for further study, with 
3 and 5 circRNAs having padj <0.1 (CircExplorer2 and CircTools respectively), and with two 
of these identified by both software packages. 
7.4 Limitations of study 
The primary limitation was small sample size, which limited the ability to detect statistically 
significant differences between the groups, particularly between CDCS patients who did or 
did not subsequently develop heart failure.  Additionally, the plasma samples had been in       
-80°C storage for several years and potentially some RNA degradation had occurred.  Despite 
this, the study provides important proof-of-principle that RNA-Seq is possible in human 
plasma.  Due to the low starting amounts of RNA approaches to enrich for human RNA 




already possible for circRNAs [239, 241] This approach to enrich for circRNAs was not used 
in the current study as a combined pipeline for linear and circRNA detection was desired. 
7.5 Conclusion 
This study has demonstrated that mRNAs, lncRNAs and circRNAs can be detected in human 
plasma and has identified several promising candidates for biomarkers for the presence of 
IHD. These candidates were higher in patients that were sampled 4 months after the index 
admission (angina or MI) and if they can be shown to also be higher prior to the index event 
then they could be promising candidates for underlying atherosclerosis. These genes could 
then be used as a panel of markers for predicting who may be at imminent risk of MI.   
The sequencing of RNA from human plasma is technically challenging due to the low input 
amounts of RNA and unavoidable contamination from bacterial nucleic acids from the RNA 
purification kits. Results from this study confirm previous work showing that a substantial 
percentage of reads are lost to these contaminating reads and/or a high degree of RNA 
degradation [453].  This contamination has impact on the percentage of reads mapping to the 
human genome and therefore the ability to detection circulating cell free RNAs by RNA-Seq. 
This could be mitigated through use of enrichment or targeted procedures but may defeat 
genome wide a priori analyses to find novel RNA biomarkers (although this is already 
possible for circRNAs with protocols that biochemically remove of linear transcripts [239-
241].  RNA extraction and sequencing kits are constantly evolving as is the sequencing 
technology itself. This issue may be alleviated with the third-generation technologies which 
offer kits that bypass the need for a PCR amplification step (which may exacerbate the 
contamination problem) and sequence RNA molecules directly [509]. Currently high amounts 
of input RNA are needed for these techniques (e.g. 500 ng of starting RNA, equivalent to 




     Chapter 8  
Discussion 
8.1 Introduction 
The overall aim of this thesis was to identify non-coding RNAs associated with IHD.  This 
was accomplished with a bioinformatics pipeline identifying differentially expressed mRNAs, 
lncRNAs, including putative novel lncRNAs, and, for the plasma experiment, circRNAs also, 
using short-read RNA Sequencing data in two different datasets. A fold change of 1.2 was 
selected (which is lower than the standard 1.5 fold change in most analyses) as I hypothesised 
if a gene is significantly differentially expressed  then it is worth analysing (I put a stricter 
adjusted p-value so the change I saw was reproducible). A subtle difference in gene 
expression may already have a substantial impact. Some genes are more dosage-sensitive than 
others, if it is regulating other genes rather than having a biological impact on its own, there 
may not need to be a large fold change. It is not known for sure what a biological relevant 
fold change for lncRNAs/circRNAs is. The thesis was ultimately exploratory for biomarkers 
but also, I wanted to identify any lncRNAs circRNAs that were biologically interesting with 
ischemia – to give us a better understanding of the underlying biology. 
Several promising candidate biomarkers for myocardial ischaemia including several novel 
lncRNAs (validated with Nanopore sequencing) were identified in ischaemic human heart 
tissue.  The subcellular localisation of three promising lncRNA candidates (two annotated 
lncRNAs, one novel lncRNA) was performed.   
This pipeline was then applied to plasma from patients with IHD and healthy controls to 
screen for candidate mRNA, lncRNA and circRNA biomarkers for progression from IHD to 
HF. Although candidate biomarkers for disease progression could not be detected in these 
patients, several additional lncRNA and circRNA candidates for the presence of ischaemic 




The first results chapter (Chapter 4) assessed the outcomes of pipeline validation on publicly 
available data and will be discussed first. I will then discuss the application of the pipeline to 
human myocardial ischaemic tissue data provided by Harvard Medical School (Chapter 5). 
Next, I will discuss the RNA-Seq protocol developed to detect RNA in plasma and the results 
of the subsequent screening study, which used the pipeline to explore candidate circulating 
RNA markers for the presence of IHD and progression to HF (Chapters 6 and 7). Finally, I 
will describe the limitations of the study and future directions. 
8.2 The performance of the bioinformatic pipeline 
A fundamental principle of bioinformatics is reproducibility: to be able to take raw data files 
and replicate the results of a previous analysis. In reality, this is rarely achieved as reference 
genomes, annotations and software are constantly updated. Moreover, multiple software 
packages are developed for the same task and so different permutations of software along a 
bioinformatic workflow can compound the discrepancy in results. With these considerations 
in mind, the high degree of concordance with previously published analyses (both in terms of 
gene detection and expression levels) suggested my pipeline was successfully integrating 
software for detection and mapping of mRNAs, lncRNAs and circRNAs and was quantifying 
read counts for each class of RNA accurately. 
Despite the high degree of concordance, some differences were observed. My pipeline 
appeared to be slightly less sensitive at detecting annotated genes of low abundance, owing to 
more stringent minimum abundance filters. This was apparent when I removed an abundance 
filter when applying my pipeline to the Yang et al mRNA dataset (Section 4.4.1) which 
increased the detection overlap from 69% (with abundance filter) to 91% (without abundance 
filter).  As mentioned previously, when first aligning the reads I used a ‘first-pass’ alignment 
with STAR2, which in effect detects all possible splice sites (including novels ones). These 
are then used as a guide for the ‘second-pass’ alignment. These splice-sites need to be filtered 




transcripts. The more possible splice junctions, the more possible multi-mapping reads and 
the less uniquely mapping reads, which affects downstream gene quantification.  This was a 
tricky trade off as my pipeline was trying to detect both annotated and novel transcripts. 
These splice sites did not affect the circRNA expression as the alignment and detection of 
circRNA reads are separate to linear reads. 
Another factor affecting detection rates was the use of a more up-to-date version of the 
reference genome (GENCODE v29) in my pipeline. The reference genome annotation is 
constantly being updated, with genes being added, reclassified, or even removed between 
releases. A notable example of this was seen in the dataset from Yang et al where 827 genes 
detected by the authors were no longer present in GENCODE v29. What was most striking 
was that a large part of reproducible research depends on the quality of the annotation. This 
was further highlighted with the fact that NORAD, a relatively well characterised lncRNA, 
had differing chromosome co-ordinates in GENCODE compared to NONCODE. Annotations 
and databases need to be regularly maintained and nomenclature needs to be exactly matching 
across them.  This was discussed in section 1.2.2 for lncRNAs and was a criticism highlighted 
by Vromman et al [272] for circRNAs databases.   
8.3 LncRNAs associated with myocardial ischaemia 
With the pipeline validated, the next part of the project was to analyse data obtained from 
human hearts pre- and post-ischaemia (Chapter 4). This data had already been used for 
identifying annotated mRNAs and lncRNAs associated with ischaemia [175] although 
whereas Saddic et al looked at neighbouring lncRNA-mRNA relationships, I placed more 
emphasis on detecting novel lncRNAs associated with ischaemia and used a gene network 
approach to explore associations between lncRNAs and mRNAs. The reason for this (as 
discussed in Section 1.2) was that lncRNAs can act in trans as well as cis and a gene 
correlation network analysis may help identify potential regulatory lncRNAs that influence 




lncRNAs identified as module ‘hubs’ may make good candidates for further analysis with 
functional experiments such as knock out studies in cardiomyocytes. 
With no abundance filter, the pipeline identified 10,567 transcripts as putative novel 
lncRNAs. The pipeline abundance filter was turned off for novel lncRNAs, as my strategy 
was to validate these transcripts with long read Nanopore sequencing. LncRNAs were 
expressed at a lower level than mRNAs (Table 5-1) [65, 108] and if I had used the mRNA 
filter of 90% of samples having at least 0.5 TPM this would have excluded 62% of the 
putative novel lncRNAs, albeit the lowly expressed ones. However, without some sort of 
abundance filter or validation strategy false positives will vastly outnumber true positives. It 
was encouraging to see that out of 39 transcripts initially identified as novel, 28 of these had 
been documented as lncRNAs in a more recent version of the GENCODE annotation, 
confirming the validity of my pipeline. The number of genuinely novel transcripts detected by 
Illumina sequencing but not detected by Nanopore sequencing and vice versa remains 
unknown, and it is likely additional novel transcripts will continue to be discovered in human 
heart as sequencing technologies improve. 
It can be difficult to decide how to prioritise candidate novel biomarkers for follow up. When 
assessing the 20 most up- and down-regulated putative novel lncRNAs detected by Illumina 
sequencing (based on log2 fold change, Appendix C-3) there were some interesting 
candidates. If one assumes ‘guilt by association’ based on the function of the nearest 
annotated gene, some interesting candidates appear. These include syndecan-4 (SDC4) which 
has been associated with cardiac remodelling [510], Ankyrin repeat domain 1 (ANKRD1) 
which codes for the cardiac stress-response protein, cardiac adriamycin-responsive protein 
[511], Aquaporin-1 (AQP1) involved with myocardial remodelling [512] Tristetraprolin 
(ZFP36) associated with regulating mitochondrial function in heart [513], ACTC1 which 
encodes the cardiac muscle alpha actin associated with dilated or hypertrophic 




cardiomyopathy [515]. This approach assumes the novel lncRNAs may be acting as cis-
regulatory factors.  However, before prioritising candidate novel biomarkers for follow up 
functional studies, all putative novel transcripts require further replication in independent 
samples, either by RNA sequencing or RT-qPCR in an independent set of human left 
ventricle samples. 
Once validated, novel lncRNAs may be prioritised for further study based on their regulatory 
potential. Of the 11 novel transcripts that were validated with Nanopore sequencing (and not 
documented in the more recent annotations), the majority overlapped enhancers or promoter 
regions, indicating a potential mechanism for their biological function. Additionally, one of 
the novel transcripts overlapped five eQTL SNPs for the RWDD3 gene. An eQTL SNP is a 
DNA sequence variant that has been associated with the expression level of an mRNA (in this 
case RWDD3). My data suggests that these variants are present in the exons of this lncRNA 
which could affect the secondary structure of the lncRNA or a target binding site for a 
miRNA, mRNA or protein. A moderate correlation was seen between the novel lncRNA and 
RWDD3. To test whether there is a direct regulatory effect of this novel lncRNA on RWDD3 
then repeat experiments would be needed or knockout studies looking to see if RWDD3 
expression levels are affected when the novel lncRNA is inhibited. A second novel lncRNA, 
which was present in one of the ischaemia-associated network modules identified by 
WGCNA also overlapped an eQTL SNP. This novel lncRNA was associated with VTCN1 in 
left ventricle (although this gene was not expressed at detectable levels in the dataset). The 
novel lncRNA was not only validated with Nanopore sequencing but also with RNAscope 
(Figure 5-12), which further corroborated the utility of the pipeline. 
LncRNAs may also be prioritised based on their degree of correlation with other genes. 
Among the mRNA, lncRNA and novel lncRNA genes identified in human heart tissues, 
WGCNA identified 18 networks of correlated genes, of which 6 were moderately to strongly 




genes including 39 annotated lncRNAs and one novel lncRNA (mentioned above) that were 
markedly enriched in cell death, apoptosis and necrosis pathways. Three of the annotated 
lncRNAs appeared to be highly correlated with other genes in the module (module 
membership correlation >0.7) and may therefore serve as network ‘hubs’ by co-regulating 
multiple genes in the module. One of these three potential hub lncRNAs (AC005523.2) also 
overlapped an eQTL for FEM1A and this time a strong (Spearman) correlation of 0.87 was 
seen suggesting AC005523.2 may have potential to regulate FEM1A directly. FEM1A is 
localised within mitochondria of cardiac muscle and is increased in mouse hearts after MI  
[414] and after ischaemia reperfusion injury [516].  
Two other lncRNAs in Module 1 overlapped eQTL SNPs linked to mRNAs associated with 
mitochondria, apoptosis and energy metabolism (AC012313.1 - ZNF584 and AC011476.3 -
RDH13, which had a Spearman correlation of 0.8).  Additionally, three out of the four 
mRNAs with the highest module membership correlation values, OGDH, MFN2 and 
MRPS27, were also associated with mitochondrial processes. It is well documented that 
mitochondria are vital to cellular metabolism but also play a central role in apoptotic cell 
death [517] and are intricately involved in MI and cardio protection [518]. It is tempting to 
propose that this module of highly correlated genes may promote activation of cell death, 
apoptosis, and necrosis in ischaemic cardiomyocytes by modulating mitochondrial function. 
Of note, mitochondrial genes also featured in the analysis of plasma RNA in patients with 
IHD in Chapter 7.  
The second module most strongly associated with ischaemia was linked to angiogenesis and 
vasculogenesis, two processes involved in the cardiomyocyte response to ischaemia [519]. 
Cardiomyocytes are highly susceptible to cell death caused by ischaemia/hypoxia and several 
attempts using targeted therapies to induce angiogenesis and reduce apoptosis in the border 
zone of the perfused and non-perfused areas of post MI hearts have been made [519]. This 




module membership overwhelmingly associated with pro-angiogenic functions. Although 
none of the lncRNAs in this module overlapped eQTLs, several (including AC093278.2, 
CARMN and AC007743.1) were in close proximity to enhancer elements and CTCF binding 
sites raising the possibility they have functional roles. This network of potentially co-
regulated mRNAs and lncRNAs appears to activate angiogenesis as part of the compensatory 
response to myocardial ischaemia. 
In summary, WGCNA analysis enabled several thousand genes to be condensed into modules 
that were most strongly associated with ischaemia and with each other and may therefore be 
co-regulated. This enabled identification of genes (including lncRNAs and novel lncRNAs) 
that appear to be highly connected within biologically relevant modules (‘hub’ genes). These 
genes may drive the early ischaemic response in human left ventricle may be good candidates 
for future functional and biomarker studies.   
8.4 The plasma transcriptome 
Only a handful of studies have analysed RNA-Seq from human plasma [451-453, 455, 485] 
and, to the best of my knowledge, this is the first study to analyse the plasma transcriptome of 
an ischaemic heart disease cohort. A common theme to emerge from these studies is that the 
results can vary wildly depending on the kit (and even the sequencing centre) [485], and from 
which plasma fraction the RNA is extracted [451, 453, 485].   
For one experiment, Everaert et al [453] sequenced platelet-rich plasma and platelet-free 
plasma (similar to the plasma samples in Chapter 7) from two healthy donors Interestingly, 
for the platelet-free plasma, the authors saw a similar percentage (~25%) of uniquely mapped 
reads with ~50% of reads being unable to be mapped due to being classified as too short 
although the authors did not investigate these reads further (assuming the RNA was 
fragmented), my data suggests the unmapped reads originate from contaminating bacterial 
transcripts in the kits. This issue appears to arise when the input amounts of endogenous RNA 




would be pertinent to enrich for human RNA so as not to lose such a large percentage of reads 
during sequencing. However, this can become tricky if novel transcripts are sought as 
enrichment usually requires knowledge of the target sequences you would like to enrich for.  
The issue of having such a low amount of starting RNA also meant that Sequins could not be 
used, as the amount of starting endogenous human RNA concentrations could not be reliably 
estimated.  
Another interesting observation from Everaert et al [453]and Savelyeva et al [451] is that 
different plasma fractions had very different percentages of reads derived from nuclear RNA 
or mitochondrial RNA (Table 8-1). The percentage of mitochondrial- and nuclear-derived 
reads from my data are presented in Table 8-1 for comparison. The highest source of 
mitochondrial RNA appears to be the platelets (from Everaert et al platelet rich plasma) ~75% 
reads compared to ~ 20% from platelet free plasma compared to ~40% of reads in my data. 
Related to this, Rodosthenous et al [485] also saw differences in the percentage of reads 
derived from different RNA species (e.g., mRNAs, lncRNAs) depending on which RNA 
sequencing library preparation kit was used and whether the RNA was extracellular vesicle 
rich or poor.  Incidentally, of the six kits tested, the kit that detected the greatest gene 
diversity and largest number of lncRNAs was the kit used in the current project - Switching 
Mechanism At 5' end of RNA Template (SMARTer) v2 Pico. 
These studies, along with my own, highlight a lack of method standardisation and 
reproducibility in plasma RNA-Seq.  Different plasma preparation protocols and library  
preparation kits may enrich for different plasma fractions which contain different RNA 
populations. This directly impacts on the detection of certain RNAs.  
A filter of >= 1 TPM for at least 90% of samples is perhaps strict and we would be missing 
genes expressed in one experimental group and completely absent from the other for most 




everyone (albeit at low levels) but which are at much higher levels in cases compared to 
controls.  It is preferable to show the assay is working in everyone, but that the levels go 
above a threshold in the disease group. 
A surprising finding was that 13 out of the top 20 most differentially expressed genes that 
were detected at higher levels in patients with ischaemic heart disease than controls were 
mitochondrial genes (Section 7.2.2).  
On consideration, it is perhaps not surprising that mitochondrial genes are among those most 
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Mitochondria are the site of cellular metabolism, producing energy in the form of adenosine 
triphosphate (ATP) in the presence of oxygen. They are major consumers of oxygen and can 
be severely affected by ischaemic conditions, which alter the composition of the electron 
transport chain complexes [520] (of which four out of five are encoded by 13 mitochondrial 
genes). 
Comparing genes that were differentially expressed both in human heart (pre- and post-
ischaemia) and plasma (IHD patients versus controls), showed that 11 out of 15 genes (all 
upregulated) were mitochondrial. These data suggest that circulating mitochondrial RNA can 
be detected in plasma and may be elevated in association with myocardial ischaemia and in 
established ischaemic heart disease. Importantly, all mitochondrial RNA transcripts were 
highly abundant making them ideal candidate biomarkers. Further work, in larger cohorts, 
will be needed to confirm these preliminary findings and test whether one (or a combination 
of) mitochondrial mRNAs have potential to identify those people who may be at risk of an 
imminent heart attack. It is currently difficult to unequivocally say whether the genes we see 
present in the plasma are solely originating from the heart but from a biomarker perspective 
this is not always needed. BNP was first discovered from brain extracts and CRP is a general 
inflammation marker but they both act as biomarkers for heart disease. A good biomarker, 
when taken in a clinical context, is specific to the phenotype regardless of its tissue of origin. 
Although the differentially expressed lncRNAs in plasma were not altered in ischaemic heart 
tissue, they may also be good candidates to follow up. All overlapped or were in very close 
proximity to CTCF binding sites, advocating a potential regulatory function.  
Prioritising those transcripts that are most abundant, and multi-exonic (less likely to be false 
positives due to the detection of the same splice junction in several samples) and strongly 
differentially expressed would be a way to prioritise lncRNAs further for possible RT-qPCR 




detected in human heart was very encouraging despite the fact they were not differentially 
expressed. Further knock out experiments could be carried out in cardiomyocytes to explore 
their functional roles. 
Not only was this project one of the first to perform RNA sequencing of mRNAs and 
lncRNAs in human plasma, to the best of my knowledge only one other study has investigated 
the ‘circRNAome’ using RNA sequencing in plasma (studying exosomes from gastric cancer 
patients) [521]. CircRNAs are potentially excellent biomarkers in biofluids as, due to their 
closed, circular structure, they are protected from RNase R degradation and exist stably in 
exosomes [522]. 
In this project, I used two circRNA detection software packages and prioritised circRNAs 
detected in both. There was good overlap between the software (180 circRNAs detected in 
both), but this could be because they both used the same back spliced junction reads (detected 
by the STAR aligner software) as input files. However, because circRNAs can only be 
detected using reads that align across the back spliced junction (rather than sequencing reads 
aligning to the whole transcript, as for their linear counterparts) only high abundance 
circRNAs will be detected. Even if the circRNA is derived from one exon we cannot 
unambiguously assign the reads that align to the ‘body’ to the circRNA as they could equally 
be originating from the linear transcript. By only counting the back spliced junction reads, the 
proportion of reads assigned to circRNA transcripts was a very small percentage of the total 
reads. This makes normalising to library size/read depth problematic, with the best strategy 
being to use the normalisation factor from the linear reads.  
To address this problem, several methods have been developed to degrade linear transcripts 
and enrich for circRNAs [239] [241].  With these methods a more quantitative and qualitative 
analysis of circRNAs can be achieved. Full length circRNA sequences can be achieved with 




my pipeline was set up to analyse both linear RNAs and circRNAs simultaneously, these 
methods could not be used. I also could not analyse the heart tissue data for circRNAs owing 
to the use of polyA selection during library preparation (circRNAs do not have poly-A tails). 
Despite not enriching for circRNAs, the pipeline robustly detected hundreds of circRNAs. No 
significantly differentially expressed circRNAs were identified when my conservative filter of 
p-adjusted < 0.01 was applied, but two promising candidates were detected by both software 
for a p-adjusted < 0.1. These candidates require confirmation in a larger cohort with RT-
qPCR to confirm their expression. One validated, RNA immunoprecipitation (RIP) or 
pulldown assays could be used to identify proteins interacting with the circRNA. Most 
intriguingly, one of the software packages detected a highly differentially expressed 
mitochondrial circRNA in all of the samples (the other package did not detect mitochondrial 
circRNAs). Historically mitochondrial derived circRNAs may have been discarded as 
potential artefacts but several studies this year have reported the discovery of mitochondrial 
circRNAs [505, 506, 523]. Potentially, if this circRNA is confirmed experimentally, then not 
only would it be discovery of a novel biomarker associated with ischaemia but also discovery 
of a novel circRNA. 
8.5 Limitations of the study and future directions. 
For robust statistical measurements large enough sample numbers and ideally paired samples 
are desired. When analysing human tissue, sample numbers are usually limited either by costs 
or accessibility to patient samples – especially human heart tissue. For this thesis I had the 
rare opportunity to access paired human heart tissue samples. As the cohort sizes for both the 
heart tissues and plasma experiments were small (n=81 Harvard data, n=92 for the plasma 
experiment) the statistical power may not be sufficient to identify differentially expressed 
genes.  
As RNA is actively transcribed, RNA-Seq has the advantage of providing a ‘real time’ insight 




reflects gene expression that is transient (unless the genes are continously up- or down-
regulated). This was not so much an issue for the plasma experiment as bloods were taken on 
average 4 months after the acute event when the patients were stable (i.e., gene expression 
changes associated with the acute injury had passed and expression changes would more 
likely to be associated with either cardiac re-modelling or compensatory mechanisms). The 
ischaemic heart tissue (Harvard) data was more suscpetible to the importance of timing. Gene 
expression changes seen here (after a median of 74 minutes of ischaemia) reflect the 
immediate response to a relatively short, mild ischaemia and changes associated with 
prolonged ischaemia or a more severe response (e.g., after myocardial infarction) may have 
been missed.Also,  it is possible some of the changes in gene expression may also be due to a 
cardioplegic cold response, rather than ischemia per se. Of course another limitation is that 
there is no perfect model for ischemia and perhaps there is a confounder effect by other 
apsects of coronary heart disease.  
With the apparent contamination by bacteria from the kits which sequester a large proprtion 
of the reads it is possbile that we are still not sequencing deep enough to get a true picture of 
the plasma transcritpome. This may be being exacerbated by the large number of read also 
being taken up by mitochondria. If we could deplete the sample of bacterial contamination 
and the mitochondrial reads we would be left with many more reads resulting in more read 
diversity. This would enable us to have a better idea of which genes in the plasma are coming 
directly from the heart. Of course, we may not want to deplete the sample of the 
mitochondrial reads as these could be a true reflection of the underlying biology. Another way 
of perhaps overcoming the read enrichment issue would be to enrich for extra-cellular vesicles 
which would allow deep sequencing if this sub-population within plasma and would be a 
good future experiment. This would also help to overcome to issue of having to have such a 




Candidates identified in this thesis worth following up are the upregulated mitochondrial 
genes, the lncRNAs that are in the modules most significantly associated with ischaemia 
identified by WGCNA – especially the ones suggested to be acting as ‘hub’ genes and the 
putative novel circRNA that was strongly downregulated in the plasma of CDCS patients. The 
fold change seen for some were relatively small but it was encouraging that they were 
consistently being changed in the same direction (strict adjusted p-values). The hope would be 
to improve areas under the curve (AUC) in Receiver Operating Characteristic (ROC) plots 
when combined with other markers as a panel.  
For the ischaemic associated genes identified in this study, due to the sample numbers, this 
analysis acts as a screen with the requirement of validation of these in larger cohorts.  Further 
validation of the candidate biomarkers would need to be carried out via qRT-PCR in larger 
cohorts. This is technically demanding due to the low amounts of starting RNA but there is 
emerging evidence that this is possible [524-526]. In addition, the tissue analysis used tissue 
blocks containing a heterogeneous combination of cells.  In future, single cell RNA-Seq may 
enable lncRNA profiling of specific cardiac cell types.  Finally, the tissue origins of the 
lncRNAs and circRNAs that were identified in plasma could be explored through regional 
sampling studies [527] or by induced pluripotent stem cells from cardiomyocytes where we 
could look for changes in the cells and media. 
8.6 Concluding remarks 
This study has established a bioinformatics pipeline and methodology for identifying and 
validating putative novel lncRNAs and circRNAs in human heart tissue and plasma. The 
pipeline was designed to identify mRNAs, lncRNAs, circRNAs and novel lncRNAs and 
detection of all four RNA classes was validated with published data. Several promising 
candidates from each of these classes have been identified for follow up studies not only for 
biomarker potential but also for functional studies to verify their functional roles and establish 




In human heart tissue, eleven novel lncRNAs were discovered and network analysis identified 
several lncRNAs that may be acting as key regulators in the ischaemic heart. One of the novel 
lncRNAs was further validated with RNA Scope showing its subcellular localisation in both 
the nucleus and cytoplasm.  In human plasma, novel candidate mRNA, lncRNA and circRNA 
biomarkers for IHD were discovered. While larger sample sizes may be needed to discover 
biomarkers for progression to HF, comparing data from ischaemic heart tissue and plasma 
from an IHD cohort may be a powerful way to prioritise candidate biomarkers for follow-up 
studies in larger cohorts and functional analysis.  
This thesis demonstrates that cutting-edge bioinformatics analysis of RNA sequencing can be 
used to interrogate the whole transcriptome in human heart tissue and plasma in the discovery 
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     Appendix A  
Summary statistics of HVOL, CDCS HF – and CDCS HF + 
patient groups 
 
Summary statistics to review the matching of patient and control groups.  
 




















Figure A-3 Chi-square tests for the selected variables present in the CDCS groups.  
BB1, Beta Blocker 1, ACE, angiotensin converting enzyme, ARB, angiotensin-receptor blockers, Stat – 
Statins, Diur – Diuretics, Hx_DM – History of Diabetes mellitus, Hx_PulmDis- History of pulmonary 
disorder, Hx_CABG – History of Coronary artery bypass grafting, Hx_ValvDis – History of (heart) 
valve disorder, Hx_PVD – History of Peripheral vascular disease, Hx_MI.priorBL – History of 
myocardial infarction prior to baseline, , Hx_AFadj – History of Atrial Fibrillation, Hx_PCI.priorBL - 
History of Percutaneous Coronary Intervention prior to baseline, HxHTN – History of hypertension, 







Figure A-4 ANOVA tests for the selected variables present in the CDCS groups. 
hsTni, High sensitivity Troponin at baseline, NT-BNP, N-Terminal Brain Natriuretic Peptide at 
baseline, LVEF, Left Ventricular Ejection Volume at baseline, EbyEprime - ECHO index of diastolic 





Appendix B  
B-1 Laboratory Methods 
 
B1-1 RNA extraction from tissue 
 
For the validation experiment using Nanopore sequencing (Section 3.4), RNA from the 
Cleveland donor heart samples was used (previously extracted by Dr Anna Pilbrow). Left 
ventricular tissue from donor hearts was broken into small blocks (100-150 mg) in liquid 
nitrogen using a pestle and mortar and placed into pre-chilled tubes on dry ice.  Automated 
grinding was performed using a Retsch Mixer Mill MM301, (Haan, Germany) at a frequency 
of 30Hz for 10 minutes in 800µL pre-chilled TRIzol® (Invitrogen, Carlsbad, CA). Samples 
were mixed with 160µL chloroform by vigorous shaking for 15 seconds, incubated at room 
temperature for 2-3 minutes and then centrifuged at 12,000g for 15 minutes. The supernatant, 
containing the RNA, was transferred to a fresh 1.5mL Eppendorf tube.  
RNA clean-up was performed with the Norgen Biotek CleanAll Kit according to 
manufacturer’s instructions (cat #23800, Norgen Biotek Corporation, Thorold, Canada). This 
kit provides a rapid method for purification, clean-up, and concentration of RNA. RNase-free 
70% ethanol (500µl) was added to the supernatant and vortexed for 10 seconds. This was 
applied to a 600µl spin column with collection tube and centrifuged at 14,000g for 1 minute, 
to bind the RNA. The flow-through was discarded and the collection tube and column 
reassembled. This was repeated until the entire ethanol-supernatant mix had been loaded onto 
the column. 500µl of wash solution was added and the column was centrifuged at 14,000g for 
1 minute. This step was repeated to wash the column a second time. A third wash was carried 
out by adding 500µl of wash solution and the column centrifuged for 14,000g for 2 minutes. 
The column was transferred to a fresh elution tube. 50µl of elution buffer was added and 
centrifuged for at 200g for 2 minutes then at 1,400g for 1 minute. RNA (1.5µl) was quantified 






B-2 RNA library preparation, the SMARTer® Stranded Total RNA-Seq Kit v2 – Pico 
Input Mammalian (Takara Bio, USA) 
 
B2-1 First strand synthesis 
 
There are two options for this part of the protocol – option 1 is for high quality RNA (and 
includes various time options for fragmentation of the RNA); option 2 is for RNA that are 
already degraded. As it was suspected that the RNA from the plasma samples would be 
partially degraded, option 2 (starting with degraded RNA) without fragmentation was used.  
Each RNA sample (8µl) was mixed with 1µl of SMART Pico Oligos Mix v2 on ice and 
incubated at 72°C in a preheated, hot-lid thermal cycler (Eppendorf® Mastercycler®, 
Hamburg, Germany) for 3 minutes, then immediately placed on an ice-cold PCR chiller rack 
for 2 minutes.  The First-Strand Master Mix was prepared by mixing (per sample) 4µl 5x 
First-Strand Buffer, 4.5µl SMART TSO Mix v2, 0.5µl RNase Inhibitor and 2µl 
SMARTScribe Reverse Transcriptase.  First-Strand Master Mix (11µl) was added to each 
reaction tube and vortexed for 2 seconds, and tubes were spun briefly to collect the contents. 
Tubes were incubated in a thermal cycler at 42°C for 90 minutes, 70°C for 10 minutes and 
then held at 4°C 
B2-2 Addition of Illumina adapters and indexes 
 
Next, the indexes (barcodes) used to distinguish samples from each other when sequencing a 
pooled library were added. A PCR master mix was prepared by mixing (per sample) 2µL 
nuclease-free water, 25 µl SeqAmp CB PCR Buffer (2X), 1µl SeqAmp DNA Polymerase, and 
28µl of this mix was added to each sample. Each 5’ and 3’ PCR Primer HT was added (1µl), 
and each sample was vortexed gently and spun briefly. The tubes were placed in a preheated 
hot-lid thermal cycler and PCR was performed using the following conditions: 94°C for 1 




55°C for 15 seconds (annealing) and 68°C for 30 seconds (extension), and a final extension of 
68°C for 2 minutes. After thermal cycling samples were held at 4°C. 
B2-3 Purification of the RNA-Seq Library Using AMPure Beads 
 
AMPure beads (40µL/sample), were equilibrated at room temperature, added to each sample 
tube, mixed by pipetting ~10 times and incubated for 8 minutes to allow the DNA to bind to 
the beads. Tubes were spun briefly then placed onto a magnetic separation device for 5 
minutes until the solution was totally clear.  While the tubes were on the magnetic device, the 
supernatant was removed and discarded and 200µl of freshly made 80% ethanol was added 
without disturbing the beads, to wash away contaminants. After 30 seconds the supernatant 
was carefully removed and discarded, and the wash step was repeated.  Tubes were briefly 
spun at 2,000g to collect the remaining ethanol, placed onto the magnetic separation device 
for a further 30 seconds, and the remaining ethanol was carefully removed. The tubes were 
opened at room temperature for 3–5 minutes until the pellets were dry. The cDNA was eluted 
from the beads by resuspended them in 52µl of nuclease-free water and mixed thoroughly by 
pipetting until all beads were washed off the side of the tube.  Tubes were incubated for 5 
minutes at room temperature to rehydrate then briefly spun and placed back onto the magnetic 
separation device for 1 minute or until the solution was clear. Supernatant (50µl) was 
transferred to a new tube and mixed well by vortexing, with a fresh aliquot (40µL) of 
AMPure beads. Tubes were incubated for 8 minutes to allow the DNA to bind to the beads. 
B2-4 Depletion of Ribosomal cDNA with ZapR v2 and R-Probes v2 
 
Library fragments originating from rRNA (18S and 28S) and mitochondrial rRNA were 
depleted with ZapR v2 in the presence of R-Probes v2 (mammalian-specific). The R-probes 
hybridise to rRNA and mitochondrial rRNA. After AMPure bead purification, tubes were 
briefly spun and placed on the magnetic separation device for 5 minutes or longer, until the 
solution was completely clear. Following 5 minutes incubation on the magnetic separation 




and 200 µl of freshly made 80% ethanol was added to each sample. After 30 seconds the 
supernatant was removed and discarded, and the wash step was repeated. The tubes were spun 
briefly (~2,000g) and placed on the magnetic separation device for 30 seconds to remove any 
remaining ethanol as described above. The open sample tubes were rested at room 
temperature until the pellets were dry. A ZapR master mix was prepared by combining the 
following reagents at room temperature in order: 16.8 µl Nuclease-Free Water, 2.2 µl 10X 
ZapR Buffer, 1.5 µl ZapR v2 and lastly 1.5 µl ‘activated’ R-Probes v2 that had been 
incubated in a preheated hot-lid thermal cycler at 72°C for 2 minutes and held at 4°C for at 
least 2 minutes. The dried, DNA-bound AMPure beads were resuspended in 22 µl of the 
ZapR master mix with thorough mixing. Tubes were incubated at room temperature for 5 
minutes to rehydrate the beads, briefly spun to collect the liquid and placed on the magnetic 
separation device for 1 minute or longer, until the solution was completely clear.  Supernatant 
(20 µl) was removed and transferred to a new PCR tube. Tubes were incubated in a preheated 
hot-lid thermal cycler at 37°C for 60 minutes followed by 72°C for 10 minutes then held at 
4°C. 
B2-5 Final RNA-Seq Library Amplification 
 
Library fragments not cleaved by the ZapR reaction were further enriched in a second round 
of PCR. A PCR master mix was prepared by adding (per sample) 26 µl Nuclease-Free Water, 
50 µl SeqAmp CB PCR Buffer, 2 µl PCR2 Primers v2 and 2 µl SeqAmp DNA Polymerase. 
80µl of master mix was added to each sample tube, mixed by gently tapping then spun down. 
Tubes were incubated in a preheated hot-lid thermal cycler under the following conditions:  
94°C for 1 minute (initial denaturation), followed by 16 cycles of 98°C for 15 seconds 
(denaturation), 55°C for 15 seconds (annealing), 68°C for 30 seconds (extension), and then 
held at 4°C. 





The amplified RNA-seq library then went through a purification step with AMPure beads. 
Essentially the process was the same as section 2.5.3 but instead of 40µ/sample of AMPure 
beads, 100µl AMPure beads were added to each sample. Also, the final elution was into12µl 






mRNAs and lncRNA genes and novel lncRNA transcripts 
associated with ischaemia in heart tissue 
 
Table C-1 The 20 most up- and down-regulated mRNAs in response to ischemia in human left 
ventricle. 
Gene Ensembl id log2 Fold Change p-adjusted Median TPM 
FOS ENSG00000170345.9 2.39 1.21E-21 13.75 
S100A8 ENSG00000143546.9 1.86 5.96E-22 2.06 
HBB ENSG00000244734.4 1.74 5.22E-40 130.01 
HBA2 ENSG00000188536.13 1.66 6.73E-39 156.32 
HBA1 ENSG00000206172.8 1.54 5.74E-32 81.77 
S100A9 ENSG00000163220.10 1.43 9.61E-19 4.72 
CXCL2 ENSG00000081041.8 1.41 1.14E-22 5.05 
ZFP36 ENSG00000128016.5 1.20 2.49E-16 19.67 
SOCS3 ENSG00000184557.4 1.15 6.25E-10 2.75 
GADD45B ENSG00000099860.8 0.97 1.45E-19 9.05 
C2CD4B ENSG00000205502.3 0.96 2.34E-14 1.08 
SLC11A1 ENSG00000018280.16 0.96 2.88E-12 1.13 
NPPA ENSG00000175206.10 0.92 6.53E-06 20.15 
GJA5 ENSG00000265107.2 0.86 1.58E-15 2.94 
AC118553.2 ENSG00000283761.1 0.84 3.64E-08 1.58 
JUNB ENSG00000171223.5 0.83 5.41E-08 14.03 
DUSP1 ENSG00000120129.5 0.80 6.84E-13 42.84 
NRGN ENSG00000154146.12 0.80 4.35E-25 3.05 




BEST1 ENSG00000167995.15 0.78 5.89E-26 1.80 
LYVE1 ENSG00000133800.8 -0.89 3.72E-12 4.55 
CD68 ENSG00000129226.13 -0.94 4.89E-12 5.29 
MLXIPL ENSG00000009950.15 -0.95 2.54E-11 1.62 
AC005943.1 ENSG00000267059.2 -0.96 1.93E-08 7.94 
ZNF385B ENSG00000144331.19 -0.98 4.89E-12 1.86 
PROB1 ENSG00000228672.3 -0.98 1.02E-05 1.70 
PTPRF ENSG00000142949.16 -1.00 2.08E-11 1.88 
CFB ENSG00000243649.8 -1.02 1.69E-08 2.80 
TMEM37 ENSG00000171227.6 -1.02 5.02E-14 0.88 
SCD ENSG00000099194.5 -1.05 3.50E-08 1.30 
HP ENSG00000257017.8 -1.06 1.79E-07 3.78 
KRT18 ENSG00000111057.10 -1.14 1.93E-12 2.22 
C3 ENSG00000125730.16 -1.18 1.37E-13 36.28 
AC026464.4 ENSG00000260914.3 -1.24 8.96E-17 3.91 
TGM1 ENSG00000092295.11 -1.25 7.08E-09 0.79 
NUDT4B ENSG00000177144.7 -1.33 8.40E-14 15.01 
CHRDL1 ENSG00000101938.14 -1.34 3.79E-12 1.08 
CCL21 ENSG00000137077.7 -1.68 3.01E-14 5.60 
PRG4 ENSG00000116690.12 -2.09 1.31E-16 1.92 







Table C-2 The 20 most up- and down- regulated annotated lncRNAs in response to ischemia in 
human left ventricle. 
Gene Ensembl id log2 Fold Change p-adjusted Median TPM 
AP005329.1 ENSG00000264235.5 1.63 3.44E-50 5.53 
AL583722.2 ENSG00000258430.1 1.43 7.19E-09 6.77 
AC084880.3 ENSG00000256609.1 1.26 1.21E-31 1.44 
AL137186.2 ENSG00000232807.2 1.25 4.58E-15 4.23 
AC241644.3 ENSG00000274415.1 0.89 3.35E-08 1.82 
AC087588.2 ENSG00000274976.1 0.75 1.36E-16 4.06 
ACTA2-AS1 ENSG00000180139.11 0.75 1.09E-12 1.70 
UTAT33 ENSG00000231851.5 0.74 1.53E-07 0.99 
AC012615.2 ENSG00000267007.1 0.71 7.97E-06 2.46 
VASH1-AS1 ENSG00000258301.3 0.70 2.06E-14 3.82 
CRNDE ENSG00000245694.9 0.69 3.32E-13 7.29 
AC135178.1 ENSG00000226871.1 0.69 6.22E-11 1.29 
AC008040.5 ENSG00000268220.1 0.65 1.24E-06 1.94 
AL136164.4 ENSG00000279312.1 0.65 2.35E-07 1.62 
AC091588.3 ENSG00000266283.1 0.63 6.10E-24 1.48 
AC009087.1 ENSG00000260252.1 0.62 0.0001 1.08 
AC025569.1 ENSG00000258168.5 0.60 6.40E-11 0.96 
SNHG25 ENSG00000266402.3 0.60 0.0004 4.32 
AL512770.1 ENSG00000228302.2 0.58 3.83E-24 0.95 
LINC01004 ENSG00000228393.3 0.58 2.50E-15 3.39 
CTBP1-DT ENSG00000196810.4 -0.46 3.49E-13 4.40 
SH3RF3-AS1 ENSG00000259863.1 -0.46 2.29E-08 0.79 




AC011476.3 ENSG00000267265.5 -0.47 4.03E-09 3.93 
LINC00957 ENSG00000235314.1 -0.47 3.23E-13 3.96 
AC010980.2 ENSG00000267034.1 -0.47 4.61E-07 1.07 
AC090515.4 ENSG00000259353.1 -0.48 2.51E-08 1.36 
AF111167.2 ENSG00000259319.1 -0.48 2.08E-21 5.75 
AL365259.1 ENSG00000237742.6 -0.48 3.09E-12 1.78 
AL450326.1 ENSG00000230555.2 -0.50 1.82E-14 2.41 
DNAAF4-CCPG1 ENSG00000261771.5 -0.51 6.17E-06 1.95 
AC090644.1 ENSG00000285731.1 -0.52 0.088066 1.04 
LINC01018 ENSG00000250056.5 -0.53 0.057317 1.60 
AC113189.2 ENSG00000262880.1 -0.57 0.084906 1.16 
AC022440.1 ENSG00000285914.1 -0.59 0.091336 3.19 
AL021068.1 ENSG00000213062.4 -0.61 0.09738 0.89 
LINC02432 ENSG00000248810.1 -0.72 0.108691 1.47 
RORB-AS1 ENSG00000224825.2 -0.78 0.081297 1.69 
AL158152.1 ENSG00000269929.1 -0.85 0.072942 1.92 




Table C-3 The 20 most up-and down-regulated novel lncRNAs in response to ischemia in human left ventricle. 
MSTRG_ID Chromosome Start Stop Strand Class code Nearest Gene # exons log2 Fold Change p-adjusted Median TPM 
MSTRG.131093.1 chr20 45325338 45325752 + x SDC4 2 4.173926 2.12E-15 0.54 
MSTRG.86175.11 chr17 447902 489122 + u - 3 2.917532 3.05E-06 8.72 
MSTRG.104032.1 chr19 39406895 39409136 - x ZFP36 4 2.457344 1.63E-45 1.50 
MSTRG.83300.1 chr16 58046102 58046839 - x MMP15 2 2.152208 1.11E-14 3.34 
MSTRG.83567.1 chr16 58707134 58708232 + x GOT2 2 2.073946 1.43E-14 13.30 
MSTRG.27879.1 chr10 90141461 90921003 + x ANKRD1 3 1.89843 3.87E-19 1.28 
MSTRG.205582.1 chr7 30895368 30925524 - x AQP1 2 1.844036 5.94E-06 1.82 
MSTRG.100871.1 chr19 3122969 3123965 - x GNA11 2 1.792638 2.22E-07 2.61 
MSTRG.43021.2 chr12 4303785 4305242 - i AC008012.1 2 1.782057 6.61E-11 10.70 
MSTRG.104750.46 chr19 45306413 45307690 + x CKM 2 1.772354 3.03E-05 0.62 
MSTRG.73900.1 chr15 40035995 40036576 + x SRP14 2 1.76072 1.01E-06 0.78 
MSTRG.18214.1 chr1 228097691 228098964 - x ARF1 2 1.508408 6.64E-14 15.30 
MSTRG.9631.7 chr1 109669340 109675230 - x GSTM2 2 1.407911 1.14E-05 5.54 




MSTRG.117955.1 chr2 133549002 133615658 + x NCKAP5 2 1.220788 0.000273 2.54 
MSTRG.1633.1 chr1 12006733 12013252 - x MFN2 3 1.220345 2.29E-17 2.50 
MSTRG.43173.1 chr12 6236930 6241095 - x CD9 2 1.210054 1.57E-13 0.62 
MSTRG.54028.2 chr12 119178965 119180265 - x HSPB8 2 1.116854 4.43E-17 0.61 
MSTRG.192545.1 chr6 44250403 44253799 - x HSP90AB1 3 1.107886 9.04E-25 0.52 
MSTRG.1910.25 chr1 16013977 16018044 + x HSPB7 3 1.090551 1.03E-11 6.55 
MSTRG.70918.1 chr14 92940915 92941414 + i ITPK1 2 -1.04909 9.31E-07 6.53 
MSTRG.124395.1 chr2 206075916 206182843 + x INO80D 3 -1.06122 6.46E-06 1.64 
MSTRG.27420.1 chr10 80155701 80169347 + x ANXA11 2 -1.09287 1.66E-11 33.00 
MSTRG.104154.5 chr19 40315848 40319525 + u - 2 -1.09853 1.39E-09 1.39 
MSTRG.11996.12 chr1 160213705 160214998 - x PEA15 3 -1.13159 2.52E-10 14.70 
MSTRG.74119.69 chr15 42413380 42417167 + x ZNF106 4 -1.1572 3.13E-12 18.50 
MSTRG.18420.37 chr1 229431992 229432867 + x ACTA1 3 -1.23328 4.09E-05 1.06 
MSTRG.130515.14 chr20 38128922 38130073 + x TGM2 3 -1.24771 0.000105 12.70 
MSTRG.184244.1 chr5 137807996 137809722 - x NPY6R 2 -1.24808 6.31E-09 8.08 




MSTRG.1365.2 chr1 8360724 8361221 + i RERE 2 -1.31139 1.76E-11 6.79 
MSTRG.192637.2 chr6 45902065 45902966 + i CLIC5 2 -1.37 3.62E-05 6.71 
MSTRG.36725.1 chr11 67424160 67424917 - i CARNS1 2 -1.43 2.52E-06 2.14 
MSTRG.93175.6 chr17 75845805 75847288 + x WBP2 3 -1.45 1.70E-08 10.2 
MSTRG.142094.1 chr3 30691524 30693583 - x TGFBR2 3 -1.53 0.014268 0.61 
MSTRG.86360.1 chr17 1714053 1715842 + i MIR22HG 2 -1.69 3.53E-47 0.89 
MSTRG.214045.1 chr7 135928089 135928528 + x MTPN 2 -1.79 3.57E-05 1.45 
MSTRG.155590.4 chr3 196234960 196236269 + x PCYT1A 2 -1.84 0.000114 1.25 
MSTRG.68787.1 chr14 69352103 69353652 - i GALNT16 4 -2.27 7.24E-11 1.85 







Table C-4. Novel lncRNA transcripts originally identified from Illumina short read RNA-Seq and validated with long read Nanopore technology. After 
comparisons with updated annotations 11 lncRNAs were considered truly novel (highlighted in red).   
 






MSTRG.8333.38 chr1 95247358 95256066 0.20 0.005 4158 i 2 0 162 0.36 
MSTRG.10127.1 chr1 115356664 115364913 0.07 0.74 402 i 3 29 133 0.51 
MSTRG.10265.1 chr1 117128696 117143589 -0.43 7.27E-13 4121 x 2 0 162 1.68 
MSTRG.10779.1 chr1 146387133 146388149 0.02 0.79 794 i 2 3 159 1.66 
MSTRG.18670.2 chr1 231795748 231854307 0.12 0.00 25443 i 3 0 162 0.50 
MSTRG.18670.5 chr1 231813360 231848025 -0.63 1.21E-10 1594 i 3 0 162 2.61 
MSTRG.18670.6 chr1 231813373 231848080 -0.54 0.00 1481 i 2 3 159 0.97 
MSTRG.109423.2 chr2 37489457 37605898 0.21 0.30 945 y 3 21 141 0.22 
MSTRG.116760.1 chr2 119723168 119759827 0.06 0.99 438 x 3 56 106 0.31 
MSTRG.139608.1 chr3 112054 131466 0.19 0.12 759 u 3 3 159 2.51 
MSTRG.140910.1 chr3 15894181 16137554 0.39 0.34 399 u 4 60 102 0.32 




MSTRG.149055.1 chr3 123335278 123338361 0.26 0.02 1183 i 3 1 161 0.47 
MSTRG.150894.1 chr3 147688931 147732462 0.03 0.99 310 u 2 43 119 0.49 
MSTRG.161102.1 chr4 62930250 62953640 -0.30 0.00 9526 u 2 0 162 0.44 
MSTRG.165657.4 chr4 114334360 114365102 -0.60 0.02 1078 u 3 27 135 0.40 
MSTRG.165657.8 chr4 114334812 114364973 -0.09 0.65 563 u 4 5 157 2.96 
MSTRG.171220.1 chr4 173692903 173699621 -0.47 1.42E-06 5519 u 2 1 161 1.80 
MSTRG.181743.2 chr5 107778856 107781422 0.11 0.66 841 u 2 35 127 0.34 
MSTRG.201880.1 chr6 157328269 157363141 0.19 0.60 476 u 4 49 113 0.37 
MSTRG.224927.1 chr8 94223489 94228144 -0.10 0.43 2298 u 3 0 162 0.30 
MSTRG.233013.2 chr9 38949702 38968353 -0.28 0.01 868 u 4 2 160 2.22 
MSTRG.233013.1 chr9 38949702 38998504 -0.22 0.17 1048 u 4 10 152 1.39 
MSTRG.233934.2 chr9 68947242 68975934 0.01 1 8161 i 3 0 162 6.02 
MSTRG.29120.1 chr10 105460553 105473362 0.39 0.07 1260 u 2 40 122 0.16 
MSTRG.29422.1 chr10 106648504 106677289 -0.12 0.45 1787 x 2 1 161 0.40 
MSTRG.31895.1 chr11 6384901 6390323 0.02 0.87 731 u 2 45 117 0.24 




MSTRG.44658.2 chr12 20104401 20109918 0.25 0.28 697 u 3 10 152 1.02 
MSTRG.50494.1 chr12 83456471 83472641 -0.59 0.00 2864 u 2 10 152 0.37 
MSTRG.52812.1 chr12 104858841 104871639 0.07 0.67 1545 x 2 11 151 0.20 
MSTRG.61980.1 chr13 90273741 90276422 0.26 0.28 685 u 2 32 130 0.49 
MSTRG.65104.1 chr14 24271210 24299055 -0.09 0.55 390 x 3 0 162 2.03 
MSTRG.65423.1 chr14 33958672 33965015 -0.01 0.91 1543 i 2 4 158 0.42 
MSTRG.72507.1 chr15 23401880 23407745 -0.21 0.16 3015 u 2 2 160 0.17 
MSTRG.79975.1 chr16 10621150 10622567 -0.23 0.29 573 u 2 39 123 0.35 
MSTRG.80356.1 chr16 14486764 14492242 0.02 0.91 4575 i 2 0 162 1.10 
MSTRG.240803.1 chrX 10039516 10045783 0.13 0.37 650 i 2 8 154 0.54 
MSTRG.609.1 KI270742.1 6 110029 0.31 3.29E-05 4805 u 3 0 162 0.55 
 
Table continued 
MSTRG_ID GWAS SNP Associated 

















MSTRG.8333.38 x x ✓ x ✓       












MSTRG.10265.1 x x ✓ x ✓       
MSTRG.10779.1 x x x x x AC245407.2      
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MSTRG.148850.
2 
x x x x ✓ AC023494.1      
MSTRG.149055.
1 
x x x x ✓       
MSTRG.150894.
1 
x x ✓ x ✓  NONHSAG03
6322.2 
    
MSTRG.161102.
1 













x x ✓ x ✓  NONHSAG03
8694.3 
    
MSTRG.165657.
8 































x x ✓ x x       
MSTRG.201880.
1 
x x ✓ x ✓       
MSTRG.224927.
1 






x x ✓ x ✓  NONHSAG05
2209.2 
    
MSTRG.233013.
1 
x x ✓ x ✓ AL953883.1 NONHSAG05
2209.2 
    
MSTRG.233934.
2 
x x ✓ x ✓  NONHSAG05
2505.2 
    





























MSTRG.40006.1 x x ✓ x ✓       










cardial valve Enhancer 































MSTRG.65104.1 x x x ✓ ✓       





MSTRG.72507.1 ✓ rs937741 / 
0.3191 

















































Appendix D  
Plasma Pilot Studies 
Table D-1. Alignment statistics from the BAM file using Samtools flagstat for pilot 4. Total reads 
aligning to the Human and Sequin reference combined and the Sequin reference alone, and the 
percentage of total reads aligning to Sequins are presented. 
Sample ID Total Reads aligned 
to both Human and 
Sequin reference 
Total Reads aligned 
to Sequin reference 
Percentage of reads 
aligning to Sequins 
(column 2/column 
1)*100 
HVOL plasma 3 (1% Sequins 
added) 
280326 91654 33 










Figure D-2 Visualisation of the taxonomic classification of the unmapped reads from STAR for pilot 2 using Kraken2 and Krona software. A) HVOL sample: 
63% of the reads were classified as bacteria (red),13% as Homo sapiens (green), 21% had ‘no hits’ (light green) and 3% were classified as ‘other’ (grey) B) 









Figure D-3 Ascertaining if any lncRNAs and heart related lncRNAs can be detected in plasma 
(pilot 2a).  
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Figure E-1 Alignment scores for the HiSeq plasma experiment.  
A) The scores show similar distributions to the pilot plots with ~30% and 70% of reads uniquely mapping and unmapped: too short, respectively. B)  Read 

















Figure E-2A) Alignment scores for the NovaSeq 6000 plasma experiment.  
The scores show similar distributions to the pilot plots with ~30% and 70% of reads uniquely mapping or unmapped: too short, respectively. B)  Read distribution 
plot showing most reads aligning to coding regions C) Infer experiment plot showing the majority of reads aligning to the antisense strand (N.B. the obvious 





Table E-1 Genes differentially expressed between CDCS HF negative and CDCS HF positive (padj<0.2) suggesting potential genes for further investigation. 
Ensemble id Gene name Gene type Base Mean log2 Fold 
Change 
padj 
ENSG00000135905.19 DOCK10 protein coding 381.3008 -1.16 0.041267 
ENSG00000249307.7 LINC01088 lncRNA 370.2495 1.25 0.121078 
ENSG00000068885.15 IFT80 protein coding 113.9025 0.94 0.127449 












































Figure F-1) Overlap of the upregulated lncRNAs with CTCF binding sites from the CDCS vs 
HVOL plasma RNA Sequencing  
